PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29898423-0	2018	Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.	salinomycin	9-20	epidermal growth factor receptor	Mus musculus	35-39
29898423-0	2018	Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.	salinomycin	9-20	prominin 1	Mus musculus	44-49
30295962-8	2018	We further demonstrated that beta-catenin siRNA or salinomycin (an inhibitor of Wnt/beta-catenin pathway) partially rescued ethanol-induced EMT.	salinomycin	51-62	catenin beta 1	Homo sapiens	84-96
29898423-1	2018	We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs).	salinomycin	24-35	prominin 1	Mus musculus	80-85
29898423-1	2018	We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs).	salinomycin	24-35	prominin 1	Mus musculus	129-134
29898423-1	2018	We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs).	salinomycin	24-28	prominin 1	Mus musculus	80-85
29898423-1	2018	We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs).	salinomycin	24-28	prominin 1	Mus musculus	129-134
30262858-4	2018	Several naturally occurring potassium ionophores (e.g. salinomycin) were shown to inhibit P-gp effectively.	salinomycin	55-66	phosphoglycolate phosphatase	Homo sapiens	90-94
29619850-5	2018	Western blotting of tumor protein extracts indicated that SAL treatment leads to up-regulation of E-cadherin, beta-catenin, and transforming growth factor beta receptor (TGFbetaR) expressions in AsPC-1 orthotopic tumor.	salinomycin	58-61	cadherin 1	Homo sapiens	98-108
29619850-5	2018	Western blotting of tumor protein extracts indicated that SAL treatment leads to up-regulation of E-cadherin, beta-catenin, and transforming growth factor beta receptor (TGFbetaR) expressions in AsPC-1 orthotopic tumor.	salinomycin	58-61	catenin beta 1	Homo sapiens	110-122
29458573-0	2018	Promoted Delivery of Salinomycin to Lung Cancer Through Epidermal Growth Factor Receptor Aptamers Coupled DSPE-PEG2000 Nanomicelles.	salinomycin	21-32	epidermal growth factor receptor	Mus musculus	56-88
29966607-0	2018	Salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells.	salinomycin	0-11	autophagy related 3	Homo sapiens	55-59
29966607-0	2018	Salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	60-63
29966607-0	2018	Salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells.	salinomycin	0-11	mechanistic target of rapamycin kinase	Homo sapiens	64-68
29966607-7	2018	We further showed that ATG3, a known critical regulator of autophagy, was downregulated and involved in the inhibition of apoptosis by salinomycin-induced autophagy via the AKT/mTOR signaling axis.	salinomycin	135-146	autophagy related 3	Homo sapiens	23-27
29966607-7	2018	We further showed that ATG3, a known critical regulator of autophagy, was downregulated and involved in the inhibition of apoptosis by salinomycin-induced autophagy via the AKT/mTOR signaling axis.	salinomycin	135-146	AKT serine/threonine kinase 1	Homo sapiens	173-176
29966607-7	2018	We further showed that ATG3, a known critical regulator of autophagy, was downregulated and involved in the inhibition of apoptosis by salinomycin-induced autophagy via the AKT/mTOR signaling axis.	salinomycin	135-146	mechanistic target of rapamycin kinase	Homo sapiens	177-181
29966607-8	2018	SIGNIFICANCE: Our data indicated that salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells, which provides new clues for the mechanisms of underlying the anti-cancer effects of salinomycin.	salinomycin	38-49	autophagy related 3	Homo sapiens	93-97
29966607-8	2018	SIGNIFICANCE: Our data indicated that salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells, which provides new clues for the mechanisms of underlying the anti-cancer effects of salinomycin.	salinomycin	38-49	AKT serine/threonine kinase 1	Homo sapiens	98-101
29966607-8	2018	SIGNIFICANCE: Our data indicated that salinomycin-induced autophagy blocks apoptosis via the ATG3/AKT/mTOR signaling axis in PC-3 cells, which provides new clues for the mechanisms of underlying the anti-cancer effects of salinomycin.	salinomycin	38-49	mechanistic target of rapamycin kinase	Homo sapiens	102-106
29458573-7	2018	Results revealed that the M-SAL-EGFR could efficiently bind to EGFR-overexpressing lung CSCs and cancer cells, and induced enhanced cyotoxic effect than non-targeted M-SAL and salinomycin.	salinomycin	176-187	epidermal growth factor receptor	Mus musculus	32-36
29458573-9	2018	The EGFR aptamers were thus able to promote effective salinomycin delivery to lung cancer.	salinomycin	54-65	epidermal growth factor receptor	Mus musculus	4-8
29974072-8	2018	In particular, salinomycin-induced ER Ca2+ depletion up-regulates C/EBP homologous protein (CHOP), which inhibits Wnt signaling by down-regulating beta-catenin.	salinomycin	15-26	DNA damage inducible transcript 3	Homo sapiens	66-90
29989650-5	2018	We observed that SAL inhibited cell proliferation, as determined by performing Cell Counting Kit-8 (CCK-8) assay, promoted cell apoptosis, as determined based on morphological changes, and increased Annexin V/propidium iodide (PI)-positive apoptotic cell percentage.	salinomycin	17-20	annexin A5	Homo sapiens	199-208
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	BCL2 associated X, apoptosis regulator	Homo sapiens	29-32
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	BCL2 apoptosis regulator	Homo sapiens	33-38
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	cytochrome c, somatic	Homo sapiens	43-55
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	caspase 3	Homo sapiens	81-97
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	poly(ADP-ribose) polymerase 1	Homo sapiens	115-142
29989650-6	2018	Treatment with SAL increased Bax/Bcl-2 and cytochrome c expression and activated caspase-3 and -9, thus leading to poly(ADP-ribose) polymerase (PARP) cleavage and resulting in cell apoptosis.	salinomycin	15-18	poly(ADP-ribose) polymerase 1	Homo sapiens	144-148
29989650-8	2018	The present study is the first to show that SAL induced the differentiation of APL cells, as determined based on mature morphological changes, increased NBT-positive cell and CD11b-positive cell percentages and increased CD11b and C/EBPbeta levels.	salinomycin	44-47	integrin subunit alpha M	Homo sapiens	175-180
29989650-8	2018	The present study is the first to show that SAL induced the differentiation of APL cells, as determined based on mature morphological changes, increased NBT-positive cell and CD11b-positive cell percentages and increased CD11b and C/EBPbeta levels.	salinomycin	44-47	integrin subunit alpha M	Homo sapiens	221-226
29989650-8	2018	The present study is the first to show that SAL induced the differentiation of APL cells, as determined based on mature morphological changes, increased NBT-positive cell and CD11b-positive cell percentages and increased CD11b and C/EBPbeta levels.	salinomycin	44-47	CCAAT enhancer binding protein beta	Homo sapiens	231-240
29989650-9	2018	Furthermore, SAL decreased the expression of beta-catenin and its targets cyclin D1 and C-myc.	salinomycin	13-16	catenin beta 1	Homo sapiens	45-57
29989650-9	2018	Furthermore, SAL decreased the expression of beta-catenin and its targets cyclin D1 and C-myc.	salinomycin	13-16	cyclin D1	Homo sapiens	74-83
29989650-9	2018	Furthermore, SAL decreased the expression of beta-catenin and its targets cyclin D1 and C-myc.	salinomycin	13-16	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-93
29989650-10	2018	Results of immunofluorescence analysis revealed that SAL markedly decreased the beta-catenin level in both the nucleus and cytoplasm.	salinomycin	53-56	catenin beta 1	Homo sapiens	80-92
29989650-12	2018	These findings demonstrated that SAL effectively inhibited cell proliferation accompanied by induction of apoptosis and promotion of cell differentiation by inhibiting Wnt/beta-catenin signaling.	salinomycin	33-36	catenin beta 1	Homo sapiens	172-184
29897525-11	2018	A significant diet X challenge interaction resulted in higher FCR in the Eimeria-challenged birds supplemented with Sal and BGZn in comparison to the other challenged groups, likely due to reduced mortality in the challenged Sal and BGZn groups.	salinomycin	116-119	FCR	Gallus gallus	62-65
29974072-8	2018	In particular, salinomycin-induced ER Ca2+ depletion up-regulates C/EBP homologous protein (CHOP), which inhibits Wnt signaling by down-regulating beta-catenin.	salinomycin	15-26	DNA damage inducible transcript 3	Homo sapiens	92-96
29974072-8	2018	In particular, salinomycin-induced ER Ca2+ depletion up-regulates C/EBP homologous protein (CHOP), which inhibits Wnt signaling by down-regulating beta-catenin.	salinomycin	15-26	catenin beta 1	Homo sapiens	147-159
29367107-6	2018	Further, selected active SAL analogs induced characteristics of apoptotic cell death and increased expression of p53.	salinomycin	25-28	tumor protein p53	Homo sapiens	113-116
29725407-6	2018	CD133-SAL-NPs efficiently bound to CD133+ ovarian cancer cells, resulting in an increased cytotoxic effect in CD133+ ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin.	salinomycin	180-191	prominin 1	Mus musculus	0-5
29725407-0	2018	The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles.	salinomycin	25-36	prominin 1	Mus musculus	40-45
29725407-0	2018	The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles.	salinomycin	25-36	prominin 1	Mus musculus	81-86
29725407-4	2018	The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133+ ovarian CSCs.	salinomycin	23-34	prominin 1	Mus musculus	124-129
29725407-4	2018	The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133+ ovarian CSCs.	salinomycin	23-34	prominin 1	Mus musculus	142-147
29725407-4	2018	The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133+ ovarian CSCs.	salinomycin	23-34	prominin 1	Mus musculus	142-147
29367107-7	2018	Moreover, SAL acted synergistically with the Bcl-2 inhibitor ABT-263, whereas 2,2,2-trifluoroethyl ester, the most active analog of SAL, antagonized ABT-263, suggesting possible differences in molecular mechanism.	salinomycin	10-13	BCL2 apoptosis regulator	Homo sapiens	45-50
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	0-11	keratin 20	Homo sapiens	57-61
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	0-11	keratin 20	Homo sapiens	98-102
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	19-23
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	109-113
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	109-113
29388568-9	2018	The uptake of CD20-SA-NPs by CD20+ melanoma CSCs was significantly higher than that of SA-NPs and salinomycin, leading to greatly enhanced cytotoxic effects in vitro, thus the IC50 values of CD20-SA-NPs were reduced to 5.7 and 2.6 mug/mL in A375 CD+20 cells and WM266-4 CD+ cells, respectively.	salinomycin	98-109	keratin 20	Homo sapiens	14-18
29388568-11	2018	In mice bearing melanoma xenografts, administration of CD20-SA-NPs (salinomycin 5 mg kg-1 d-1, iv, for 60 d) showed a superior efficacy in inhibition of melanoma growth compared with SA-NPs and salinomycin.	salinomycin	68-79	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	55-59
29388568-11	2018	In mice bearing melanoma xenografts, administration of CD20-SA-NPs (salinomycin 5 mg kg-1 d-1, iv, for 60 d) showed a superior efficacy in inhibition of melanoma growth compared with SA-NPs and salinomycin.	salinomycin	194-205	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	55-59
29388568-13	2018	CD20-SA-NPs display effective delivery of salinomycin to CD20+ melanoma CSCs and represent a promising treatment for melanoma.	salinomycin	42-53	keratin 20	Homo sapiens	0-4
29388568-13	2018	CD20-SA-NPs display effective delivery of salinomycin to CD20+ melanoma CSCs and represent a promising treatment for melanoma.	salinomycin	42-53	keratin 20	Homo sapiens	57-61
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	9-20	keratin 20	Homo sapiens	66-70
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	9-20	keratin 20	Homo sapiens	107-111
28937680-4	2017	Here, we provide evidence that a synthetic derivative of salinomycin, which we named ironomycin (AM5), exhibits a more potent and selective activity against breast CSCs in vitro and in vivo, by accumulating and sequestering iron in lysosomes.	salinomycin	57-68	adrenomedullin 5 (putative)	Homo sapiens	97-100
29399118-0	2018	Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells.	salinomycin	95-106	epidermal growth factor receptor	Homo sapiens	0-32
29399118-6	2018	The present study aimed to develop EGFR aptamer-conjugated salinomycin-loaded polymer-lipid hybrid nanoparticles (EGFR-SNPs) to target both osteosarcoma cells and CSCs.	salinomycin	59-70	epidermal growth factor receptor	Homo sapiens	35-39
29399118-6	2018	The present study aimed to develop EGFR aptamer-conjugated salinomycin-loaded polymer-lipid hybrid nanoparticles (EGFR-SNPs) to target both osteosarcoma cells and CSCs.	salinomycin	59-70	epidermal growth factor receptor	Homo sapiens	114-118
29399118-7	2018	The results revealed that EGFR was overexpressed in these cells, and that EGFR-SNPs possessed a small size of 95 nm, suitable drug encapsulation efficiency (63%) and sustained drug release over 120 h. EGFR-SNPs targeted EGFR-overexpressing osteosarcoma cells and CSCs, resulting in an enhanced cytotoxic effect compared with non-targeted SNPs and salinomycin.	salinomycin	347-358	epidermal growth factor receptor	Homo sapiens	74-78
29399118-7	2018	The results revealed that EGFR was overexpressed in these cells, and that EGFR-SNPs possessed a small size of 95 nm, suitable drug encapsulation efficiency (63%) and sustained drug release over 120 h. EGFR-SNPs targeted EGFR-overexpressing osteosarcoma cells and CSCs, resulting in an enhanced cytotoxic effect compared with non-targeted SNPs and salinomycin.	salinomycin	347-358	epidermal growth factor receptor	Homo sapiens	74-78
29399118-7	2018	The results revealed that EGFR was overexpressed in these cells, and that EGFR-SNPs possessed a small size of 95 nm, suitable drug encapsulation efficiency (63%) and sustained drug release over 120 h. EGFR-SNPs targeted EGFR-overexpressing osteosarcoma cells and CSCs, resulting in an enhanced cytotoxic effect compared with non-targeted SNPs and salinomycin.	salinomycin	347-358	epidermal growth factor receptor	Homo sapiens	74-78
29399118-8	2018	Notably, EGFR-SNPs was able to reduce the osteosarcoma tumorsphere formation rate and proportion of CD133+ osteosarcoma CSCs in the osteosarcoma cell lines more effectively compared with SNPs and salinomycin, suggesting that EGFR-SNPs effectively reduced the proportion of osteosarcoma CSCs.	salinomycin	196-207	epidermal growth factor receptor	Homo sapiens	9-13
29399118-9	2018	In conclusion, the interaction of EGFR aptamers and EGFR is a potential approach to promote the effective delivery of salinomycin to osteosarcoma.	salinomycin	118-129	epidermal growth factor receptor	Homo sapiens	34-38
29399118-9	2018	In conclusion, the interaction of EGFR aptamers and EGFR is a potential approach to promote the effective delivery of salinomycin to osteosarcoma.	salinomycin	118-129	epidermal growth factor receptor	Homo sapiens	52-56
28692437-7	2017	We found that both salinomycin and salinomycin-loaded nanoparticles (salinomycin-NPs) could selectively eradicate GC SCs, as reflected by reduced tumorsphere formation capacity and the frequency of CD44 GC cells, whereas docetaxel and docetaxel-loaded nanoparticles (docetaxel-NPs) could significantly eradicate GC cells.	salinomycin	19-30	CD44 antigen	Mus musculus	198-202
28692437-7	2017	We found that both salinomycin and salinomycin-loaded nanoparticles (salinomycin-NPs) could selectively eradicate GC SCs, as reflected by reduced tumorsphere formation capacity and the frequency of CD44 GC cells, whereas docetaxel and docetaxel-loaded nanoparticles (docetaxel-NPs) could significantly eradicate GC cells.	salinomycin	35-46	CD44 antigen	Mus musculus	198-202
28692437-7	2017	We found that both salinomycin and salinomycin-loaded nanoparticles (salinomycin-NPs) could selectively eradicate GC SCs, as reflected by reduced tumorsphere formation capacity and the frequency of CD44 GC cells, whereas docetaxel and docetaxel-loaded nanoparticles (docetaxel-NPs) could significantly eradicate GC cells.	salinomycin	35-46	CD44 antigen	Mus musculus	198-202
28832761-0	2017	Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.	salinomycin	0-11	NUAK family kinase 1	Homo sapiens	143-147
29075110-0	2017	Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.	salinomycin	58-69	erb-b2 receptor tyrosine kinase 2	Mus musculus	26-30
29075110-0	2017	Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.	salinomycin	58-69	erb-b2 receptor tyrosine kinase 2	Mus musculus	82-86
29075110-5	2017	We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.	salinomycin	13-24	erb-b2 receptor tyrosine kinase 2	Mus musculus	58-62
29075110-5	2017	We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.	salinomycin	13-24	erb-b2 receptor tyrosine kinase 2	Mus musculus	86-90
29075110-5	2017	We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.	salinomycin	13-24	erb-b2 receptor tyrosine kinase 2	Mus musculus	86-90
29075110-6	2017	METHODS: The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo.	salinomycin	113-124	erb-b2 receptor tyrosine kinase 2	Mus musculus	43-47
28832761-8	2017	Moreover, we showed that salinomycin treatment downregulated the AMP-activated protein kinase family member 5 (ARK5) expression, which regulates the EMT process of cholangiocarcinoma.	salinomycin	25-36	NUAK family kinase 1	Homo sapiens	65-109
28832761-8	2017	Moreover, we showed that salinomycin treatment downregulated the AMP-activated protein kinase family member 5 (ARK5) expression, which regulates the EMT process of cholangiocarcinoma.	salinomycin	25-36	NUAK family kinase 1	Homo sapiens	111-115
28832761-9	2017	Our results indicated that salinomycin reversed the EMT process in cholangiocarcinoma cells by inhibiting ARK5 expression and enhanced the chemosensitivity of cholangiocarcinoma cells to doxorubicin.	salinomycin	27-38	NUAK family kinase 1	Homo sapiens	106-110
28454878-0	2017	Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.	salinomycin	0-11	thymidylate synthetase	Homo sapiens	48-68
28454878-0	2017	Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	34-37
28454878-2	2017	Salinomycin, a polyether antibiotic, has been promising a novel therapeutic agent for lung cancer, and down-regulated the expression of thymidylate synthase (TS) in NSCLC cell lines.	salinomycin	0-11	thymidylate synthetase	Homo sapiens	136-156
28454878-2	2017	Salinomycin, a polyether antibiotic, has been promising a novel therapeutic agent for lung cancer, and down-regulated the expression of thymidylate synthase (TS) in NSCLC cell lines.	salinomycin	0-11	thymidylate synthetase	Homo sapiens	158-160
28454878-6	2017	A combination of erlotinib and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced protein levels of phospho-AKT(Ser473), phospho-AKT(Thr308), and TS.	salinomycin	31-42	AKT serine/threonine kinase 1	Homo sapiens	189-192
28454878-6	2017	A combination of erlotinib and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced protein levels of phospho-AKT(Ser473), phospho-AKT(Thr308), and TS.	salinomycin	31-42	AKT serine/threonine kinase 1	Homo sapiens	210-213
28454878-6	2017	A combination of erlotinib and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced protein levels of phospho-AKT(Ser473), phospho-AKT(Thr308), and TS.	salinomycin	31-42	thymidylate synthetase	Homo sapiens	227-229
28454878-7	2017	Overexpression of a constitutive active AKT (AKT-CA) or Flag-TS expression vector reversed the salinomycin and erlotinib-induced synergistic cytotoxicity.	salinomycin	95-106	AKT serine/threonine kinase 1	Homo sapiens	40-43
28454878-7	2017	Overexpression of a constitutive active AKT (AKT-CA) or Flag-TS expression vector reversed the salinomycin and erlotinib-induced synergistic cytotoxicity.	salinomycin	95-106	AKT serine/threonine kinase 1	Homo sapiens	45-51
28454878-7	2017	Overexpression of a constitutive active AKT (AKT-CA) or Flag-TS expression vector reversed the salinomycin and erlotinib-induced synergistic cytotoxicity.	salinomycin	95-106	thymidylate synthetase	Homo sapiens	61-63
28454878-8	2017	Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the erlotinib-induced cytotoxicity in NSCLC cells.	salinomycin	81-92	AKT serine/threonine kinase 1	Homo sapiens	51-54
28454878-8	2017	Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the erlotinib-induced cytotoxicity in NSCLC cells.	salinomycin	81-92	thymidylate synthetase	Homo sapiens	64-66
28627587-7	2017	Furthermore, salinomycin significantly increased the protein expression of Fas-L and decreased the protein expression of NF-kappaB p65.	salinomycin	13-24	Fas ligand	Homo sapiens	75-80
28627587-7	2017	Furthermore, salinomycin significantly increased the protein expression of Fas-L and decreased the protein expression of NF-kappaB p65.	salinomycin	13-24	nuclear factor kappa B subunit 1	Homo sapiens	121-130
28627601-8	2017	Furthermore, marked FasL upregulation and NF-kappaB p65 downregulation were observed in cancer cells treated with the combination of SAL and DDP.	salinomycin	133-136	Fas ligand	Homo sapiens	20-24
28627587-7	2017	Furthermore, salinomycin significantly increased the protein expression of Fas-L and decreased the protein expression of NF-kappaB p65.	salinomycin	13-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	131-134
28627601-8	2017	Furthermore, marked FasL upregulation and NF-kappaB p65 downregulation were observed in cancer cells treated with the combination of SAL and DDP.	salinomycin	133-136	nuclear factor kappa B subunit 1	Homo sapiens	42-51
28605700-11	2017	Significantly downregulated canonical Wnt signaling proteins and marker of epithelial-mesenchymal transition (EMT), vimentin were observed in cells treated with resveratrol-salinomycin combination.	salinomycin	173-184	vimentin	Homo sapiens	116-124
28627601-8	2017	Furthermore, marked FasL upregulation and NF-kappaB p65 downregulation were observed in cancer cells treated with the combination of SAL and DDP.	salinomycin	133-136	RELA proto-oncogene, NF-kB subunit	Homo sapiens	52-55
28746279-7	2017	Furthermore, human capsular fibroblasts were treated with a new antiscarring compound, salinomycin, to determine whether Thy1 expression and myofibroblast formation were blocked by salinomycin.	salinomycin	181-192	Thy-1 cell surface antigen	Homo sapiens	121-125
28746279-11	2017	Furthermore, the authors show for the first time that salinomycin decreased Thy1 expression and prevented myofibroblast formation in capsular fibroblasts.	salinomycin	54-65	Thy-1 cell surface antigen	Homo sapiens	76-80
28415776-9	2017	Sporadic cancer cell lines with hyperactive mTORC1 signalling were also susceptible to this nelfinavir/salinomycin drug combination.	salinomycin	103-114	CREB regulated transcription coactivator 1	Mus musculus	44-50
28415776-0	2017	Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.	salinomycin	46-57	CREB regulated transcription coactivator 1	Mus musculus	100-106
28498472-8	2017	Salinomycin increased the expression of autophagy marker protein, LC3B, and accumulation of acidic vesicular organelles.	salinomycin	0-11	microtubule associated protein 1 light chain 3 beta	Homo sapiens	66-70
28415776-4	2017	We found a nelfinavir and salinomycin combination specifically killed TSC2-deficient, mTORC1 hyperactive cells.	salinomycin	26-37	CREB regulated transcription coactivator 1	Mus musculus	86-92
28453992-0	2017	Salinomycin overcomes radioresistance in nasopharyngeal carcinoma cells by inhibiting Nrf2 level and promoting ROS generation.	salinomycin	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	86-90
28453992-8	2017	Our data show that radioresistant SUNE1IR cells exhibited a significant increase in the protein level of Nrf2 compared to parental cells, and SAL inhibited increased Nrf2 in SUNE1IR cells.	salinomycin	142-145	NFE2 like bZIP transcription factor 2	Homo sapiens	166-170
28453992-11	2017	Importantly, we confirmed that combination treatment of Nrf2-deficient CNE2 cells with SAL and IR markedly increased the level of reactive oxygen species (ROS) and DNA damage.	salinomycin	87-90	NFE2 like bZIP transcription factor 2	Homo sapiens	56-60
28693187-8	2017	Furthermore, SAL decreased the CD44+/CD24-/low population and downregulated the expression of Wnt/beta-catenin signaling-associated proteins (beta-catenin, Cyclin D1 and octamer-binding transcription factor 4) in the spheres.	salinomycin	13-16	CD44 molecule	Canis lupus familiaris	31-35
28693187-8	2017	Furthermore, SAL decreased the CD44+/CD24-/low population and downregulated the expression of Wnt/beta-catenin signaling-associated proteins (beta-catenin, Cyclin D1 and octamer-binding transcription factor 4) in the spheres.	salinomycin	13-16	catenin beta 1	Canis lupus familiaris	98-110
28693187-8	2017	Furthermore, SAL decreased the CD44+/CD24-/low population and downregulated the expression of Wnt/beta-catenin signaling-associated proteins (beta-catenin, Cyclin D1 and octamer-binding transcription factor 4) in the spheres.	salinomycin	13-16	catenin beta 1	Canis lupus familiaris	142-154
28693187-8	2017	Furthermore, SAL decreased the CD44+/CD24-/low population and downregulated the expression of Wnt/beta-catenin signaling-associated proteins (beta-catenin, Cyclin D1 and octamer-binding transcription factor 4) in the spheres.	salinomycin	13-16	cyclin D1	Canis lupus familiaris	156-208
28395993-0	2017	Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway.	salinomycin	0-11	protein tyrosine kinase 2	Homo sapiens	124-127
28395993-0	2017	Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway.	salinomycin	0-11	mitogen-activated protein kinase 3	Homo sapiens	128-134
28395993-5	2017	Moreover, western blot analysis showed that salinomycin repressed the phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK1/2).	salinomycin	44-55	protein tyrosine kinase 2	Homo sapiens	89-110
28395993-5	2017	Moreover, western blot analysis showed that salinomycin repressed the phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK1/2).	salinomycin	44-55	protein tyrosine kinase 2	Homo sapiens	112-115
28395993-5	2017	Moreover, western blot analysis showed that salinomycin repressed the phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK1/2).	salinomycin	44-55	mitogen-activated protein kinase 3	Homo sapiens	160-166
28395993-6	2017	Taken together, these findings provide new evidence that salinomycin suppresses the migration and invasion of LCSCs by inhibiting the expression of the FAK-ERK1/2 signalling pathway.	salinomycin	57-68	protein tyrosine kinase 2	Homo sapiens	152-155
28395993-6	2017	Taken together, these findings provide new evidence that salinomycin suppresses the migration and invasion of LCSCs by inhibiting the expression of the FAK-ERK1/2 signalling pathway.	salinomycin	57-68	mitogen-activated protein kinase 3	Homo sapiens	156-162
28395993-7	2017	In addition, the analysis of the mechanical properties showed that salinomycin increased cell stiffness in LCSCs via the FAK, and ERK1/2 pathways, suggesting that the inhibition of LCSC migration might partially contribute to the increase in cell stiffness stimulated by salinomycin.	salinomycin	67-78	protein tyrosine kinase 2	Homo sapiens	121-124
28395993-7	2017	In addition, the analysis of the mechanical properties showed that salinomycin increased cell stiffness in LCSCs via the FAK, and ERK1/2 pathways, suggesting that the inhibition of LCSC migration might partially contribute to the increase in cell stiffness stimulated by salinomycin.	salinomycin	67-78	mitogen-activated protein kinase 3	Homo sapiens	130-136
28395993-10	2017	Overall, these results showed that salinomycin inhibits the migration and invasion of LCSCs through the dephosphorylated FAK and ERK1/2 pathways, reflecting the changes in cell stiffness resulting from the increased actin cytoskeleton.	salinomycin	35-46	protein tyrosine kinase 2	Homo sapiens	121-124
28395993-10	2017	Overall, these results showed that salinomycin inhibits the migration and invasion of LCSCs through the dephosphorylated FAK and ERK1/2 pathways, reflecting the changes in cell stiffness resulting from the increased actin cytoskeleton.	salinomycin	35-46	mitogen-activated protein kinase 3	Homo sapiens	129-135
28524116-0	2017	Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.	salinomycin	33-44	AKT serine/threonine kinase 1	Homo sapiens	105-108
28524116-0	2017	Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.	salinomycin	33-44	mechanistic target of rapamycin kinase	Homo sapiens	109-113
28524116-10	2017	However, pretreatment with PD98059 and SB203580, an extracellular signal-regulated kinases (ERK), and p38 inhibitors, suppressed the salinomycin-induced autophagy by reversing the upregulation of ERK and p38.	salinomycin	133-144	mitogen-activated protein kinase 1	Homo sapiens	102-105
28524116-0	2017	Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.	salinomycin	33-44	mitogen-activated protein kinase 1	Homo sapiens	118-121
28524116-10	2017	However, pretreatment with PD98059 and SB203580, an extracellular signal-regulated kinases (ERK), and p38 inhibitors, suppressed the salinomycin-induced autophagy by reversing the upregulation of ERK and p38.	salinomycin	133-144	mitogen-activated protein kinase 1	Homo sapiens	196-199
28524116-10	2017	However, pretreatment with PD98059 and SB203580, an extracellular signal-regulated kinases (ERK), and p38 inhibitors, suppressed the salinomycin-induced autophagy by reversing the upregulation of ERK and p38.	salinomycin	133-144	mitogen-activated protein kinase 1	Homo sapiens	204-207
28524116-0	2017	Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.	salinomycin	33-44	mitogen-activated protein kinase 1	Homo sapiens	122-125
28524116-8	2017	Notably, salinomycin decreased phosphorylated of AKT and phosphorylated mammalian target of rapamycin (mTOR) in prostate cancer cells.	salinomycin	9-20	AKT serine/threonine kinase 1	Homo sapiens	49-52
28524116-12	2017	Our results suggested that salinomycin induces apoptosis, which was related to ROS-mediated autophagy through regulation of the PI3K/AKT/mTOR and ERK/p38 MAPK signaling pathways.	salinomycin	27-38	AKT serine/threonine kinase 1	Homo sapiens	133-136
28524116-8	2017	Notably, salinomycin decreased phosphorylated of AKT and phosphorylated mammalian target of rapamycin (mTOR) in prostate cancer cells.	salinomycin	9-20	mechanistic target of rapamycin kinase	Homo sapiens	72-101
28524116-12	2017	Our results suggested that salinomycin induces apoptosis, which was related to ROS-mediated autophagy through regulation of the PI3K/AKT/mTOR and ERK/p38 MAPK signaling pathways.	salinomycin	27-38	mechanistic target of rapamycin kinase	Homo sapiens	137-141
28524116-8	2017	Notably, salinomycin decreased phosphorylated of AKT and phosphorylated mammalian target of rapamycin (mTOR) in prostate cancer cells.	salinomycin	9-20	mechanistic target of rapamycin kinase	Homo sapiens	103-107
28524116-12	2017	Our results suggested that salinomycin induces apoptosis, which was related to ROS-mediated autophagy through regulation of the PI3K/AKT/mTOR and ERK/p38 MAPK signaling pathways.	salinomycin	27-38	mitogen-activated protein kinase 1	Homo sapiens	146-149
28524116-9	2017	Pretreatment with LY294002, an autophagy and PI3K inhibitor, enhanced the salinomycin-induced apoptosis by decreasing the AKT and mTOR activities and suppressing autophagy.	salinomycin	74-85	AKT serine/threonine kinase 1	Homo sapiens	122-125
28524116-12	2017	Our results suggested that salinomycin induces apoptosis, which was related to ROS-mediated autophagy through regulation of the PI3K/AKT/mTOR and ERK/p38 MAPK signaling pathways.	salinomycin	27-38	mitogen-activated protein kinase 1	Homo sapiens	150-153
28524116-9	2017	Pretreatment with LY294002, an autophagy and PI3K inhibitor, enhanced the salinomycin-induced apoptosis by decreasing the AKT and mTOR activities and suppressing autophagy.	salinomycin	74-85	mechanistic target of rapamycin kinase	Homo sapiens	130-134
28524116-12	2017	Our results suggested that salinomycin induces apoptosis, which was related to ROS-mediated autophagy through regulation of the PI3K/AKT/mTOR and ERK/p38 MAPK signaling pathways.	salinomycin	27-38	mitogen-activated protein kinase 1	Homo sapiens	154-158
28524116-10	2017	However, pretreatment with PD98059 and SB203580, an extracellular signal-regulated kinases (ERK), and p38 inhibitors, suppressed the salinomycin-induced autophagy by reversing the upregulation of ERK and p38.	salinomycin	133-144	mitogen-activated protein kinase 1	Homo sapiens	52-90
28524116-10	2017	However, pretreatment with PD98059 and SB203580, an extracellular signal-regulated kinases (ERK), and p38 inhibitors, suppressed the salinomycin-induced autophagy by reversing the upregulation of ERK and p38.	salinomycin	133-144	mitogen-activated protein kinase 1	Homo sapiens	92-95
28358414-0	2017	Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.	salinomycin	0-11	vascular endothelial growth factor A	Homo sapiens	107-111
28358414-0	2017	Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.	salinomycin	0-11	kinase insert domain receptor	Homo sapiens	112-118
28358414-0	2017	Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	119-122
28358414-0	2017	Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.	salinomycin	0-11	protein tyrosine kinase 2	Homo sapiens	123-126
28358414-6	2017	Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs.	salinomycin	62-65	protein tyrosine kinase 2	Homo sapiens	86-89
28358414-6	2017	Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs.	salinomycin	62-65	AKT serine/threonine kinase 1	Homo sapiens	94-97
28358414-6	2017	Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs.	salinomycin	62-65	vascular endothelial growth factor A	Homo sapiens	133-167
28358414-6	2017	Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs.	salinomycin	62-65	vascular endothelial growth factor A	Homo sapiens	169-173
28358414-7	2017	Pretreatment of cells with a PI3K inhibitor (LY294002) and FAK inhibitor (PF562271) markedly enhanced SAL-induced inhibition of HUVEC proliferation and migration, respectively.	salinomycin	102-105	protein tyrosine kinase 2	Homo sapiens	59-62
28358414-8	2017	Moreover, U251 human glioma xenograft growth was also effectively blocked by SAL treatment in vivo via inhibition of angiogenesis involving FAK and AKT depho-sphorylation.	salinomycin	77-80	protein tyrosine kinase 2	Homo sapiens	140-143
28358414-8	2017	Moreover, U251 human glioma xenograft growth was also effectively blocked by SAL treatment in vivo via inhibition of angiogenesis involving FAK and AKT depho-sphorylation.	salinomycin	77-80	AKT serine/threonine kinase 1	Homo sapiens	148-151
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	44-47	vascular endothelial growth factor A	Homo sapiens	121-125
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	44-47	kinase insert domain receptor	Homo sapiens	126-132
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	44-47	AKT serine/threonine kinase 1	Homo sapiens	133-136
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	44-47	protein tyrosine kinase 2	Homo sapiens	137-140
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	197-200	vascular endothelial growth factor A	Homo sapiens	121-125
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	197-200	kinase insert domain receptor	Homo sapiens	126-132
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	197-200	AKT serine/threonine kinase 1	Homo sapiens	133-136
28358414-9	2017	Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.	salinomycin	197-200	protein tyrosine kinase 2	Homo sapiens	137-140
26461472-1	2017	Here, we showed the antibiotic salinomycin (SAL) combined with GEF exerted synergistic cytotoxicity effects in colorectal cancer cells irrespective of their EGFR and KRAS status, with a relatively low toxicity to normal cells.	salinomycin	31-42	epidermal growth factor receptor	Mus musculus	157-161
26461472-1	2017	Here, we showed the antibiotic salinomycin (SAL) combined with GEF exerted synergistic cytotoxicity effects in colorectal cancer cells irrespective of their EGFR and KRAS status, with a relatively low toxicity to normal cells.	salinomycin	31-42	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	166-170
26461472-1	2017	Here, we showed the antibiotic salinomycin (SAL) combined with GEF exerted synergistic cytotoxicity effects in colorectal cancer cells irrespective of their EGFR and KRAS status, with a relatively low toxicity to normal cells.	salinomycin	44-47	epidermal growth factor receptor	Mus musculus	157-161
28373437-7	2017	Interestingly, treatment of N-acetyl-L-cysteine (NAC), a scavenger of ROS, attenuated salinomycin-induced apoptosis and autophagy.	salinomycin	86-97	X-linked Kx blood group	Homo sapiens	49-52
28927939-8	2017	RESULTS: Salinomycin suppressed the proliferation of pancreatic cancer cells in a concentration dependent manner, and reduced the CD133 positive fraction.	salinomycin	9-20	prominin 1	Homo sapiens	130-135
27995497-6	2017	Mechanically, salinomycin-induced cell growth inhibition against human glioma was mainly achieved by induction of G1-phase arrest via triggering reactive oxide species (ROS)-mediated DNA damage, as convinced by the activation of histone, p53, p21 and p27.	salinomycin	14-25	tumor protein p53	Homo sapiens	238-241
27995497-6	2017	Mechanically, salinomycin-induced cell growth inhibition against human glioma was mainly achieved by induction of G1-phase arrest via triggering reactive oxide species (ROS)-mediated DNA damage, as convinced by the activation of histone, p53, p21 and p27.	salinomycin	14-25	H3 histone pseudogene 16	Homo sapiens	243-246
27995497-6	2017	Mechanically, salinomycin-induced cell growth inhibition against human glioma was mainly achieved by induction of G1-phase arrest via triggering reactive oxide species (ROS)-mediated DNA damage, as convinced by the activation of histone, p53, p21 and p27.	salinomycin	14-25	interferon alpha inducible protein 27	Homo sapiens	251-254
28179289-0	2017	Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	22-27
28179289-0	2017	Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.	salinomycin	0-11	signal transducer and activator of transcription 1	Homo sapiens	32-37
28179289-8	2017	RESULTS: IL-6 and TNF-alpha induced STAT3 and STAT1 interactions, however the interactions were abolished by salinomycin challenge.	salinomycin	109-120	interleukin 6	Homo sapiens	9-13
28179289-8	2017	RESULTS: IL-6 and TNF-alpha induced STAT3 and STAT1 interactions, however the interactions were abolished by salinomycin challenge.	salinomycin	109-120	tumor necrosis factor	Homo sapiens	18-27
28179289-8	2017	RESULTS: IL-6 and TNF-alpha induced STAT3 and STAT1 interactions, however the interactions were abolished by salinomycin challenge.	salinomycin	109-120	signal transducer and activator of transcription 3	Homo sapiens	36-41
28133913-4	2017	We also present evidence for differential EMT across PC-3 and DU145 in vitro resistance models as characterised by differential migration, cell colony scattering and susceptibility to the CSC inhibitor salinomycin.	salinomycin	202-213	proprotein convertase subtilisin/kexin type 1	Homo sapiens	53-57
28280366-0	2017	Salinomycin repressed the epithelial-mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/beta-catenin pathway.	salinomycin	0-11	catenin beta 1	Homo sapiens	118-130
28280366-6	2017	The western blot assay showed that salinomycin could increase the expression of epithelial markers (E-cadherin and Keratin) while decrease the expression of mesenchymal markers (N-cadherin and vimentin) in a dose-dependent manner.	salinomycin	35-46	cadherin 1	Homo sapiens	100-110
28280366-6	2017	The western blot assay showed that salinomycin could increase the expression of epithelial markers (E-cadherin and Keratin) while decrease the expression of mesenchymal markers (N-cadherin and vimentin) in a dose-dependent manner.	salinomycin	35-46	cadherin 2	Homo sapiens	178-188
28280366-6	2017	The western blot assay showed that salinomycin could increase the expression of epithelial markers (E-cadherin and Keratin) while decrease the expression of mesenchymal markers (N-cadherin and vimentin) in a dose-dependent manner.	salinomycin	35-46	vimentin	Homo sapiens	193-201
28280366-8	2017	Besides, salinomycin could downregulate the expression of proteins associated with the Wnt/beta-catenin pathway and repress the nuclear translocation of beta-catenin.	salinomycin	9-20	catenin beta 1	Homo sapiens	91-103
28280366-8	2017	Besides, salinomycin could downregulate the expression of proteins associated with the Wnt/beta-catenin pathway and repress the nuclear translocation of beta-catenin.	salinomycin	9-20	catenin beta 1	Homo sapiens	153-165
28280366-9	2017	It was also shown that salinomycin could reverse the aberrant activation of the canonical Wnt pathway induced by GSK-3beta inhibitor (SB216763).	salinomycin	23-34	glycogen synthase kinase 3 beta	Homo sapiens	113-122
28280366-11	2017	In addition, the inhibitive effect of salinomycin on the invasive ability was mediated by repressing the epithelial-mesenchymal transition (EMT) program, which may be achieved through its inhibition of the Wnt/beta-catenin pathway.	salinomycin	38-49	catenin beta 1	Homo sapiens	210-222
27740704-6	2017	Mechanistically, the importance of the ionophore properties of salinomycin is highlighted by a significant loss of activity by modifications directly interfering with either of the two primary ion coordinating motifs in salinomycin, the C11 ketone and the C1 carboxylate.	salinomycin	63-74	aldo-keto reductase family 1 member C4	Homo sapiens	237-240
28676857-5	2017	A mechanistic study found salinomycin suppressed Wnt/beta-catenin pathway to induce apoptosis of PC-3 cells.	salinomycin	26-37	catenin beta 1	Homo sapiens	53-65
28676857-6	2017	An in vivo experiment confirmed that salinomycin suppressed tumorigenesis in a NOD/SCID mice xenograft model generated from implanted PC-3 cells by inhibiting the Wnt/beta-catenin pathway, since the total beta-catenin protein level was reduced and the downstream target c-Myc level was significantly downregulated.	salinomycin	37-48	catenin (cadherin associated protein), beta 1	Mus musculus	167-179
28676857-6	2017	An in vivo experiment confirmed that salinomycin suppressed tumorigenesis in a NOD/SCID mice xenograft model generated from implanted PC-3 cells by inhibiting the Wnt/beta-catenin pathway, since the total beta-catenin protein level was reduced and the downstream target c-Myc level was significantly downregulated.	salinomycin	37-48	catenin (cadherin associated protein), beta 1	Mus musculus	205-217
27666600-0	2016	Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	102-105
27666600-5	2016	Knockdown of TS using small interfering RNA (siRNA) or inhibiting AKT activity with PI3K inhibitor LY294002 enhanced the cytotoxicity and cell growth inhibition of salinomycin.	salinomycin	164-175	thymidylate synthetase	Homo sapiens	13-15
27666600-0	2016	Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.	salinomycin	0-11	thymidylate synthetase	Homo sapiens	116-136
27666600-5	2016	Knockdown of TS using small interfering RNA (siRNA) or inhibiting AKT activity with PI3K inhibitor LY294002 enhanced the cytotoxicity and cell growth inhibition of salinomycin.	salinomycin	164-175	AKT serine/threonine kinase 1	Homo sapiens	66-69
27666600-6	2016	A combination of cisplatin and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-AKT, and TS expression.	salinomycin	31-42	AKT serine/threonine kinase 1	Homo sapiens	185-188
27666600-4	2016	In this study, we showed that salinomycin (0.5-2mug/mL) treatment down-regulating of TS expression in an AKT inactivation manner in two NSCLC cell lines, human lung adenocarcinoma A549 and squamous cell carcinoma H1703 cells.	salinomycin	30-41	thymidylate synthetase	Homo sapiens	85-87
27666600-6	2016	A combination of cisplatin and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-AKT, and TS expression.	salinomycin	31-42	thymidylate synthetase	Homo sapiens	194-196
27666600-7	2016	Overexpression of a constitutive active AKT (AKT-CA) expression vector reversed the salinomycin and cisplatin-induced synergistic cytotoxicity.	salinomycin	84-95	AKT serine/threonine kinase 1	Homo sapiens	40-43
27666600-4	2016	In this study, we showed that salinomycin (0.5-2mug/mL) treatment down-regulating of TS expression in an AKT inactivation manner in two NSCLC cell lines, human lung adenocarcinoma A549 and squamous cell carcinoma H1703 cells.	salinomycin	30-41	AKT serine/threonine kinase 1	Homo sapiens	105-108
27666600-7	2016	Overexpression of a constitutive active AKT (AKT-CA) expression vector reversed the salinomycin and cisplatin-induced synergistic cytotoxicity.	salinomycin	84-95	AKT serine/threonine kinase 1	Homo sapiens	45-51
27612428-0	2016	Low-dose salinomycin induces anti-leukemic responses in AML and MLL.	salinomycin	9-20	lysine methyltransferase 2A	Homo sapiens	64-67
27666600-9	2016	Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the cisplatin-induced cytotoxicity in NSCLC cells.	salinomycin	81-92	AKT serine/threonine kinase 1	Homo sapiens	51-54
27666600-9	2016	Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the cisplatin-induced cytotoxicity in NSCLC cells.	salinomycin	81-92	thymidylate synthetase	Homo sapiens	64-66
27765904-0	2016	Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.	salinomycin	61-72	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	18-26
27765904-4	2016	Here we characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells.	salinomycin	93-104	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	22-68
27765904-4	2016	Here we characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells.	salinomycin	93-104	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	70-78
27765904-5	2016	DNA-PKcs inhibitors (NU7026, NU7441 and LY294002) or DNA-PKcs shRNA knockdown dramatically potentiated salinomycin-induced death and apoptosis of OS cells (U2OS and MG-63 lines).	salinomycin	103-114	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-8
27765904-5	2016	DNA-PKcs inhibitors (NU7026, NU7441 and LY294002) or DNA-PKcs shRNA knockdown dramatically potentiated salinomycin-induced death and apoptosis of OS cells (U2OS and MG-63 lines).	salinomycin	103-114	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	53-61
27765904-7	2016	Reversely, over-expression of DNA-PKcs in OS cells inhibited salinomycin"s lethality.	salinomycin	61-72	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	30-38
27765904-8	2016	For the mechanism study, we show that DNA-PKcs is required for salinomycin-induced pro-survival autophagy activation.	salinomycin	63-74	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	38-46
27765904-9	2016	DNA-PKcs inhibition (by NU7441), shRNA knockdown or miR-101 expression inhibited salinomycin-induced Beclin-1 expression and autophagy induction.	salinomycin	81-92	beclin 1	Homo sapiens	101-109
27765904-10	2016	Meanwhile, knockdown of Beclin-1 by shRNA significantly sensitized salinomycin-induced OS cell lethality.	salinomycin	67-78	beclin 1	Homo sapiens	24-32
27765904-11	2016	In vivo, salinomycin administration suppressed U2OS xenograft tumor growth in severe combined immuno-deficient (SCID) mice, and its anti-tumor activity was dramatically potentiated with co-administration of the DNA-PKcs inhibitor NU7026.	salinomycin	9-20	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	211-219
27765904-12	2016	Together, these results suggest that DNA-PKcs could be a primary resistance factor of salinomycin in OS cells.	salinomycin	86-97	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	37-45
27765904-13	2016	DNA-PKcs inhibition or silence may thus significantly increase salinomycin"s sensitivity in OS cells.	salinomycin	63-74	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-8
27855654-0	2016	Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/beta-catenin signaling in CD133+ human colorectal cancer cells.	salinomycin	0-11	catenin beta 1	Homo sapiens	81-93
27855654-12	2016	Interference with Wnt signaling and reduced expression of the Wnt target genes Fibronectin and Lgr5 indicates a novel molecular mechanism, mediating anti-tumoral effects of Sal in CRC.	salinomycin	173-176	fibronectin 1	Homo sapiens	79-90
27855654-12	2016	Interference with Wnt signaling and reduced expression of the Wnt target genes Fibronectin and Lgr5 indicates a novel molecular mechanism, mediating anti-tumoral effects of Sal in CRC.	salinomycin	173-176	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	95-99
27855654-14	2016	Furthermore, Sal acts as an inhibitor of Wnt/beta-catenin signaling.	salinomycin	13-16	catenin beta 1	Homo sapiens	45-57
27612428-8	2016	Additionally, increased protein expression of p62/Sqstm1, encoded for by one of the 17 signature genes, demonstrates a role for salinomycin in aggresome/vesicle formation indicative of an autophagic response.Together, the data support the efficacy of salinomycin as an anti-leukemic at non-hemotoxic concentrations.	salinomycin	128-139	sequestosome 1	Homo sapiens	46-49
27612428-8	2016	Additionally, increased protein expression of p62/Sqstm1, encoded for by one of the 17 signature genes, demonstrates a role for salinomycin in aggresome/vesicle formation indicative of an autophagic response.Together, the data support the efficacy of salinomycin as an anti-leukemic at non-hemotoxic concentrations.	salinomycin	128-139	sequestosome 1	Homo sapiens	50-56
27612428-8	2016	Additionally, increased protein expression of p62/Sqstm1, encoded for by one of the 17 signature genes, demonstrates a role for salinomycin in aggresome/vesicle formation indicative of an autophagic response.Together, the data support the efficacy of salinomycin as an anti-leukemic at non-hemotoxic concentrations.	salinomycin	251-262	sequestosome 1	Homo sapiens	46-49
27612428-8	2016	Additionally, increased protein expression of p62/Sqstm1, encoded for by one of the 17 signature genes, demonstrates a role for salinomycin in aggresome/vesicle formation indicative of an autophagic response.Together, the data support the efficacy of salinomycin as an anti-leukemic at non-hemotoxic concentrations.	salinomycin	251-262	sequestosome 1	Homo sapiens	50-56
26973241-4	2016	Here, we show that salinomycin very specifically interferes with the activity of K-ras4B, but not H-ras, by disrupting its nanoscale membrane organization.	salinomycin	19-30	KRAS proto-oncogene, GTPase	Homo sapiens	81-88
26973241-6	2016	On the basis of this novel mechanistic insight, we defined a K-ras-associated and stem cell-derived gene expression signature that predicts the drug response of cancer cells to salinomycin.	salinomycin	177-188	KRAS proto-oncogene, GTPase	Homo sapiens	61-66
27457761-6	2016	However, two salinomycin derivatives (salinomycin n-butyl amide and salinomycin 2,2,2-trifluoroethyl ester) were identified that showed increased anti-trypanosomal activity with 50 % growth inhibition values in the mid nanomolar range and minimum inhibitory concentrations of below 1 muM similar to suramin, a drug used in the treatment of sleeping sickness.	salinomycin	13-24	latexin	Homo sapiens	284-287
27557496-4	2016	AR expression, its transcriptional activity, and androgen biosynthesis regulating enzymes CYP17A1, HSD3beta1 were reduced by sub-micro molar salinomycin.	salinomycin	141-152	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	90-97
27557496-12	2016	Our novel finding on dual inhibition of AR and mTORC1 suggests that salinomycin is potentially active as monotherapy against advanced prostate cancer.	salinomycin	68-79	androgen receptor	Homo sapiens	40-42
27557496-12	2016	Our novel finding on dual inhibition of AR and mTORC1 suggests that salinomycin is potentially active as monotherapy against advanced prostate cancer.	salinomycin	68-79	CREB regulated transcription coactivator 1	Mus musculus	47-53
27409163-4	2016	We have found that salinomycin induces an additional cytotoxic effect by inhibiting the ligand independent activation of ERalpha.	salinomycin	19-30	estrogen receptor 1	Homo sapiens	121-128
27557496-0	2016	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.	salinomycin	50-61	CREB regulated transcription coactivator 1	Mus musculus	40-46
27557496-3	2016	We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors.	salinomycin	30-41	androgen receptor	Homo sapiens	88-90
27557496-3	2016	We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors.	salinomycin	30-41	CREB regulated transcription coactivator 1	Mus musculus	95-101
27557496-3	2016	We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors.	salinomycin	30-41	phosphatase and tensin homolog	Homo sapiens	124-128
27557496-4	2016	AR expression, its transcriptional activity, and androgen biosynthesis regulating enzymes CYP17A1, HSD3beta1 were reduced by sub-micro molar salinomycin.	salinomycin	141-152	androgen receptor	Homo sapiens	0-2
27045981-0	2016	CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel.	salinomycin	124-135	CD44 molecule (Indian blood group)	Homo sapiens	0-4
27058891-0	2016	Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.	salinomycin	0-11	kinase insert domain receptor	Homo sapiens	81-126
27462592-10	2016	And growth inhibition of OVCAR3 CD44(+)CD117(+) cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.	salinomycin	82-93	CD44 molecule (Indian blood group)	Homo sapiens	32-36
27462592-10	2016	And growth inhibition of OVCAR3 CD44(+)CD117(+) cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.	salinomycin	82-93	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	39-44
27462592-12	2016	Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44(+)CD117(+) cells.	salinomycin	47-58	CD44 molecule (Indian blood group)	Homo sapiens	100-104
27462592-12	2016	Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44(+)CD117(+) cells.	salinomycin	47-58	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	107-112
27035160-8	2016	Inhibition of PI3-kinase, ERK-1/2, and p38 kinase with LY294002, PD98059, and SB203580, respectively, in the presence of SAL suppressed the metastatic capacity by reducing MMP-2 expression, as determined by gelatin zymography.	salinomycin	121-124	mitogen-activated protein kinase 3	Homo sapiens	26-33
27035160-8	2016	Inhibition of PI3-kinase, ERK-1/2, and p38 kinase with LY294002, PD98059, and SB203580, respectively, in the presence of SAL suppressed the metastatic capacity by reducing MMP-2 expression, as determined by gelatin zymography.	salinomycin	121-124	mitogen-activated protein kinase 1	Homo sapiens	39-42
27035160-8	2016	Inhibition of PI3-kinase, ERK-1/2, and p38 kinase with LY294002, PD98059, and SB203580, respectively, in the presence of SAL suppressed the metastatic capacity by reducing MMP-2 expression, as determined by gelatin zymography.	salinomycin	121-124	matrix metallopeptidase 2	Homo sapiens	172-177
27035160-10	2016	In conclusion, SAL significantly increases the metastatic capacity of HT1080 cells by inducing MMP-2 expression via PI3-kinase and MAPK pathways.	salinomycin	15-18	matrix metallopeptidase 2	Homo sapiens	95-100
27035160-10	2016	In conclusion, SAL significantly increases the metastatic capacity of HT1080 cells by inducing MMP-2 expression via PI3-kinase and MAPK pathways.	salinomycin	15-18	mitogen-activated protein kinase 3	Homo sapiens	131-135
27035160-0	2016	Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways.	salinomycin	0-11	matrix metallopeptidase 2	Homo sapiens	82-87
27035160-0	2016	Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways.	salinomycin	0-11	mitogen-activated protein kinase 3	Homo sapiens	115-122
27035160-0	2016	Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways.	salinomycin	0-11	mitogen-activated protein kinase 1	Homo sapiens	127-130
27035160-4	2016	Treatment of SAL promoted the expression and activation of MMP-2 in a dose- and time-dependent manner, as detected by western blot analysis, gelatin zymography, and real-time polymerase chain reaction.	salinomycin	13-16	matrix metallopeptidase 2	Homo sapiens	59-64
27058891-4	2016	In this study, we describe a novel and safely VEGFR2 inhibitor, Salinomycin (Sal), which was screened from the drug libraries of Food and Drug Administration (FDA) and prohibited the binding of the ATP at its binding pocket of VEGFR2 using molecular docking model.	salinomycin	64-67	kinase insert domain receptor	Homo sapiens	227-233
27058891-5	2016	Sal could interfere a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation in HUVECS in vitro.	salinomycin	0-3	vascular endothelial growth factor A	Homo sapiens	32-36
27058891-7	2016	We found that Sal significantly decreased VEGF-induced phosphorylation of VEGFR2 and its downstream STAT3 in dose- and time-dependent manner in HUVECs.	salinomycin	14-17	vascular endothelial growth factor A	Homo sapiens	42-46
27058891-7	2016	We found that Sal significantly decreased VEGF-induced phosphorylation of VEGFR2 and its downstream STAT3 in dose- and time-dependent manner in HUVECs.	salinomycin	14-17	kinase insert domain receptor	Homo sapiens	74-80
27058891-7	2016	We found that Sal significantly decreased VEGF-induced phosphorylation of VEGFR2 and its downstream STAT3 in dose- and time-dependent manner in HUVECs.	salinomycin	14-17	signal transducer and activator of transcription 3	Homo sapiens	100-105
27058891-9	2016	Sal inhibited constitutive STAT3 activation by blocking its DNA binding and reduced various gene products including Bcl-2, Bcl-xL and VEGF both at mRNA and protein levels.	salinomycin	0-3	signal transducer and activator of transcription 3	Homo sapiens	27-32
27058891-9	2016	Sal inhibited constitutive STAT3 activation by blocking its DNA binding and reduced various gene products including Bcl-2, Bcl-xL and VEGF both at mRNA and protein levels.	salinomycin	0-3	BCL2 apoptosis regulator	Homo sapiens	116-121
27058891-9	2016	Sal inhibited constitutive STAT3 activation by blocking its DNA binding and reduced various gene products including Bcl-2, Bcl-xL and VEGF both at mRNA and protein levels.	salinomycin	0-3	BCL2 like 1	Homo sapiens	123-129
27058891-9	2016	Sal inhibited constitutive STAT3 activation by blocking its DNA binding and reduced various gene products including Bcl-2, Bcl-xL and VEGF both at mRNA and protein levels.	salinomycin	0-3	vascular endothelial growth factor A	Homo sapiens	134-138
27058891-4	2016	In this study, we describe a novel and safely VEGFR2 inhibitor, Salinomycin (Sal), which was screened from the drug libraries of Food and Drug Administration (FDA) and prohibited the binding of the ATP at its binding pocket of VEGFR2 using molecular docking model.	salinomycin	64-75	kinase insert domain receptor	Homo sapiens	46-52
27058891-4	2016	In this study, we describe a novel and safely VEGFR2 inhibitor, Salinomycin (Sal), which was screened from the drug libraries of Food and Drug Administration (FDA) and prohibited the binding of the ATP at its binding pocket of VEGFR2 using molecular docking model.	salinomycin	64-75	kinase insert domain receptor	Homo sapiens	227-233
27058891-4	2016	In this study, we describe a novel and safely VEGFR2 inhibitor, Salinomycin (Sal), which was screened from the drug libraries of Food and Drug Administration (FDA) and prohibited the binding of the ATP at its binding pocket of VEGFR2 using molecular docking model.	salinomycin	64-67	kinase insert domain receptor	Homo sapiens	46-52
26827662-2	2016	Here, we propose to evaluate the potential therapeutic efficacy of combining Paclitaxel and Salinomycin drugs actively targeted to both breast cancer and CSCs in xenograft murine model after conjugation with biocompatible CD44 antibody conjugated SWCNTs via hydrazone linker allowing pH-responsive release mechanism near the acidic tumor microenvironment.	salinomycin	92-103	CD44 antigen	Mus musculus	222-226
27033598-6	2016	As a result, salinomycin triggered apoptosis of U2OS cells, which was accompanied by change of MMP and cleavage of caspases-3 and poly (ADP-ribose) polymerase.	salinomycin	13-24	poly(ADP-ribose) polymerase 1	Homo sapiens	115-158
27033598-8	2016	Salinomycin-induced ROS production promotes both apoptosis and autophagy, as evidenced by the result that treatment of N-acetyl-l-cysteine (NAC), a ROS scavenger, attenuated both apoptosis and autophagy.	salinomycin	0-11	X-linked Kx blood group	Homo sapiens	140-143
27073581-0	2016	The impact of metformin and salinomycin on transforming growth factor beta-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines.	salinomycin	28-39	transforming growth factor beta 1	Homo sapiens	43-74
27073581-7	2016	Metformin or salinomycin was added simultaneously with TGFbeta to inhibit TGFbeta-induced EMT.	salinomycin	13-24	transforming growth factor beta 1	Homo sapiens	74-81
26896736-0	2016	Salinomycin suppresses TGF-beta1-induced epithelial-to-mesenchymal transition in MCF-7 human breast cancer cells.	salinomycin	0-11	transforming growth factor beta 1	Homo sapiens	23-32
26896736-4	2016	In the present study, we showed that Sal reversed transforming growth factor-beta1 (TGF-beta1) induced invasion and metastasis accompanied with down-regulation of MMP-2 by experiments on human breast cancer cell line MCF-7.	salinomycin	37-40	transforming growth factor beta 1	Homo sapiens	50-82
26896736-4	2016	In the present study, we showed that Sal reversed transforming growth factor-beta1 (TGF-beta1) induced invasion and metastasis accompanied with down-regulation of MMP-2 by experiments on human breast cancer cell line MCF-7.	salinomycin	37-40	transforming growth factor beta 1	Homo sapiens	84-93
26896736-4	2016	In the present study, we showed that Sal reversed transforming growth factor-beta1 (TGF-beta1) induced invasion and metastasis accompanied with down-regulation of MMP-2 by experiments on human breast cancer cell line MCF-7.	salinomycin	37-40	matrix metallopeptidase 2	Homo sapiens	163-168
26896736-5	2016	Sal was able to inhibit TGF-beta1-induced EMT phenotypic transition and the activation of key signaling molecules involved in Smad (p-Smad2/3,Snail1) and non-Smad (beta-catenin, p-p38 MAPK) signals which cooperatively regulate the induction of EMT.	salinomycin	0-3	transforming growth factor beta 1	Homo sapiens	24-33
26896736-5	2016	Sal was able to inhibit TGF-beta1-induced EMT phenotypic transition and the activation of key signaling molecules involved in Smad (p-Smad2/3,Snail1) and non-Smad (beta-catenin, p-p38 MAPK) signals which cooperatively regulate the induction of EMT.	salinomycin	0-3	snail family transcriptional repressor 1	Homo sapiens	142-148
26896736-5	2016	Sal was able to inhibit TGF-beta1-induced EMT phenotypic transition and the activation of key signaling molecules involved in Smad (p-Smad2/3,Snail1) and non-Smad (beta-catenin, p-p38 MAPK) signals which cooperatively regulate the induction of EMT.	salinomycin	0-3	catenin beta 1	Homo sapiens	164-176
26528725-4	2015	Salinomycin significantly induced anoikis-sensitivity, accompanied by caspase-3 and caspase-8 activation and PARP cleavage, during anchorage-independent growth.	salinomycin	0-11	caspase 8	Homo sapiens	84-93
26476239-3	2016	Salinomycin-encapsulated polysorbate 80-coated poly(lactic-co-glycolic acid) nanoparticles (P80-SAL-PLGA) were prepared and characterized with respect to particle size, morphology, thermal properties, drug encapsulation efficiency and controlled salinomycin-release behaviour.	salinomycin	0-11	coilin	Homo sapiens	92-95
26476239-7	2016	Thus, P80-SAL-PLGA nanoparticles induced cell death, suggesting a potential therapeutic role for this salinomycin delivery system in the treatment of human glioblastoma.	salinomycin	102-113	coilin	Homo sapiens	6-9
26209294-11	2016	The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of gamma-H2AX nuclear foci.	salinomycin	24-35	BCL2 associated X, apoptosis regulator	Homo sapiens	81-84
26209294-11	2016	The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of gamma-H2AX nuclear foci.	salinomycin	24-35	caspase 3	Homo sapiens	97-105
26209294-11	2016	The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of gamma-H2AX nuclear foci.	salinomycin	24-35	BCL2 apoptosis regulator	Homo sapiens	117-122
26528725-0	2015	Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	47-51
26528725-0	2015	Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells.	salinomycin	0-11	CD24 molecule	Homo sapiens	53-57
26546046-11	2016	A549 cells overexpressing TMPRSS4 conferred the opposite phenotype and were also more sensitive to the CSC-targeted drug salinomycin than control cells, but were more resistant to regular chemotherapeutic drugs (cisplatin, gemcitabine and 5-fluorouracil).	salinomycin	121-132	transmembrane serine protease 4	Homo sapiens	26-33
26528725-4	2015	Salinomycin significantly induced anoikis-sensitivity, accompanied by caspase-3 and caspase-8 activation and PARP cleavage, during anchorage-independent growth.	salinomycin	0-11	collagen type XI alpha 2 chain	Homo sapiens	109-113
26528725-0	2015	Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	98-103
26528725-4	2015	Salinomycin significantly induced anoikis-sensitivity, accompanied by caspase-3 and caspase-8 activation and PARP cleavage, during anchorage-independent growth.	salinomycin	0-11	caspase 3	Homo sapiens	70-79
26528725-5	2015	Salinomycin treatment also caused a marked suppression of cell migration and invasion with concomitant downregulation of MMP-9 and MMP-2 mRNA levels.	salinomycin	0-11	matrix metallopeptidase 9	Homo sapiens	121-126
26528725-5	2015	Salinomycin treatment also caused a marked suppression of cell migration and invasion with concomitant downregulation of MMP-9 and MMP-2 mRNA levels.	salinomycin	0-11	matrix metallopeptidase 2	Homo sapiens	131-136
26528725-6	2015	Notably, salinomycin inhibited the formation of mammospheres and effectively reduced the CD44+/CD24- stem-like population during anchorage-independent growth.	salinomycin	9-20	CD44 molecule (Indian blood group)	Homo sapiens	89-93
26528725-6	2015	Notably, salinomycin inhibited the formation of mammospheres and effectively reduced the CD44+/CD24- stem-like population during anchorage-independent growth.	salinomycin	9-20	CD24 molecule	Homo sapiens	95-99
26528725-8	2015	Furthermore, interleukin-6 (IL-6)-induced STAT3 activation was strongly suppressed by salinomycin challenge.	salinomycin	86-97	interleukin 6	Homo sapiens	13-26
26528725-8	2015	Furthermore, interleukin-6 (IL-6)-induced STAT3 activation was strongly suppressed by salinomycin challenge.	salinomycin	86-97	interleukin 6	Homo sapiens	28-32
26528725-8	2015	Furthermore, interleukin-6 (IL-6)-induced STAT3 activation was strongly suppressed by salinomycin challenge.	salinomycin	86-97	signal transducer and activator of transcription 3	Homo sapiens	42-47
26528725-9	2015	These findings support the notion that salinomycin may be potentially efficacious for targeting breast cancer stem-like cells through the inhibition of STAT3 activation.	salinomycin	39-50	signal transducer and activator of transcription 3	Homo sapiens	152-157
26352531-3	2015	In the present study, we examined the ability of salinomycin to induce cell death in the colorectal cancer stem cell line CD44+EpCAM+ HCT-116, and we measured its in vivo tumor inhibition capacity.	salinomycin	49-60	CD44 molecule (Indian blood group)	Homo sapiens	122-126
26201092-7	2015	The expression of the critical components of Hh pathway, i.e., PTCH (Patched), SMO (Smoothened), Gli1 and Gli2, was significantly up-regulated in MCF-7 MS cells; salinomycin, but not paclitaxel, treatment caused a remarkable decrease in expression of those genes in MCF-7 MS cells, but not in MCF-7 cells.	salinomycin	162-173	patched 1	Homo sapiens	63-67
26201092-7	2015	The expression of the critical components of Hh pathway, i.e., PTCH (Patched), SMO (Smoothened), Gli1 and Gli2, was significantly up-regulated in MCF-7 MS cells; salinomycin, but not paclitaxel, treatment caused a remarkable decrease in expression of those genes in MCF-7 MS cells, but not in MCF-7 cells.	salinomycin	162-173	smoothened, frizzled class receptor	Homo sapiens	79-82
26201092-7	2015	The expression of the critical components of Hh pathway, i.e., PTCH (Patched), SMO (Smoothened), Gli1 and Gli2, was significantly up-regulated in MCF-7 MS cells; salinomycin, but not paclitaxel, treatment caused a remarkable decrease in expression of those genes in MCF-7 MS cells, but not in MCF-7 cells.	salinomycin	162-173	smoothened, frizzled class receptor	Homo sapiens	84-94
26201092-8	2015	Salinomycin, but not paclitaxel, increased apoptosis, decreased the migration capacity of MCF-7 MS cells, accompanied by a decreased expression of c-Myc, Bcl-2 and Snail, the target genes of the Hh pathway.	salinomycin	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	147-152
26201092-8	2015	Salinomycin, but not paclitaxel, increased apoptosis, decreased the migration capacity of MCF-7 MS cells, accompanied by a decreased expression of c-Myc, Bcl-2 and Snail, the target genes of the Hh pathway.	salinomycin	0-11	BCL2 apoptosis regulator	Homo sapiens	154-159
26201092-8	2015	Salinomycin, but not paclitaxel, increased apoptosis, decreased the migration capacity of MCF-7 MS cells, accompanied by a decreased expression of c-Myc, Bcl-2 and Snail, the target genes of the Hh pathway.	salinomycin	0-11	snail family transcriptional repressor 1	Homo sapiens	164-169
26201092-9	2015	The salinomycin-induced cytotoxic effect could be blocked by Shh (Sonic Hedgehog)-mediated Hh signalling activation.	salinomycin	4-15	sonic hedgehog signaling molecule	Homo sapiens	61-64
26201092-9	2015	The salinomycin-induced cytotoxic effect could be blocked by Shh (Sonic Hedgehog)-mediated Hh signalling activation.	salinomycin	4-15	sonic hedgehog signaling molecule	Homo sapiens	66-80
26201092-11	2015	In addition, salinomycin, but not paclitaxel, significantly reduced the tumour growth, accompanied by decreased expression of PTCH, SMO, Gli1 and Gli2 in xenograft tumours.	salinomycin	13-24	patched 1	Homo sapiens	126-130
26201092-11	2015	In addition, salinomycin, but not paclitaxel, significantly reduced the tumour growth, accompanied by decreased expression of PTCH, SMO, Gli1 and Gli2 in xenograft tumours.	salinomycin	13-24	smoothened, frizzled class receptor	Homo sapiens	132-135
26201092-11	2015	In addition, salinomycin, but not paclitaxel, significantly reduced the tumour growth, accompanied by decreased expression of PTCH, SMO, Gli1 and Gli2 in xenograft tumours.	salinomycin	13-24	GLI family zinc finger 1	Homo sapiens	137-141
26201092-11	2015	In addition, salinomycin, but not paclitaxel, significantly reduced the tumour growth, accompanied by decreased expression of PTCH, SMO, Gli1 and Gli2 in xenograft tumours.	salinomycin	13-24	GLI family zinc finger 2	Homo sapiens	146-150
26228105-10	2015	It was also observed that SAL micellar formulations inhibited invasion and harnessed EMT in spite of induced expression of Snail.	salinomycin	26-29	snail family transcriptional repressor 1	Homo sapiens	123-128
26352531-3	2015	In the present study, we examined the ability of salinomycin to induce cell death in the colorectal cancer stem cell line CD44+EpCAM+ HCT-116, and we measured its in vivo tumor inhibition capacity.	salinomycin	49-60	epithelial cell adhesion molecule	Homo sapiens	127-132
26352531-4	2015	Salinomycin dose-dependently induced cytotoxicity in the CD44+EpCAM+ HCT-116 cells and inhibited colony formation.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	57-61
26352531-4	2015	Salinomycin dose-dependently induced cytotoxicity in the CD44+EpCAM+ HCT-116 cells and inhibited colony formation.	salinomycin	0-11	epithelial cell adhesion molecule	Homo sapiens	62-67
26352531-5	2015	Salinomycin treatment was shown to induce apoptosis, as evidenced by nuclear fragmentation, an increase in the proportion of acridine orange/ethidium bromide-positive cells and an increase in the percentage of Annexin V-positive cells.	salinomycin	0-11	annexin A5	Homo sapiens	210-219
26352531-8	2015	In addition, salinomycin treatment of xenograft mice inhibited the growth of tumors derived from the CD44+EpCAM+ HCT-116 cells.	salinomycin	13-24	CD44 antigen	Mus musculus	101-105
26352531-8	2015	In addition, salinomycin treatment of xenograft mice inhibited the growth of tumors derived from the CD44+EpCAM+ HCT-116 cells.	salinomycin	13-24	epithelial cell adhesion molecule	Mus musculus	106-111
26492365-8	2015	Compatible with its direct modulation of mitochondrial function, salinomycin was able to induce cell death also in Bax/Bak-less double-knockout MEF cells.	salinomycin	65-76	BCL2 associated X, apoptosis regulator	Homo sapiens	115-118
26407842-4	2015	Salinomycin suppressed cell viability, concomitant with the downregulation of cyclin D1 and increased p27(kip1) nuclear accumulation.	salinomycin	0-11	cyclin D1	Homo sapiens	78-87
26407842-4	2015	Salinomycin suppressed cell viability, concomitant with the downregulation of cyclin D1 and increased p27(kip1) nuclear accumulation.	salinomycin	0-11	interferon alpha inducible protein 27	Homo sapiens	102-105
26407842-4	2015	Salinomycin suppressed cell viability, concomitant with the downregulation of cyclin D1 and increased p27(kip1) nuclear accumulation.	salinomycin	0-11	cyclin dependent kinase inhibitor 1B	Homo sapiens	106-110
26407842-5	2015	Mammosphere formation assays revealed that salinomycin suppresses self-renewal of ALDH1-positive BCSCs and downregulates the transcription factors Nanog, Oct4 and Sox2.	salinomycin	43-54	aldehyde dehydrogenase 1 family member A1	Homo sapiens	82-87
26407842-5	2015	Mammosphere formation assays revealed that salinomycin suppresses self-renewal of ALDH1-positive BCSCs and downregulates the transcription factors Nanog, Oct4 and Sox2.	salinomycin	43-54	Nanog homeobox	Homo sapiens	147-152
26407842-5	2015	Mammosphere formation assays revealed that salinomycin suppresses self-renewal of ALDH1-positive BCSCs and downregulates the transcription factors Nanog, Oct4 and Sox2.	salinomycin	43-54	POU class 5 homeobox 1	Homo sapiens	154-158
26407842-5	2015	Mammosphere formation assays revealed that salinomycin suppresses self-renewal of ALDH1-positive BCSCs and downregulates the transcription factors Nanog, Oct4 and Sox2.	salinomycin	43-54	SRY-box transcription factor 2	Homo sapiens	163-167
26407842-6	2015	TUNEL analysis of MDA-MB-231-derived xenografts revealed that salinomycin administration elicited a significant reduction in tumor growth with a marked downregulation of ALDH1 and CD44 levels, but seemingly without the induction of apoptosis.	salinomycin	62-73	aldehyde dehydrogenase 1 family member A1	Homo sapiens	170-175
26407842-6	2015	TUNEL analysis of MDA-MB-231-derived xenografts revealed that salinomycin administration elicited a significant reduction in tumor growth with a marked downregulation of ALDH1 and CD44 levels, but seemingly without the induction of apoptosis.	salinomycin	62-73	CD44 molecule (Indian blood group)	Homo sapiens	180-184
26492365-8	2015	Compatible with its direct modulation of mitochondrial function, salinomycin was able to induce cell death also in Bax/Bak-less double-knockout MEF cells.	salinomycin	65-76	BCL2 antagonist/killer 1	Homo sapiens	119-122
26492365-9	2015	Since at the concentration range used in most studies (around 10 muM) salinomycin exerts its effect at the level of mitochondria and alters bioenergetic performance, the specificity of its action on pathologic B cells isolated from patients with chronic lymphocytic leukemia (CLL) versus B cells from healthy subjects was investigated.	salinomycin	70-81	latexin	Homo sapiens	65-68
26492365-12	2015	The results indicate that salinomycin, when used above muM concentrations, exerts direct, mitochondrial effects, thus compromising cell survival.	salinomycin	26-37	latexin	Homo sapiens	55-58
26282489-6	2015	SAL metabolism is mainly mediated by CYP enzymes; CYP3A4 the major enzyme metabolising SAL.	salinomycin	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
26282489-6	2015	SAL metabolism is mainly mediated by CYP enzymes; CYP3A4 the major enzyme metabolising SAL.	salinomycin	87-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
26282489-9	2015	SAL was found to be a moderate inhibitor of CYP2D6 as well as CYP3A4.	salinomycin	0-3	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
26282489-9	2015	SAL was found to be a moderate inhibitor of CYP2D6 as well as CYP3A4.	salinomycin	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
26282489-10	2015	As CYP3A4 was the major enzyme responsible for metabolism of SAL, in vivo pharmacokinetic study in rats was done to check the effect of concomitant administration of Ketoconazole (KTC) on SAL pharmacokinetics.	salinomycin	61-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	3-9
26254364-4	2015	Furthermore, fluorescence-activated cell sorting (FACS) analysis, Hoechst staining, and annexin V staining revealed that co-treatment with salinomycin sensitizes AZD5363-treated cancer cells via increased apoptosis with S-phase arrest.	salinomycin	139-150	annexin A5	Homo sapiens	88-97
26208903-10	2015	Maspin expression correlated with higher sensitivity to MS275 in both 2D and suspension and to salinomycin in 2D and 3D collagen I.	salinomycin	95-106	serpin family B member 5	Homo sapiens	0-6
26208903-11	2015	Our data suggest that maspin reduces prostate tumor cell plasticity and enhances tumor sensitivity to salinomycin, which may hold promise in overcoming tumor cell heterogeneity and plasticity.	salinomycin	102-113	serpin family B member 5	Homo sapiens	22-28
25904215-10	2015	Treatment of HCC1937 cells with LBH589 and salinomycin had a potent synergistic effect inhibiting TNBC cell proliferation, ALDH1-positive cells, and mammosphere growth.	salinomycin	43-54	aldehyde dehydrogenase 1 family member A1	Homo sapiens	123-128
26139123-0	2015	The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.	salinomycin	17-28	epidermal growth factor receptor	Mus musculus	80-84
26139123-0	2015	The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.	salinomycin	17-28	prominin 1	Mus musculus	89-94
26139123-1	2015	AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133.	salinomycin	17-28	prominin 1	Mus musculus	101-106
26139123-1	2015	AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133.	salinomycin	17-28	epidermal growth factor receptor	Mus musculus	124-128
26139123-1	2015	AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133.	salinomycin	17-28	carboxylesterase 1C	Mus musculus	143-147
26139123-1	2015	AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133.	salinomycin	17-28	epidermal growth factor receptor	Mus musculus	223-227
26139123-1	2015	AIMS: To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133.	salinomycin	17-28	prominin 1	Mus musculus	232-237
26139123-3	2015	RESULTS & CONCLUSION: The cytotoxicity of CESN in HCC cells and CD133(+) HCC cells was superior to that of A15 or CL4-conjugted or nontargeted salinomycin-loaded nanoparticles.	salinomycin	147-158	carboxylesterase 1C	Mus musculus	46-50
26139123-5	2015	We speculated that the improved therapeutic effect of CESN may be attributed to both targeting a higher percentage of HCC cells and increased delivery of salinomycin to HCC cells.	salinomycin	154-165	carboxylesterase 1C	Mus musculus	54-58
26099997-6	2015	By inhibiting the mitochondrial Na+/Ca2+ exchanger using the benzodiazepine derivate, CGP37157 (CGP), a significant reduction in salinomycin neuronal toxicity has been observed.	salinomycin	129-140	solute carrier family 8 member A1	Homo sapiens	32-50
26099997-13	2015	The HLaC79 C1 cells were more sensitive to salinomycin, compared with the FaDu cells, with this sensitivity being due to high expression levels of MDR-1 by the HLaC79 C1 cells.	salinomycin	43-54	ATP binding cassette subfamily B member 1	Homo sapiens	147-152
25904215-11	2015	In xenograft mouse models treated with LBH589 and salinomycin, the drug combination effectively and synergistically inhibited tumor growth of ALDH1-positive cells.	salinomycin	50-61	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	142-147
26024660-0	2015	ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis.	salinomycin	41-52	tumor protein p53	Homo sapiens	4-7
26704834-10	2015	RT-PCR and Western blot showed that the expression of key elements Shh, Smo and Gli1 in the Hedgehog pathway was inhibited by salinomycin in a concentration dependent manner (P < 0.05).	salinomycin	126-137	sonic hedgehog signaling molecule	Homo sapiens	67-70
26704834-10	2015	RT-PCR and Western blot showed that the expression of key elements Shh, Smo and Gli1 in the Hedgehog pathway was inhibited by salinomycin in a concentration dependent manner (P < 0.05).	salinomycin	126-137	smoothened, frizzled class receptor	Homo sapiens	72-75
26704834-10	2015	RT-PCR and Western blot showed that the expression of key elements Shh, Smo and Gli1 in the Hedgehog pathway was inhibited by salinomycin in a concentration dependent manner (P < 0.05).	salinomycin	126-137	GLI family zinc finger 1	Homo sapiens	80-84
25769976-4	2015	Primary human nasal mucosa cells (monolayer and mini organ cultures) and peripheral blood lymphocytes from 10 individuals were used to study the cytotoxic effects of salinomycin (0.1-175 muM) by annexin-propidiumiodide- and MTT-test.	salinomycin	166-177	latexin	Homo sapiens	187-190
25769976-7	2015	Flow cytometry and MTT assay revealed significant cytotoxic effects in nasal mucosa cells and lymphocytes at low salinomycin concentrations of 10-20 muM.	salinomycin	113-124	latexin	Homo sapiens	149-152
26024660-5	2015	Salinomycin induced p53 translocation to mitochondria, where it formed a complex with cyclophilin-D (CyPD).	salinomycin	0-11	tumor protein p53	Homo sapiens	20-23
26024660-5	2015	Salinomycin induced p53 translocation to mitochondria, where it formed a complex with cyclophilin-D (CyPD).	salinomycin	0-11	peptidylprolyl isomerase F	Homo sapiens	86-99
26024660-0	2015	ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis.	salinomycin	41-52	peptidylprolyl isomerase F	Homo sapiens	8-21
26024660-5	2015	Salinomycin induced p53 translocation to mitochondria, where it formed a complex with cyclophilin-D (CyPD).	salinomycin	0-11	peptidylprolyl isomerase F	Homo sapiens	101-105
26024660-7	2015	Blockade of Cyp-D by siRNA-mediated depletion or pharmacological inhibitors (cyclosporin A and sanglifehrin A) significantly suppressed salinomycin-induced glioma cell necrosis.	salinomycin	136-147	peptidylprolyl isomerase F	Homo sapiens	12-17
25871400-0	2015	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via FOXO3a activation.	salinomycin	0-11	catenin beta 1	Homo sapiens	97-109
26024660-8	2015	Meanwhile, p53 stable knockdown alleviated salinomycin-induced necrosis in glioma cells.	salinomycin	43-54	tumor protein p53	Homo sapiens	11-14
26024660-9	2015	Reactive oxygen species (ROS) production was required for salinomycin-induced p53 mitochondrial translocation, mPTP opening and necrosis, and anti-oxidants n-acetylcysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) inhibited p53 translocation, mPTP opening and glioma cell death.	salinomycin	58-69	tumor protein p53	Homo sapiens	78-81
26024660-9	2015	Reactive oxygen species (ROS) production was required for salinomycin-induced p53 mitochondrial translocation, mPTP opening and necrosis, and anti-oxidants n-acetylcysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) inhibited p53 translocation, mPTP opening and glioma cell death.	salinomycin	58-69	tumor protein p53	Homo sapiens	228-231
25871400-0	2015	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via FOXO3a activation.	salinomycin	0-11	hepatocyte nuclear factor 4 alpha	Homo sapiens	110-113
25871400-0	2015	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via FOXO3a activation.	salinomycin	0-11	forkhead box O3	Homo sapiens	138-144
25871400-5	2015	Further experiments revealed that FOXO3a, a multifunctional transcription factor that can be activated by salinomycin, was vital in mediating doxorubicin-induced EMT.	salinomycin	106-117	forkhead box O3	Homo sapiens	34-40
25522777-0	2015	Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression.	salinomycin	0-11	mitogen-activated protein kinase 8	Homo sapiens	82-85
25848270-0	2015	Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.	salinomycin	88-99	prominin 1	Homo sapiens	60-65
25848270-0	2015	Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.	salinomycin	88-99	prominin 1	Homo sapiens	112-117
25848270-5	2015	The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133(+) osteosarcoma CSCs.	salinomycin	43-54	prominin 1	Homo sapiens	89-94
25848270-6	2015	METHODS: The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evaporation method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133(+) osteosarcoma CSCs were evaluated.	salinomycin	13-24	prominin 1	Homo sapiens	111-116
25848270-6	2015	METHODS: The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evaporation method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133(+) osteosarcoma CSCs were evaluated.	salinomycin	13-24	prominin 1	Homo sapiens	247-252
25529011-6	2015	Whereas salinomycin moderately induced apoptosis and retarded proliferation at 5-10 microM, it strongly inhibited cancer cell migration that was accompanied by a marked loss of actin stress fibers after 6-9 h. Salinomycin silenced RhoA activity, and loss of stress fibers could be reversed by Rho activation.	salinomycin	8-19	ras homolog family member A	Mus musculus	231-235
25529011-6	2015	Whereas salinomycin moderately induced apoptosis and retarded proliferation at 5-10 microM, it strongly inhibited cancer cell migration that was accompanied by a marked loss of actin stress fibers after 6-9 h. Salinomycin silenced RhoA activity, and loss of stress fibers could be reversed by Rho activation.	salinomycin	210-221	ras homolog family member A	Mus musculus	231-235
25529011-7	2015	Moreover, salinomycin dislocated fascin from filopodia and stimulated Rac-associated circular dorsal ruffle formation.	salinomycin	10-21	fascin actin-bundling protein 1	Mus musculus	33-39
25522777-0	2015	Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression.	salinomycin	0-11	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
25522777-0	2015	Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression.	salinomycin	0-11	matrix metallopeptidase 9	Homo sapiens	108-112
25469339-7	2014	Salinomycin activated caspase-3, -8, and -9, causing apoptosis in uterine leiomyoma cells.	salinomycin	0-11	caspase 3	Homo sapiens	22-43
25538236-6	2015	Salinomycin (250 nm) blocked TGFbeta-dependent expression of the cardinal myofibroblast products alpha smooth muscle actin, calponin, and collagen in primary human fibroblasts without causing cell death.	salinomycin	0-11	transforming growth factor beta 1	Homo sapiens	29-36
25538236-7	2015	Salinomycin blocked phosphorylation and activation of TAK1 and p38, two proteins fundamentally involved in signaling myofibroblast and scar formation.	salinomycin	0-11	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	54-58
25538236-7	2015	Salinomycin blocked phosphorylation and activation of TAK1 and p38, two proteins fundamentally involved in signaling myofibroblast and scar formation.	salinomycin	0-11	mitogen-activated protein kinase 14	Homo sapiens	63-66
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	123-134	mitogen-activated protein kinase 14	Homo sapiens	87-90
25483103-7	2015	Targeting CD44 with salinomycin and siRNA could inhibit cell transition and decrease PCa invasion.	salinomycin	20-31	CD44 molecule (Indian blood group)	Homo sapiens	10-14
24717091-8	2014	A 48-hr exposure to salinomycin (5-100 nM) was followed by a significant increase in Fluo3-fluorescence, DCFDA fluorescence and annexin-V binding, as well as a significant decrease in forward scatter (at 5-10 nM, but not at 50 and 100 nM).	salinomycin	20-31	annexin A5	Homo sapiens	128-137
24717091-9	2014	The annexin-V binding after salinomycin treatment was significantly blunted but not abrogated in the nominal absence of extracellular Ca(2+) or in the presence of antioxidant n-acetyl cysteine (1 mM).	salinomycin	28-39	annexin A5	Homo sapiens	4-13
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	123-134	mitogen-activated protein kinase 14	Homo sapiens	212-215
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	123-134	transforming growth factor beta 1	Homo sapiens	242-249
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	188-199	mitogen-activated protein kinase 14	Homo sapiens	87-90
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	188-199	mitogen-activated protein kinase 14	Homo sapiens	212-215
25538236-8	2015	Expression of constitutively active mitogen activated kinase kinase 6, which activates p38 MAPK, attenuated the ability of salinomycin to block myofibroblast formation, demonstrating that salinomycin targets the p38 kinase pathway to disrupt TGFbeta signaling.	salinomycin	188-199	transforming growth factor beta 1	Homo sapiens	242-249
25500079-5	2014	We demonstrated that long-term salinomycin treatment of mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as E-cadherin and miR-200c, a decreased migratory capability, and a higher susceptibility to the classic chemotherapeutic drug doxorubicin.	salinomycin	31-42	cadherin 1	Homo sapiens	173-183
25500079-5	2014	We demonstrated that long-term salinomycin treatment of mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as E-cadherin and miR-200c, a decreased migratory capability, and a higher susceptibility to the classic chemotherapeutic drug doxorubicin.	salinomycin	31-42	microRNA 200c	Homo sapiens	188-196
25500079-5	2014	We demonstrated that long-term salinomycin treatment of mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as E-cadherin and miR-200c, a decreased migratory capability, and a higher susceptibility to the classic chemotherapeutic drug doxorubicin.	salinomycin	93-104	cadherin 1	Homo sapiens	173-183
25500079-5	2014	We demonstrated that long-term salinomycin treatment of mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as E-cadherin and miR-200c, a decreased migratory capability, and a higher susceptibility to the classic chemotherapeutic drug doxorubicin.	salinomycin	93-104	microRNA 200c	Homo sapiens	188-196
25500079-6	2014	The formation of salinomycin resistance through the acquisition of epithelial traits was further validated by inducing mesenchymal-epithelial transition through an overexpression of miR-200c.	salinomycin	17-28	microRNA 200c	Homo sapiens	182-190
25238228-4	2014	When pharmacological ablation of ALK oncogene was accompanied with PI3K inhibitor or salinomycin therapy, cancer stem-like cell features were reversed which was accompanied with decreased colony formation.	salinomycin	85-96	ALK receptor tyrosine kinase	Homo sapiens	33-36
25198997-2	2014	MND induced apoptosis, inhibited migration and invasion, strongly inhibited cancer stem cell population on a par with salinomycin, and demonstrated orally potent tumor regression in mouse MCF-7 xenografts.	salinomycin	118-129	CLN8 transmembrane ER and ERGIC protein	Mus musculus	0-3
24740347-0	2014	Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines.	salinomycin	0-11	TNF superfamily member 10	Homo sapiens	49-54
24841425-1	2014	Salinomycin, a naturally occurring polyether ionophore was recently found to selectively reduce the proportion of CD44(+)/CD24(-) cells, a phenotype associated with breast cancer stem cells.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	114-118
24841425-1	2014	Salinomycin, a naturally occurring polyether ionophore was recently found to selectively reduce the proportion of CD44(+)/CD24(-) cells, a phenotype associated with breast cancer stem cells.	salinomycin	0-11	CD24 molecule	Homo sapiens	122-126
24841425-7	2014	Importantly, the proportion of CD44(+)/CD24(-) cells showed a pronounced U-shaped dose response curve for salinomycin and its derivatives, but not for paclitaxel.	salinomycin	106-117	CD44 molecule (Indian blood group)	Homo sapiens	31-35
24841425-7	2014	Importantly, the proportion of CD44(+)/CD24(-) cells showed a pronounced U-shaped dose response curve for salinomycin and its derivatives, but not for paclitaxel.	salinomycin	106-117	CD24 molecule	Homo sapiens	39-43
24841425-8	2014	The concentration for maximum response in this assay followed differences in IC50 for salinomycin and its analogues, which emphasizes the importance of taking concentration dependence into account when comparing effects on the CD44(+)/CD24(-) phenotype.	salinomycin	86-97	CD44 molecule (Indian blood group)	Homo sapiens	227-231
24841425-8	2014	The concentration for maximum response in this assay followed differences in IC50 for salinomycin and its analogues, which emphasizes the importance of taking concentration dependence into account when comparing effects on the CD44(+)/CD24(-) phenotype.	salinomycin	86-97	CD24 molecule	Homo sapiens	235-239
24816638-5	2014	Sal reversed the 5-FU-induced increase in CD133(+) EPCAM(+) cells, epithelial-mesenchymal transition and activation of the Wnt/beta-catenin signaling pathway.	salinomycin	0-3	prominin 1	Homo sapiens	42-47
24816638-5	2014	Sal reversed the 5-FU-induced increase in CD133(+) EPCAM(+) cells, epithelial-mesenchymal transition and activation of the Wnt/beta-catenin signaling pathway.	salinomycin	0-3	catenin beta 1	Homo sapiens	127-139
24905570-0	2014	Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1 signaling in breast and prostate cancer cells.	salinomycin	0-11	LDL receptor related protein 6	Homo sapiens	23-27
24905570-0	2014	Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1 signaling in breast and prostate cancer cells.	salinomycin	0-11	catenin beta 1	Homo sapiens	61-73
24905570-0	2014	Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1 signaling in breast and prostate cancer cells.	salinomycin	0-11	CREB regulated transcription coactivator 1	Mus musculus	78-84
24905570-3	2014	Salinomycin is a novel small molecule inhibitor of LRP6.	salinomycin	0-11	LDL receptor related protein 6	Homo sapiens	51-55
24905570-4	2014	In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/beta-catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells.	salinomycin	118-129	LDL receptor related protein 6	Homo sapiens	36-40
24905570-4	2014	In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/beta-catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells.	salinomycin	118-129	catenin beta 1	Homo sapiens	156-168
24905570-4	2014	In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/beta-catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells.	salinomycin	118-129	CREB regulated transcription coactivator 1	Mus musculus	208-214
24905570-5	2014	Mechanistically, salinomycin activated GSK3beta in cancer cells.	salinomycin	17-28	glycogen synthase kinase 3 beta	Homo sapiens	39-47
24905570-6	2014	Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/beta-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity.	salinomycin	10-21	cyclin D1	Homo sapiens	61-70
24905570-6	2014	Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/beta-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity.	salinomycin	10-21	catenin beta 1	Homo sapiens	109-121
24905570-6	2014	Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/beta-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity.	salinomycin	10-21	CREB regulated transcription coactivator 1	Mus musculus	126-132
24960465-9	2014	In NP3-treated 4T1 orthotopic tumors, the mean CSC frequency is 55.62%, a significant reduction from the mean frequencies of untreated tumors, 75.00%, or free Sali-treated tumors, 64.32%.	salinomycin	159-163	leukemia NUP98 fusion partner 1	Homo sapiens	3-6
24740347-4	2014	Here we found that the ionophore antibiotic salinomycin acts in synergism with TRAIL, enhancing TRAIL-induced apoptosis in glioma cells.	salinomycin	44-55	TNF superfamily member 10	Homo sapiens	79-84
24740347-4	2014	Here we found that the ionophore antibiotic salinomycin acts in synergism with TRAIL, enhancing TRAIL-induced apoptosis in glioma cells.	salinomycin	44-55	TNF superfamily member 10	Homo sapiens	96-101
24740347-5	2014	Treatment with low doses of salinomycin in combination with TRAIL augmented the activation of caspase-3 and increased TRAIL-R2 cell surface expression.	salinomycin	28-39	caspase 3	Homo sapiens	94-103
24740347-5	2014	Treatment with low doses of salinomycin in combination with TRAIL augmented the activation of caspase-3 and increased TRAIL-R2 cell surface expression.	salinomycin	28-39	TNF receptor superfamily member 10b	Homo sapiens	118-126
24740347-6	2014	TRAIL-R2 upmodulation was required for mediating the stimulatory effect of salinomycin on TRAIL-mediated apoptosis, since it was abrogated by siRNA-mediated TRAIL-R2 knockdown.	salinomycin	75-86	TNF receptor superfamily member 10b	Homo sapiens	0-8
24740347-6	2014	TRAIL-R2 upmodulation was required for mediating the stimulatory effect of salinomycin on TRAIL-mediated apoptosis, since it was abrogated by siRNA-mediated TRAIL-R2 knockdown.	salinomycin	75-86	TNF superfamily member 10	Homo sapiens	0-5
24740347-6	2014	TRAIL-R2 upmodulation was required for mediating the stimulatory effect of salinomycin on TRAIL-mediated apoptosis, since it was abrogated by siRNA-mediated TRAIL-R2 knockdown.	salinomycin	75-86	TNF receptor superfamily member 10b	Homo sapiens	157-165
24740347-8	2014	Our results suggest that the combination of TRAIL and salinomycin may be a useful tool to overcome TRAIL resistance in glioma cells and may represent a potential drug for treatment of these tumors.	salinomycin	54-65	TNF superfamily member 10	Homo sapiens	99-104
24351423-4	2014	Salinomycin increased the levels of autophagosomes that correlated with increased p62 and LC3II levels; valproate co-treatment correlated with reduced LC3II and p62 expression, and increased caspase 3 cleavage.	salinomycin	0-11	nucleoporin 62	Homo sapiens	82-85
24351423-4	2014	Salinomycin increased the levels of autophagosomes that correlated with increased p62 and LC3II levels; valproate co-treatment correlated with reduced LC3II and p62 expression, and increased caspase 3 cleavage.	salinomycin	0-11	caspase 3	Homo sapiens	191-200
25478603-0	2014	Salinomycin Suppresses PDGFRbeta, MYC, and Notch Signaling in Human Medulloblastoma.	salinomycin	0-11	platelet derived growth factor receptor beta	Homo sapiens	23-32
24013721-5	2014	ZEB1 expression in MCL cells depends on Wnt, being downregulated by beta-catenin knockdown or blocking of Wnt signaling by salinomycin.	salinomycin	123-134	zinc finger E-box binding homeobox 1	Mus musculus	0-4
24013721-9	2014	Downregulation of ZEB1 by salinomycin increases the sensitivity of MCL cells to the cytotoxic effect of doxorubicin, cytarabine and gemcitabine.	salinomycin	26-37	zinc finger E-box binding homeobox 1	Mus musculus	18-22
24481453-0	2014	Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment.	salinomycin	87-98	catenin (cadherin associated protein), beta 1	Mus musculus	13-25
24481453-5	2014	Salinomycin, an antitumor agent, significantly reduced the volume of tumor caused by Wnt1-overexpressing AGS cells in vivo.	salinomycin	0-11	wingless-type MMTV integration site family, member 1	Mus musculus	85-89
25114899-4	2014	We found that the treatment of cancer cells with a high concentration of salinomycin (Sal) reduced total Akt protein levels but increased activated Akt levels.	salinomycin	73-84	AKT serine/threonine kinase 1	Homo sapiens	105-108
25114899-4	2014	We found that the treatment of cancer cells with a high concentration of salinomycin (Sal) reduced total Akt protein levels but increased activated Akt levels.	salinomycin	73-84	AKT serine/threonine kinase 1	Homo sapiens	148-151
25114899-4	2014	We found that the treatment of cancer cells with a high concentration of salinomycin (Sal) reduced total Akt protein levels but increased activated Akt levels.	salinomycin	86-89	AKT serine/threonine kinase 1	Homo sapiens	105-108
24333874-4	2014	Salinomycin efficiently inhibited proliferation and invasion of 3 NPC cell lines (CNE-1, CNE-2, and CNE-2/DDP) and activated a extensive apoptotic process that is accompanied by activation of caspase-3 and caspase-9, and decreased mitochondrial membrane potential.	salinomycin	0-11	caspase 3	Homo sapiens	192-201
24333874-4	2014	Salinomycin efficiently inhibited proliferation and invasion of 3 NPC cell lines (CNE-1, CNE-2, and CNE-2/DDP) and activated a extensive apoptotic process that is accompanied by activation of caspase-3 and caspase-9, and decreased mitochondrial membrane potential.	salinomycin	0-11	caspase 9	Homo sapiens	206-215
24333874-5	2014	Meanwhile, the protein expression level of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and beta-catenin was down-regulated, which showed that the Wnt/beta-catenin signaling was involved in salinomycin-induced apoptosis of NPC cells.	salinomycin	210-221	LDL receptor related protein 6	Homo sapiens	102-106
24333874-5	2014	Meanwhile, the protein expression level of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and beta-catenin was down-regulated, which showed that the Wnt/beta-catenin signaling was involved in salinomycin-induced apoptosis of NPC cells.	salinomycin	210-221	catenin beta 1	Homo sapiens	112-124
24333874-5	2014	Meanwhile, the protein expression level of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and beta-catenin was down-regulated, which showed that the Wnt/beta-catenin signaling was involved in salinomycin-induced apoptosis of NPC cells.	salinomycin	210-221	catenin beta 1	Homo sapiens	171-183
24333874-6	2014	In a nude mouse NPC xenograft model, the anti-tumor effect of salinomycin was associated with the downregulation of beta-catenin expression.	salinomycin	62-73	catenin (cadherin associated protein), beta 1	Mus musculus	116-128
24333874-7	2014	The present study demonstrated that salinomycin can effectively inhibit proliferation and invasion, and induce apoptosis of NPC cells in vitro and inhibit tumor growth in vivo, probably via the inhibition of Wnt/beta-catenin signaling, suggesting salinomycin as a potential candidate for the chemotherapy of NPC.	salinomycin	36-47	catenin beta 1	Homo sapiens	212-224
25114899-4	2014	We found that the treatment of cancer cells with a high concentration of salinomycin (Sal) reduced total Akt protein levels but increased activated Akt levels.	salinomycin	86-89	AKT serine/threonine kinase 1	Homo sapiens	148-151
25114899-5	2014	When cancer cells were cotreated with MK-2206 and Sal, both pAkt and total Akt levels were reduced.	salinomycin	50-53	AKT serine/threonine kinase 1	Homo sapiens	61-64
25478603-0	2014	Salinomycin Suppresses PDGFRbeta, MYC, and Notch Signaling in Human Medulloblastoma.	salinomycin	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-37
25114899-6	2014	Using microscopic observation, an assessment of cleaved PARP, FACS analysis of pre-G1 region, and Hoechst staining, we found that Sal increased apoptosis of MK-2206-treated cancer cells.	salinomycin	130-133	collagen type XI alpha 2 chain	Homo sapiens	56-60
25114899-9	2014	In addition, Sal-induced activation of GSK3beta, TSC2, and 4EBP1 was abolished by MK-2206 cotreatment.	salinomycin	13-16	glycogen synthase kinase 3 beta	Homo sapiens	39-47
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	0-11	platelet derived growth factor receptor beta	Homo sapiens	178-187
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	189-192
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	0-11	cyclin dependent kinase inhibitor 1A	Homo sapiens	194-197
25114899-9	2014	In addition, Sal-induced activation of GSK3beta, TSC2, and 4EBP1 was abolished by MK-2206 cotreatment.	salinomycin	13-16	TSC complex subunit 2	Homo sapiens	49-53
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	0-11	BCL2 apoptosis regulator	Homo sapiens	202-207
25114899-9	2014	In addition, Sal-induced activation of GSK3beta, TSC2, and 4EBP1 was abolished by MK-2206 cotreatment.	salinomycin	13-16	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	59-64
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	0-11	cyclin A2	Homo sapiens	250-258
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	133-144	platelet derived growth factor receptor beta	Homo sapiens	178-187
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	133-144	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	189-192
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	133-144	cyclin dependent kinase inhibitor 1A	Homo sapiens	194-197
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	133-144	BCL2 apoptosis regulator	Homo sapiens	202-207
25478603-5	2014	Salinomycin was also tested on the expression levels of key genes involved in proliferation and survival signaling and revealed that salinomycin down-regulates the expression of PDGFRbeta, MYC, p21 and Bcl-2 as well as up-regulates the expression of cyclin A.	salinomycin	133-144	cyclin A2	Homo sapiens	250-258
25478603-6	2014	In addition, the results reveal that salinomycin suppresses the expression of Hes1 and Hes5 in MB cells.	salinomycin	37-48	hes family bHLH transcription factor 1	Homo sapiens	78-82
25478603-6	2014	In addition, the results reveal that salinomycin suppresses the expression of Hes1 and Hes5 in MB cells.	salinomycin	37-48	hes family bHLH transcription factor 5	Homo sapiens	87-91
24358342-0	2013	Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosis.	salinomycin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	22-50
24358342-4	2013	Inhibition of autophagy by 3-methyladenine (3-MA), or by RNA interference (RNAi) of light chain 3B (LC3B), enhanced salinomycin-induced cytotoxicity and apoptosis.	salinomycin	116-127	microtubule associated protein 1 light chain 3 beta	Homo sapiens	84-98
24358342-11	2013	AMPK-autophagy inhibition might be a novel strategy to sensitize salinomycin"s effect in cancer cells.	salinomycin	65-76	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-4
24358342-4	2013	Inhibition of autophagy by 3-methyladenine (3-MA), or by RNA interference (RNAi) of light chain 3B (LC3B), enhanced salinomycin-induced cytotoxicity and apoptosis.	salinomycin	116-127	microtubule associated protein 1 light chain 3 beta	Homo sapiens	100-104
24358342-5	2013	Salinomycin induced a profound AMP-activated protein kinase (AMPK) activation, which was required for autophagy induction.	salinomycin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	31-59
24358342-5	2013	Salinomycin induced a profound AMP-activated protein kinase (AMPK) activation, which was required for autophagy induction.	salinomycin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	61-65
24358342-6	2013	AMPK inhibition by compound C, or by AMPKalpha RNAi prevented salinomycin-induced autophagy activation, while facilitating cancer cell death and apoptosis.	salinomycin	62-73	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-4
24358342-8	2013	Salinomycin-induced AMPK activation was dependent on reactive oxygen species (ROS) production in osteoblastoma cells.	salinomycin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	20-24
24358342-9	2013	Antioxidant n-acetyl cysteine (NAC) significantly inhibited salinomycin-induced AMPK activation and autophagy induction.	salinomycin	60-71	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	80-84
24358342-10	2013	CONCLUSIONS: Salinomycin activates AMPK-dependent autophagy in osteoblastoma cells, which serves as a negative regulator against cell apoptosis.	salinomycin	13-24	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	35-39
24278179-6	2013	Salinomycin reduced the proportion of ALDH+ CSCs in LLC cells, whereas paclitaxel increased such population.	salinomycin	0-11	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	38-42
24278179-14	2013	These results show that salinomycin targets ALDH+ lung CSCs, which has important therapeutic effects in vivo by reducing metastatic lesions.	salinomycin	24-35	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	44-48
23545383-0	2013	Salinomycin inhibits Akt/NF-kappaB and induces apoptosis in cisplatin resistant ovarian cancer cells.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	21-24
23639289-2	2013	Various studies reported that Ca(2+), cytochrome c, and caspase activation play a role in Salinomycin-induced cytotoxicity.	salinomycin	90-101	cytochrome c, somatic	Homo sapiens	38-50
23639289-3	2013	Furthermore, Salinomycin may target Wnt/beta-catenin signaling pathway to promote differentiation and thus elimination of cancer stem cells.	salinomycin	13-24	catenin beta 1	Homo sapiens	40-52
23975168-0	2013	Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels.	salinomycin	14-25	AKT serine/threonine kinase 1	Homo sapiens	44-47
23975168-0	2013	Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels.	salinomycin	14-25	ribosomal protein S6 kinase B1	Homo sapiens	82-88
23975168-5	2013	Interestingly, Akt was the only signal protein to be significantly activated by Sal treatment.	salinomycin	80-83	AKT serine/threonine kinase 1	Homo sapiens	15-18
23975168-7	2013	The Akt activation by Sal was conserved in the other cell lines analyzed, which originated from other organs.	salinomycin	22-25	AKT serine/threonine kinase 1	Homo sapiens	4-7
23975168-10	2013	Co-treatment with Akt inhibitors sensitized the Sal-treated cancer cells.	salinomycin	48-51	AKT serine/threonine kinase 1	Homo sapiens	18-21
23545383-13	2013	CONCLUSION: The result suggested that salinomycin-induced apoptosis in A2780cis was associated with inhibition of Akt/NF-kappaB.	salinomycin	38-49	nuclear factor kappa B subunit 1	Homo sapiens	118-127
23545383-0	2013	Salinomycin inhibits Akt/NF-kappaB and induces apoptosis in cisplatin resistant ovarian cancer cells.	salinomycin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	25-34
23545383-4	2013	The present study focused on investigating important cell signaling molecules such as Akt and NF-kappaB during salinomycin-induced apoptosis in cisplatin resistant ovarian cancer cells (A2780cis).	salinomycin	111-122	AKT serine/threonine kinase 1	Homo sapiens	86-89
23545383-4	2013	The present study focused on investigating important cell signaling molecules such as Akt and NF-kappaB during salinomycin-induced apoptosis in cisplatin resistant ovarian cancer cells (A2780cis).	salinomycin	111-122	nuclear factor kappa B subunit 1	Homo sapiens	94-103
23545383-10	2013	Salinomycin inhibited the nuclear transportation of NF-kappaB, and downregulated Akt expression.	salinomycin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	52-61
23545383-10	2013	Salinomycin inhibited the nuclear transportation of NF-kappaB, and downregulated Akt expression.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	81-84
23545383-13	2013	CONCLUSION: The result suggested that salinomycin-induced apoptosis in A2780cis was associated with inhibition of Akt/NF-kappaB.	salinomycin	38-49	AKT serine/threonine kinase 1	Homo sapiens	114-117
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	mechanistic target of rapamycin kinase	Homo sapiens	144-148
23615398-5	2013	Interestingly, other polyether antibiotics, such as salinomycin, nigericin, narasin and lasalocid A, also stimulated TRAIL-mediated apoptosis in glioma cells via ER stress, CHOP-mediated DR5 upregulation and c-FLIP downregulation.	salinomycin	52-63	TNF superfamily member 10	Homo sapiens	117-122
23615398-5	2013	Interestingly, other polyether antibiotics, such as salinomycin, nigericin, narasin and lasalocid A, also stimulated TRAIL-mediated apoptosis in glioma cells via ER stress, CHOP-mediated DR5 upregulation and c-FLIP downregulation.	salinomycin	52-63	DNA damage inducible transcript 3	Homo sapiens	173-177
23615398-5	2013	Interestingly, other polyether antibiotics, such as salinomycin, nigericin, narasin and lasalocid A, also stimulated TRAIL-mediated apoptosis in glioma cells via ER stress, CHOP-mediated DR5 upregulation and c-FLIP downregulation.	salinomycin	52-63	TNF receptor superfamily member 10b	Homo sapiens	187-190
23615398-5	2013	Interestingly, other polyether antibiotics, such as salinomycin, nigericin, narasin and lasalocid A, also stimulated TRAIL-mediated apoptosis in glioma cells via ER stress, CHOP-mediated DR5 upregulation and c-FLIP downregulation.	salinomycin	52-63	CASP8 and FADD like apoptosis regulator	Homo sapiens	208-214
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	activating transcription factor 4	Homo sapiens	117-121
23670030-6	2013	We also showed that salinomycin triggered more apoptosis and less autophagy in A549 cells in which CDH1 expression was inhibited, suggesting that the inhibition of autophagy might represent a promising strategy to target cancer stem cells.	salinomycin	20-31	cadherin 1	Homo sapiens	99-103
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	DNA damage inducible transcript 3	Homo sapiens	122-127
23805285-5	2013	Salinomycin caused concentration- and time-dependent reduction in viability of LNM35 and A549 cells through a caspase 3/7-associated cell death pathway.	salinomycin	0-11	caspase 3	Homo sapiens	110-119
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	DNA damage inducible transcript 3	Homo sapiens	128-132
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	tribbles pseudokinase 3	Homo sapiens	133-138
23670030-4	2013	Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis.	salinomycin	34-45	AKT serine/threonine kinase 1	Homo sapiens	139-143
23807222-0	2013	Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	51-56
23807222-0	2013	Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.	salinomycin	0-11	S-phase kinase associated protein 2	Homo sapiens	79-83
23807222-6	2013	Salinomycin inhibited signal transducer and activator of transcription 3 (Stat3) activity and thus decreased expression of Stat3-target genes, including cyclin D1, Skp2, and survivin.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	22-72
23807222-6	2013	Salinomycin inhibited signal transducer and activator of transcription 3 (Stat3) activity and thus decreased expression of Stat3-target genes, including cyclin D1, Skp2, and survivin.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	74-79
23807222-6	2013	Salinomycin inhibited signal transducer and activator of transcription 3 (Stat3) activity and thus decreased expression of Stat3-target genes, including cyclin D1, Skp2, and survivin.	salinomycin	0-11	signal transducer and activator of transcription 3	Homo sapiens	123-128
23807222-6	2013	Salinomycin inhibited signal transducer and activator of transcription 3 (Stat3) activity and thus decreased expression of Stat3-target genes, including cyclin D1, Skp2, and survivin.	salinomycin	0-11	cyclin D1	Homo sapiens	153-162
23807222-6	2013	Salinomycin inhibited signal transducer and activator of transcription 3 (Stat3) activity and thus decreased expression of Stat3-target genes, including cyclin D1, Skp2, and survivin.	salinomycin	0-11	S-phase kinase associated protein 2	Homo sapiens	164-168
23807222-7	2013	Salinomycin induced degradation of Skp2 and thus accumulated p27Kip1.	salinomycin	0-11	S-phase kinase associated protein 2	Homo sapiens	35-39
23807222-7	2013	Salinomycin induced degradation of Skp2 and thus accumulated p27Kip1.	salinomycin	0-11	cyclin dependent kinase inhibitor 1B	Homo sapiens	61-68
23807222-8	2013	Knockdown of Skp2 further increased salinomycin-induced G1 arrest, but knockdown of p27Kip1 attenuated salinomycin effect on G1 arrest.	salinomycin	36-47	S-phase kinase associated protein 2	Homo sapiens	13-17
23807222-8	2013	Knockdown of Skp2 further increased salinomycin-induced G1 arrest, but knockdown of p27Kip1 attenuated salinomycin effect on G1 arrest.	salinomycin	103-114	cyclin dependent kinase inhibitor 1B	Homo sapiens	84-91
23807222-9	2013	Cdh1, an E3 ligase for Skp2, was shifted to nuclear fractions upon salinomycin treatment.	salinomycin	67-78	cadherin 1	Homo sapiens	0-4
23807222-9	2013	Cdh1, an E3 ligase for Skp2, was shifted to nuclear fractions upon salinomycin treatment.	salinomycin	67-78	S-phase kinase associated protein 2	Homo sapiens	23-27
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	cadherin 1	Homo sapiens	0-4
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	S-phase kinase associated protein 2	Homo sapiens	53-57
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	cyclin dependent kinase inhibitor 1B	Homo sapiens	77-84
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	cadherin 1	Homo sapiens	145-149
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	S-phase kinase associated protein 2	Homo sapiens	151-155
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	33-44	cyclin dependent kinase inhibitor 1B	Homo sapiens	156-163
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	cadherin 1	Homo sapiens	0-4
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	S-phase kinase associated protein 2	Homo sapiens	53-57
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	cyclin dependent kinase inhibitor 1B	Homo sapiens	77-84
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	cadherin 1	Homo sapiens	145-149
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	S-phase kinase associated protein 2	Homo sapiens	151-155
23807222-10	2013	Cdh1 knockdown by siRNA reversed salinomycin-induced Skp2 downregulation and p27Kip1 upregulation, indicating that salinomycin activates the APC(Cdh1)-Skp2-p27Kip1 pathway.	salinomycin	115-126	cyclin dependent kinase inhibitor 1B	Homo sapiens	156-163
23807222-11	2013	Concomitantly, si-Cdh1 inhibited salinomycin-induced G1 arrest.	salinomycin	33-44	cadherin 1	Homo sapiens	18-22
23807222-12	2013	Taken together, our data indicate that salinomycin induces cell cycle arrest and apoptosis via downregulation or inactivation of cell cycle-associated oncogenes, such as Stat3, cyclin D1, and Skp2, regardless of multidrug resistance.	salinomycin	39-50	signal transducer and activator of transcription 3	Homo sapiens	170-175
23807222-12	2013	Taken together, our data indicate that salinomycin induces cell cycle arrest and apoptosis via downregulation or inactivation of cell cycle-associated oncogenes, such as Stat3, cyclin D1, and Skp2, regardless of multidrug resistance.	salinomycin	39-50	cyclin D1	Homo sapiens	177-186
23807222-12	2013	Taken together, our data indicate that salinomycin induces cell cycle arrest and apoptosis via downregulation or inactivation of cell cycle-associated oncogenes, such as Stat3, cyclin D1, and Skp2, regardless of multidrug resistance.	salinomycin	39-50	S-phase kinase associated protein 2	Homo sapiens	192-196
23805285-9	2013	We also demonstrated for the first time that salinomycin induced a marked increase in the expression of the pro-apoptotic protein NAG-1 leading to the inhibition of lung cancer cell invasion but not cell survival.	salinomycin	45-56	growth differentiation factor 15	Homo sapiens	130-135
23395573-11	2013	Compared with control groups, Bax and E-cadherin were significantly upregulated, and Bcl-2 and PCNA were significantly downregulated in Sal-treated cells.	salinomycin	136-139	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
23685072-5	2013	Upon activation by ras, p38 induces the acetyltransferase activity of Tip60 through phosphorylation of Thr158; activated Tip60 in turn directly interacts with and induces the protein kinase activity of PRAK through acetylation of K364 in a manner that depends on phosphorylation of both Tip60 and PRAK by p38.	salinomycin	230-234	mitogen-activated protein kinase 14	Homo sapiens	24-27
23685072-5	2013	Upon activation by ras, p38 induces the acetyltransferase activity of Tip60 through phosphorylation of Thr158; activated Tip60 in turn directly interacts with and induces the protein kinase activity of PRAK through acetylation of K364 in a manner that depends on phosphorylation of both Tip60 and PRAK by p38.	salinomycin	230-234	lysine acetyltransferase 5	Homo sapiens	70-75
23685072-5	2013	Upon activation by ras, p38 induces the acetyltransferase activity of Tip60 through phosphorylation of Thr158; activated Tip60 in turn directly interacts with and induces the protein kinase activity of PRAK through acetylation of K364 in a manner that depends on phosphorylation of both Tip60 and PRAK by p38.	salinomycin	230-234	lysine acetyltransferase 5	Homo sapiens	121-126
23685072-5	2013	Upon activation by ras, p38 induces the acetyltransferase activity of Tip60 through phosphorylation of Thr158; activated Tip60 in turn directly interacts with and induces the protein kinase activity of PRAK through acetylation of K364 in a manner that depends on phosphorylation of both Tip60 and PRAK by p38.	salinomycin	230-234	MAPK activated protein kinase 5	Homo sapiens	202-206
23685072-5	2013	Upon activation by ras, p38 induces the acetyltransferase activity of Tip60 through phosphorylation of Thr158; activated Tip60 in turn directly interacts with and induces the protein kinase activity of PRAK through acetylation of K364 in a manner that depends on phosphorylation of both Tip60 and PRAK by p38.	salinomycin	230-234	lysine acetyltransferase 5	Homo sapiens	121-126
23352703-0	2013	Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation.	salinomycin	0-11	H3 histone pseudogene 16	Homo sapiens	79-82
23352703-10	2013	Interestingly, treatment with low concentrations of Salinomycin induced a transient G1 arrest at earlier time point and G2 arrest at later point and senescence associated with enlarged cellmorphology, upregulation of p21 protein, increase in histone H3 and H4 hyperacetylation and expression of SA-beta-Gal activity.	salinomycin	52-63	H3 histone pseudogene 16	Homo sapiens	217-220
23338561-6	2013	The Bio-Plex phosphoprotein 5-plex assay (Akt, IkappaB-alpha, ERK1/2, JNK and p38 MAPK) demonstrated a marked time- and concentration-dependent increase in the phosphorylation of p38 MAPK, subsequent to salinomycin treatment.	salinomycin	203-214	AKT serine/threonine kinase 1	Homo sapiens	42-45
23338561-6	2013	The Bio-Plex phosphoprotein 5-plex assay (Akt, IkappaB-alpha, ERK1/2, JNK and p38 MAPK) demonstrated a marked time- and concentration-dependent increase in the phosphorylation of p38 MAPK, subsequent to salinomycin treatment.	salinomycin	203-214	mitogen-activated protein kinase 1	Homo sapiens	179-182
23338561-8	2013	These findings suggested that salinomycin efficiently inhibits the cisplatin-resistant human ovarian cancer cell line growth through the induction of apoptosis, potentially associated with the p38 MAPK activation.	salinomycin	30-41	mitogen-activated protein kinase 1	Homo sapiens	193-196
23338561-8	2013	These findings suggested that salinomycin efficiently inhibits the cisplatin-resistant human ovarian cancer cell line growth through the induction of apoptosis, potentially associated with the p38 MAPK activation.	salinomycin	30-41	mitogen-activated protein kinase 3	Homo sapiens	197-201
23500085-9	2013	RESULTS: We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.	salinomycin	166-177	fibronectin 1	Homo sapiens	120-131
23500085-9	2013	RESULTS: We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.	salinomycin	166-177	fibronectin 1	Homo sapiens	199-210
23500085-9	2013	RESULTS: We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.	salinomycin	228-239	fibronectin 1	Homo sapiens	120-131
23500085-9	2013	RESULTS: We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.	salinomycin	228-239	fibronectin 1	Homo sapiens	120-131
23564786-0	2013	Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells.	salinomycin	0-11	TNF receptor superfamily member 10b	Homo sapiens	34-50
23564786-9	2013	Salinomycin increased the expression of death receptor-5 (DR5), caspase-8 and Fas-associated protein with death domain (FADD).	salinomycin	0-11	TNF receptor superfamily member 10b	Homo sapiens	40-56
23564786-9	2013	Salinomycin increased the expression of death receptor-5 (DR5), caspase-8 and Fas-associated protein with death domain (FADD).	salinomycin	0-11	TNF receptor superfamily member 10b	Homo sapiens	58-61
23564786-9	2013	Salinomycin increased the expression of death receptor-5 (DR5), caspase-8 and Fas-associated protein with death domain (FADD).	salinomycin	0-11	caspase 8	Homo sapiens	64-73
23564786-9	2013	Salinomycin increased the expression of death receptor-5 (DR5), caspase-8 and Fas-associated protein with death domain (FADD).	salinomycin	0-11	Fas associated via death domain	Homo sapiens	120-124
23564786-12	2013	CONCLUSION: These findings provide important insights regarding the activation of caspase-8 and DR5, to our knowledge, for the first time in salinomycin-treated cisplatin-resistant ovarian cancer and demonstrate that salinomycin could be a prominent anticancer agent.	salinomycin	141-152	caspase 8	Homo sapiens	82-91
23564786-12	2013	CONCLUSION: These findings provide important insights regarding the activation of caspase-8 and DR5, to our knowledge, for the first time in salinomycin-treated cisplatin-resistant ovarian cancer and demonstrate that salinomycin could be a prominent anticancer agent.	salinomycin	141-152	TNF receptor superfamily member 10b	Homo sapiens	96-99
23564786-12	2013	CONCLUSION: These findings provide important insights regarding the activation of caspase-8 and DR5, to our knowledge, for the first time in salinomycin-treated cisplatin-resistant ovarian cancer and demonstrate that salinomycin could be a prominent anticancer agent.	salinomycin	217-228	caspase 8	Homo sapiens	82-91
23564786-12	2013	CONCLUSION: These findings provide important insights regarding the activation of caspase-8 and DR5, to our knowledge, for the first time in salinomycin-treated cisplatin-resistant ovarian cancer and demonstrate that salinomycin could be a prominent anticancer agent.	salinomycin	217-228	TNF receptor superfamily member 10b	Homo sapiens	96-99
23238817-8	2013	The BT-20-HNO cells were also more resistant to the apoptotic inducing agent salinomycin, which suggests that p53 may be mutated in these cells.	salinomycin	77-88	tumor protein p53	Homo sapiens	110-113
23395573-11	2013	Compared with control groups, Bax and E-cadherin were significantly upregulated, and Bcl-2 and PCNA were significantly downregulated in Sal-treated cells.	salinomycin	136-139	cadherin 1	Homo sapiens	38-48
23395573-11	2013	Compared with control groups, Bax and E-cadherin were significantly upregulated, and Bcl-2 and PCNA were significantly downregulated in Sal-treated cells.	salinomycin	136-139	BCL2 apoptosis regulator	Homo sapiens	85-90
23395573-11	2013	Compared with control groups, Bax and E-cadherin were significantly upregulated, and Bcl-2 and PCNA were significantly downregulated in Sal-treated cells.	salinomycin	136-139	proliferating cell nuclear antigen	Homo sapiens	95-99
23395573-13	2013	CONCLUSIONS: These results indicate that Sal could influence the cell growth and migration in pancreatic cancer cells in vitro, which may occur by inhibition of Wnt/beta-catenin signaling.	salinomycin	41-44	catenin beta 1	Homo sapiens	165-177
22511343-0	2012	Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.	salinomycin	61-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
22511343-9	2012	Treatment of mammospheres with salinomycin reduced the expression of SOX2 indicating a selective targeting of cancer stem cells.	salinomycin	31-42	SRY-box transcription factor 2	Homo sapiens	69-73
22215106-6	2012	Salinomycin impacted on prostate cancer stem cell functions as evidenced by reduced aldehyde dehydrogenase activity and the fraction of CD44(+) cells.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	136-140
22773373-0	2012	Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.	salinomycin	11-22	mitogen-activated protein kinase 14	Homo sapiens	95-98
22773373-11	2012	Salinomycin also enhanced the phosphorylation of p38 MAPK.	salinomycin	0-11	mitogen-activated protein kinase 14	Homo sapiens	49-57
22773373-14	2012	The data suggested that salinomycin-induced apoptosis in OV2008 might be associated with activating p38 MAPK and merits further investigations.	salinomycin	24-35	mitogen-activated protein kinase 14	Homo sapiens	100-108
23123626-7	2012	In addition, salinomycin also suppresses the transcriptional activity of the CCAAT/enhancer binding proteins and the peroxisome proliferator-activated receptor gamma.	salinomycin	13-24	peroxisome proliferator activated receptor gamma	Homo sapiens	117-165
23176396-9	2012	RESULTS: In putative HNSCC stem cells, salinomycin was found to significantly inhibit cell viability, induce a 71.5% increase in levels of apoptosis, elevate the Bax/Bcl-2 ratio, and work synergistically with cisplatin and paclitaxel in inducing cell death.	salinomycin	39-50	BCL2 associated X, apoptosis regulator	Homo sapiens	162-165
23176396-9	2012	RESULTS: In putative HNSCC stem cells, salinomycin was found to significantly inhibit cell viability, induce a 71.5% increase in levels of apoptosis, elevate the Bax/Bcl-2 ratio, and work synergistically with cisplatin and paclitaxel in inducing cell death.	salinomycin	39-50	BCL2 apoptosis regulator	Homo sapiens	166-171
23176396-10	2012	It was observed that salinomycin significantly inhibited sphere forming-capability and repressed the expression of CD44 and BMI-1 by 3.2-fold and 6.2-fold, respectively.	salinomycin	21-32	CD44 molecule (Indian blood group)	Homo sapiens	115-119
23176396-10	2012	It was observed that salinomycin significantly inhibited sphere forming-capability and repressed the expression of CD44 and BMI-1 by 3.2-fold and 6.2-fold, respectively.	salinomycin	21-32	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	124-129
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	snail family transcriptional repressor 1	Homo sapiens	76-81
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	vimentin	Homo sapiens	83-91
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	zinc finger E-box binding homeobox 1	Homo sapiens	97-102
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	cadherin 1	Homo sapiens	128-138
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	AKT serine/threonine kinase 1	Homo sapiens	176-179
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	glycogen synthase kinase 3 beta	Homo sapiens	207-216
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	mechanistic target of rapamycin kinase	Homo sapiens	221-225
23176396-13	2012	CONCLUSIONS: These results demonstrate that in HNSCC cancer stem cells, salinomycin can cause cell death and decrease stem cell properties despite activation of both EMT and Akt.	salinomycin	72-83	AKT serine/threonine kinase 1	Homo sapiens	174-177
23057720-9	2012	RESULTS: By demonstrating Annexin V and TUNEL positivity of human CC cells, we provide evidence that Salinomycin reveals the capacity to break apoptosis-resistance in CC cells.	salinomycin	101-112	annexin A5	Homo sapiens	26-35
21573958-0	2012	Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.	salinomycin	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	15-29
21573958-4	2012	Sal treatment also reduced p21 levels in radiation-treated cells.	salinomycin	0-3	H3 histone pseudogene 16	Homo sapiens	27-30
21573958-5	2012	Considering that Sal sensitizes doxorubicin (DOX)- or etoposide (ETO)-treated cancer cells by causing DNA damage and reducing p21 expression, the results from our study suggest that the mechanism underlying Sal sensitization is conserved in both chemo- and radiation-treated cells.	salinomycin	17-20	H3 histone pseudogene 16	Homo sapiens	126-129
21573958-5	2012	Considering that Sal sensitizes doxorubicin (DOX)- or etoposide (ETO)-treated cancer cells by causing DNA damage and reducing p21 expression, the results from our study suggest that the mechanism underlying Sal sensitization is conserved in both chemo- and radiation-treated cells.	salinomycin	207-210	H3 histone pseudogene 16	Homo sapiens	126-129
21573958-6	2012	We also tested the ability of Sal to inhibit p-glycoprotein (P-gp), which plays a role in the efflux of anti-cancer drugs to reduce cellular damage.	salinomycin	30-33	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
21573958-6	2012	We also tested the ability of Sal to inhibit p-glycoprotein (P-gp), which plays a role in the efflux of anti-cancer drugs to reduce cellular damage.	salinomycin	30-33	ATP binding cassette subfamily B member 1	Homo sapiens	61-65
21573958-8	2012	Sal inhibits P-gp with a different substrate distinct from that of Ver.	salinomycin	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
21573958-10	2012	Taken together, the results from our study may contribute to the development of Sal-based therapy for cancer patients treated with P-gp-inhibiting drugs or radiation therapy.	salinomycin	80-83	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
22215106-7	2012	Moreover, salinomycin reduced the expression of MYC, AR and ERG, induced oxidative stress as well as inhibited nuclear factor-kappaB activity and cell migration.	salinomycin	10-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	48-51
21898546-5	2012	Furthermore, salinomycin, a selective breast cancer stem cell killer, was recently demonstrated to be an inhibitor of Wnt/beta-catenin signaling by inducing LRP6 degradation.	salinomycin	13-24	catenin beta 1	Homo sapiens	122-134
23251084-4	2012	Salinomycin, a polyether ionophore antibiotic isolated from Streptomyces albus, has been shown to kill CSCs in different types of human cancers, most likely by interfering with ABC drug transporters, the Wnt/beta-catenin signaling pathway, and other CSC pathways.	salinomycin	0-11	catenin beta 1	Homo sapiens	208-220
21898546-5	2012	Furthermore, salinomycin, a selective breast cancer stem cell killer, was recently demonstrated to be an inhibitor of Wnt/beta-catenin signaling by inducing LRP6 degradation.	salinomycin	13-24	LDL receptor related protein 6	Homo sapiens	157-161
21871443-5	2011	Salinomycin triggered apoptosis of PC-3 cells by elevating the intracellular ROS level, which was accompanied by decreased mitochondrial membrane potential, translocation of Bax protein to mitochondria, cytochrome c release to the cytoplasm, activation of the caspase-3 and cleavage of PARP-1, a caspase-3 substrate.	salinomycin	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
23028492-7	2012	Salinomycin also led to the formation of reactive oxygen species (ROS) eliciting JNK activation and induction of the transcription factor JUN.	salinomycin	0-11	mitogen-activated protein kinase 8	Homo sapiens	81-84
21835542-6	2011	Further investigation found that salinomycin inhibited osteosarcoma by selectively targeting its stem cells both in vitro and in vivo without severe side effects, and the Wnt/beta-catenin signaling pathway may be involved in this inhibition of salinomycin.	salinomycin	244-255	catenin beta 1	Homo sapiens	175-187
23284640-6	2012	We found that Sal inhibits proliferation and decreases PCNA levels as well as the proportion of HCC CD133(+)cell subpopulations in HCC cells.	salinomycin	14-17	proliferating cell nuclear antigen	Homo sapiens	55-59
23284640-9	2012	Sal induced apoptosis as characterized by an increase in the Bax/Bcl-2 ratio.	salinomycin	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	61-64
23284640-9	2012	Sal induced apoptosis as characterized by an increase in the Bax/Bcl-2 ratio.	salinomycin	0-3	BCL2 apoptosis regulator	Homo sapiens	65-70
23284640-15	2012	Finally, the role of Sal on in vivo Wnt/beta-catenin signaling was evaluated by Western blot and immunohistochemistry.	salinomycin	21-24	catenin beta 1	Homo sapiens	40-52
23284640-16	2012	This study demonstrates Sal inhibits proliferation and induces apoptosis of HCC cells in vitro and in vivo and one potential mechanism is inhibition of Wnt/beta-catenin signaling via increased intracellular Ca(2+) levels.	salinomycin	24-27	catenin beta 1	Homo sapiens	156-168
21871443-5	2011	Salinomycin triggered apoptosis of PC-3 cells by elevating the intracellular ROS level, which was accompanied by decreased mitochondrial membrane potential, translocation of Bax protein to mitochondria, cytochrome c release to the cytoplasm, activation of the caspase-3 and cleavage of PARP-1, a caspase-3 substrate.	salinomycin	0-11	cytochrome c, somatic	Homo sapiens	203-215
21871443-5	2011	Salinomycin triggered apoptosis of PC-3 cells by elevating the intracellular ROS level, which was accompanied by decreased mitochondrial membrane potential, translocation of Bax protein to mitochondria, cytochrome c release to the cytoplasm, activation of the caspase-3 and cleavage of PARP-1, a caspase-3 substrate.	salinomycin	0-11	caspase 3	Homo sapiens	260-269
21871443-5	2011	Salinomycin triggered apoptosis of PC-3 cells by elevating the intracellular ROS level, which was accompanied by decreased mitochondrial membrane potential, translocation of Bax protein to mitochondria, cytochrome c release to the cytoplasm, activation of the caspase-3 and cleavage of PARP-1, a caspase-3 substrate.	salinomycin	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	286-292
21871443-5	2011	Salinomycin triggered apoptosis of PC-3 cells by elevating the intracellular ROS level, which was accompanied by decreased mitochondrial membrane potential, translocation of Bax protein to mitochondria, cytochrome c release to the cytoplasm, activation of the caspase-3 and cleavage of PARP-1, a caspase-3 substrate.	salinomycin	0-11	caspase 3	Homo sapiens	296-305
21558812-6	2011	This stability allowed testing of segregated subpopulations for relative sensitivity to the cytotoxic agent cisplatin in comparison to salinomycin, a compound with reported activity against CD44(+)CD24(-) stem-like cells in breast carcinomas.	salinomycin	135-146	CD44 molecule (Indian blood group)	Homo sapiens	190-194
21906282-6	2011	RESULTS: New metal(II) complexes of the polyether ionophorous antibiotic salinomycin with Cd(II) and Pb(II) ions were prepared and structurally characterized by IR, FAB-MS and NMR techniques.	salinomycin	73-84	FA complementation group B	Homo sapiens	165-168
21788521-4	2011	In Wnt-transfected HEK293 cells, salinomycin blocked the phosphorylation of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and induced its degradation.	salinomycin	33-44	LDL receptor related protein 6	Homo sapiens	135-139
21788521-6	2011	In otherwise unmanipulated chronic lymphocytic leukemia cells with constitutive Wnt activation nanomolar concentrations of salinomycin down-regulated the expression of Wnt target genes such as LEF1, cyclin D1, and fibronectin, depressed LRP6 levels, and limited cell survival.	salinomycin	123-134	lymphoid enhancer binding factor 1	Homo sapiens	193-197
21788521-6	2011	In otherwise unmanipulated chronic lymphocytic leukemia cells with constitutive Wnt activation nanomolar concentrations of salinomycin down-regulated the expression of Wnt target genes such as LEF1, cyclin D1, and fibronectin, depressed LRP6 levels, and limited cell survival.	salinomycin	123-134	cyclin D1	Homo sapiens	199-208
21788521-6	2011	In otherwise unmanipulated chronic lymphocytic leukemia cells with constitutive Wnt activation nanomolar concentrations of salinomycin down-regulated the expression of Wnt target genes such as LEF1, cyclin D1, and fibronectin, depressed LRP6 levels, and limited cell survival.	salinomycin	123-134	fibronectin 1	Homo sapiens	214-225
21788521-6	2011	In otherwise unmanipulated chronic lymphocytic leukemia cells with constitutive Wnt activation nanomolar concentrations of salinomycin down-regulated the expression of Wnt target genes such as LEF1, cyclin D1, and fibronectin, depressed LRP6 levels, and limited cell survival.	salinomycin	123-134	LDL receptor related protein 6	Homo sapiens	237-241
21558812-6	2011	This stability allowed testing of segregated subpopulations for relative sensitivity to the cytotoxic agent cisplatin in comparison to salinomycin, a compound with reported activity against CD44(+)CD24(-) stem-like cells in breast carcinomas.	salinomycin	135-146	CD24 molecule	Homo sapiens	197-201
21558812-7	2011	Salinomycin showed comparable efficacy against both Ecad-hi and Ecad-lo cells in contrast to cisplatin, which selectively depleted Ecad-hi cells.	salinomycin	0-11	cadherin 1	Homo sapiens	52-56
21558812-7	2011	Salinomycin showed comparable efficacy against both Ecad-hi and Ecad-lo cells in contrast to cisplatin, which selectively depleted Ecad-hi cells.	salinomycin	0-11	cadherin 1	Homo sapiens	64-68
21558812-7	2011	Salinomycin showed comparable efficacy against both Ecad-hi and Ecad-lo cells in contrast to cisplatin, which selectively depleted Ecad-hi cells.	salinomycin	0-11	cadherin 1	Homo sapiens	64-68
21633391-0	2011	Salinomycin induces calpain and cytochrome c-mediated neuronal cell death.	salinomycin	0-11	cytochrome c, somatic	Homo sapiens	32-44
20973777-0	2011	Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.	salinomycin	0-11	H3 histone pseudogene 16	Homo sapiens	128-131
21222617-6	2011	Expression of stem cell markers OCT-4, NANOG and SOX2 in ALDH positive A549 lung cells was decreased significantly by real-time RT-PCR analysis after 24 hour salinomycin treatment.	salinomycin	158-169	POU class 5 homeobox 1	Homo sapiens	32-37
21222617-6	2011	Expression of stem cell markers OCT-4, NANOG and SOX2 in ALDH positive A549 lung cells was decreased significantly by real-time RT-PCR analysis after 24 hour salinomycin treatment.	salinomycin	158-169	Nanog homeobox	Homo sapiens	39-44
21222617-6	2011	Expression of stem cell markers OCT-4, NANOG and SOX2 in ALDH positive A549 lung cells was decreased significantly by real-time RT-PCR analysis after 24 hour salinomycin treatment.	salinomycin	158-169	SRY-box transcription factor 2	Homo sapiens	49-53
21267784-0	2011	Salinomycin selectively targets "CD133+" cell subpopulations and decreases malignant traits in colorectal cancer lines.	salinomycin	0-11	prominin 1	Homo sapiens	33-38
21267784-8	2011	RESULTS: We report that salinomycin reduces the proportion of CD133+ subpopulations in human CRC HT29 and SW480 cells.	salinomycin	24-35	prominin 1	Homo sapiens	62-67
21267784-10	2011	Moreover, salinomycin downregulates the expression of vimentin and induces the E-cadherin expression in HT29 cells.	salinomycin	10-21	vimentin	Homo sapiens	54-62
21267784-10	2011	Moreover, salinomycin downregulates the expression of vimentin and induces the E-cadherin expression in HT29 cells.	salinomycin	10-21	cadherin 1	Homo sapiens	79-89
21267784-11	2011	CONCLUSIONS: This study demonstrates the ability of salinomycin to selectively target "CD133+" cell subpopulations and decrease the malignant traits in colorectal cancer lines.	salinomycin	52-63	prominin 1	Homo sapiens	87-92
20973777-8	2011	We found that pH2AX, pBRCA1, p53BP1 and pChk1 levels were greatly increased after co-treatment of Sal with DOX or ETO.	salinomycin	98-101	tumor protein p53 binding protein 1	Homo sapiens	29-35
20973777-9	2011	The level of anti-apoptotic p21 protein was increased by DOX or ETO but decreased by Sal, which increased proteasome activity.	salinomycin	85-88	H3 histone pseudogene 16	Homo sapiens	28-31
20973777-11	2011	Overall, we demonstrated that the ability of Sal to sensitize cancer cells to the effects of DOX or ETO is associated with an increase in DNA damage and a decrease in anti-apoptotic protein p21 levels.	salinomycin	45-48	H3 histone pseudogene 16	Homo sapiens	190-193
20444629-0	2010	The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.	salinomycin	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
20621681-11	2010	In contrast, the cancer stem, cell-targeting drug salinomycin blocked the proliferation of Kit(low)Cd44(+)Cd34(+) cells and increased their sensitivity to imatinib.	salinomycin	50-61	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	91-94
20444629-2	2010	In the present study we report that salinomycin acts as a potent inhibitor of multidrug resistance gp170, as evidenced through drug efflux assays in MDR cancer cell lines overexpressing P-gp (CEM-VBL 10 and CEM-VBL 100; A2780/ADR).	salinomycin	36-47	phosphoglycolate phosphatase	Homo sapiens	186-190
20444629-3	2010	Conformational P-gp assay provided evidence that the inhibitory effect of salinomycin on P-gp function could be mediated by the induction of a conformational change of the ATP transporter.	salinomycin	74-85	phosphoglycolate phosphatase	Homo sapiens	15-19
20444629-3	2010	Conformational P-gp assay provided evidence that the inhibitory effect of salinomycin on P-gp function could be mediated by the induction of a conformational change of the ATP transporter.	salinomycin	74-85	phosphoglycolate phosphatase	Homo sapiens	89-93
20444629-5	2010	The observation that salinomycin is a MDR-1 inhibitor may have important implications for the understanding of the mechanisms through which this drug impairs the viability of cancer stem cells.	salinomycin	21-32	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
33820552-9	2021	Alpha-1-acid glycoprotein was decreased by 28.7% in the salinomycin-fed chickens but increased by 38.1% in the essential oil group compared with the challenged control group.	salinomycin	56-67	orosomucoid 1 (ovoglycoprotein)	Gallus gallus	0-25
20350531-0	2010	Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.	salinomycin	0-11	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	22-25
20350531-7	2010	Thus, salinomycin should be regarded as a novel and effective agent for the elimination of leukemia stem cells and other tumor cells exhibiting ABC transporter-mediated multidrug resistance.	salinomycin	6-17	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	144-147
12607930-4	2002	Most of the veterinary drugs showed no action, though the ionophores lasalocid, salinomycin and the steroid hormone hexestrol promoted beta-hexosaminidase release from injured cells.	salinomycin	80-91	O-GlcNAcase	Rattus norvegicus	135-154
19835841-5	2009	Moreover, salinomycin is able to induce apoptosis in cancer cells that exhibit resistance to apoptosis and anticancer agents by overexpression of Bcl-2, P-glycoprotein or 26S proteasomes with enhanced proteolytic activity.	salinomycin	10-21	BCL2 apoptosis regulator	Homo sapiens	146-151
19835841-6	2009	Salinomycin activates a distinct apoptotic pathway that is not accompanied by cell cycle arrest and that is independent of tumor suppressor protein p53, caspase activation, the CD95/CD95L system and the proteasome.	salinomycin	0-11	Fas cell surface death receptor	Homo sapiens	177-181
19835841-6	2009	Salinomycin activates a distinct apoptotic pathway that is not accompanied by cell cycle arrest and that is independent of tumor suppressor protein p53, caspase activation, the CD95/CD95L system and the proteasome.	salinomycin	0-11	Fas ligand	Homo sapiens	182-187
18195061-0	2008	P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.	salinomycin	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
18195061-6	2008	Salinomycin was actively transported by human MDR1 P-gp expressed in polarized MDCK-II monolayers but not by the known organic anion transporters human MRP2 and murine Bcrp1.	salinomycin	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
18195061-12	2008	Variation in P-gp activity might thus directly affect the effective exposure to salinomycin and possibly to other anionic drugs and toxin substrates.	salinomycin	80-91	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
18195061-13	2008	Individuals with reduced or absent P-gp activity could therefore be more susceptible to salinomycin toxicity.	salinomycin	88-99	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
33825488-8	2021	Mechanistically, salinomycin inhibits cardiac fibroblast activation by preventing p38/MAPK and Rho signaling.	salinomycin	17-28	mitogen-activated protein kinase 14	Homo sapiens	82-90
34265289-7	2021	Mechanistically, the SAL analogues induced late apoptosis in colon cancer cells and necrosis in prostate cancer cells, as well as reduced secretion of interleukin 6 (IL-6) in these cells.	salinomycin	21-24	interleukin 6	Homo sapiens	151-164
34806536-0	2022	Salinomycin induces cell cycle arrest and apoptosis and modulates hepatic cytochrome P450 mRNA expression in HepG2/C3a cells.	salinomycin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	74-89
34806536-5	2022	SAL induced cell cycle arrest in G2/M phase, upregulation of CDKN1A and GADD45A and downregulation of cyclin genes including CCNB1 and CCNA2.	salinomycin	0-3	cyclin dependent kinase inhibitor 1A	Homo sapiens	61-67
34806536-5	2022	SAL induced cell cycle arrest in G2/M phase, upregulation of CDKN1A and GADD45A and downregulation of cyclin genes including CCNB1 and CCNA2.	salinomycin	0-3	growth arrest and DNA damage inducible alpha	Homo sapiens	72-79
34806536-5	2022	SAL induced cell cycle arrest in G2/M phase, upregulation of CDKN1A and GADD45A and downregulation of cyclin genes including CCNB1 and CCNA2.	salinomycin	0-3	cyclin B1	Homo sapiens	102-108
34806536-5	2022	SAL induced cell cycle arrest in G2/M phase, upregulation of CDKN1A and GADD45A and downregulation of cyclin genes including CCNB1 and CCNA2.	salinomycin	0-3	cyclin B1	Homo sapiens	125-130
34806536-5	2022	SAL induced cell cycle arrest in G2/M phase, upregulation of CDKN1A and GADD45A and downregulation of cyclin genes including CCNB1 and CCNA2.	salinomycin	0-3	cyclin A2	Homo sapiens	135-140
34806536-6	2022	SAL effectively suppressed mRNA levels of CTNNB1 gene, an important oncogene that promotes tumorigenesis.	salinomycin	0-3	catenin beta 1	Homo sapiens	42-48
34806536-7	2022	The decrease of HepG2/C3A cells survival can also be due to downregulation of antiapoptotic BCL-2 expression, thus promoting the induction of apoptosis by SAL.	salinomycin	155-158	BCL2 apoptosis regulator	Homo sapiens	92-97
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	168-174
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	44-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	198-204
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-85
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	119-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
34806536-8	2022	This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of CYP1A members and CYP3A5; and downregulation of CYP3A4.	salinomycin	119-122	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	168-174
34265289-7	2021	Mechanistically, the SAL analogues induced late apoptosis in colon cancer cells and necrosis in prostate cancer cells, as well as reduced secretion of interleukin 6 (IL-6) in these cells.	salinomycin	21-24	interleukin 6	Homo sapiens	166-170
34320348-6	2021	HOXC10 inhibitor salinomycin exerts efficient therapeutic effects in APC-wild-type colorectal tumors, but not in tumors with APC nonsense mutations.	salinomycin	17-28	homeobox C10	Homo sapiens	0-6
34365583-10	2021	Mechanistic studies show that salinomycin inhibits mitochondrial respiration via specifically suppressing complex I and II activities, reduces mitochondrial membrane potential and decreases energy reduction, followed by induction of oxidative stress and damage, AMPK activation and mTOR inhibition.	salinomycin	30-41	mechanistic target of rapamycin kinase	Mus musculus	282-286
34130123-9	2021	Compound 17 was more potent than SAL in inhibiting cell migration and cell renewal properties of MDA-MB-231 cells, as well as inducing selective loss of the CD44+/CD24/low stem-cell-like subpopulation in both monolayer (2D) and organoid (3D) culture.	salinomycin	33-36	CD44 molecule (Indian blood group)	Homo sapiens	157-161
34130123-9	2021	Compound 17 was more potent than SAL in inhibiting cell migration and cell renewal properties of MDA-MB-231 cells, as well as inducing selective loss of the CD44+/CD24/low stem-cell-like subpopulation in both monolayer (2D) and organoid (3D) culture.	salinomycin	33-36	CD24 molecule	Homo sapiens	163-167
34306210-10	2021	Furthermore, the Nrf2 activator, tert-butylhydroquinone, significantly reversed the therapeutic effects of salinomycin by stimulating the Nrf2 pathway and increasing the activity of antioxidant enzymes.	salinomycin	107-118	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21
34306210-10	2021	Furthermore, the Nrf2 activator, tert-butylhydroquinone, significantly reversed the therapeutic effects of salinomycin by stimulating the Nrf2 pathway and increasing the activity of antioxidant enzymes.	salinomycin	107-118	NFE2 like bZIP transcription factor 2	Homo sapiens	138-142
34306210-11	2021	Taken together, these findings demonstrated that salinomycin may trigger apoptosis by inducing oxidative and ER stress in prostate cancer cells via suppressing Nrf2 signaling.	salinomycin	49-60	NFE2 like bZIP transcription factor 2	Homo sapiens	160-164
34306210-0	2021	Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling.	salinomycin	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	123-127
34306210-8	2021	In addition, salinomycin induced the activation of unfolded protein response and endoplasmic reticulum stress in DU145 and PC-3 cells, as indicated by the elevated expression of binding immunoglobulin protein, activating transcription factor 4, phosphorylated eukaryotic initiation factor 2alpha, phosphorylated protein kinase RNA-like endoplasmic reticulum kinase and C/EBP homologous protein.	salinomycin	13-24	activating transcription factor 4	Homo sapiens	210-243
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	NFE2 like bZIP transcription factor 2	Homo sapiens	71-114
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	NFE2 like bZIP transcription factor 2	Homo sapiens	116-120
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	heme oxygenase 1	Homo sapiens	123-139
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	NAD(P)H quinone dehydrogenase 1	Homo sapiens	141-172
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	glutamate-cysteine ligase catalytic subunit	Homo sapiens	177-220
34306210-9	2021	In addition, salinomycin significantly downregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1, NAD(P)H quinone dehydrogenase 1 and glutamate-cysteine ligase catalytic subunit and decreased the activity of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase in PC-3 and DU145 cells.	salinomycin	13-24	catalase	Homo sapiens	297-305
34320348-6	2021	HOXC10 inhibitor salinomycin exerts efficient therapeutic effects in APC-wild-type colorectal tumors, but not in tumors with APC nonsense mutations.	salinomycin	17-28	APC regulator of WNT signaling pathway	Homo sapiens	69-72
34308783-7	2021	It was observed that mRNA expression patterns of CD44v6, Nanog, AKT1, CDKN2A and beta-catenin of Salinomycin treated CD44+ cells.	salinomycin	97-108	catenin beta 1	Homo sapiens	81-93
34308783-3	2021	Docking of potential investigational molecules and simulation results identified Salinomycin as a potential lead compound that could effectively inhibit CD44 receptor.	salinomycin	81-92	CD44 molecule (Indian blood group)	Homo sapiens	153-157
34308783-7	2021	It was observed that mRNA expression patterns of CD44v6, Nanog, AKT1, CDKN2A and beta-catenin of Salinomycin treated CD44+ cells.	salinomycin	97-108	CD44 molecule (Indian blood group)	Homo sapiens	117-121
34308783-5	2021	Salinomycin demonstrated significant cytotoxic effect towards the CD44+ subpopulation in a dose and time dependent manner.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	66-70
34308783-9	2021	Thus, this study demonstrated the potential of Salinomycin to target the chemo-resistant circulating CD44 population by attenuating its proliferation and survival.Communicated by Ramaswamy H. Sarma.	salinomycin	47-58	CD44 molecule (Indian blood group)	Homo sapiens	101-105
34308783-7	2021	It was observed that mRNA expression patterns of CD44v6, Nanog, AKT1, CDKN2A and beta-catenin of Salinomycin treated CD44+ cells.	salinomycin	97-108	Nanog homeobox	Homo sapiens	57-62
7329917-1	1981	Five experiments were conducted to test the anticoccidial efficacy of salinomycin (AHR-3096C, A. H. Robins) at 66 ppm and its compatibility with roxarsone (50 ppm) under floor pen conditions Monensin (100, 121 ppm), lasalocid (75, 125 ppm), and shuttle programs of salinomycin-monensin (66/100 ppm) or monensin-salinomycin (100/66 ppm) were included for comparison.	salinomycin	70-81	aryl hydrocarbon receptor	Homo sapiens	83-86
34308783-7	2021	It was observed that mRNA expression patterns of CD44v6, Nanog, AKT1, CDKN2A and beta-catenin of Salinomycin treated CD44+ cells.	salinomycin	97-108	AKT serine/threonine kinase 1	Homo sapiens	64-68
34308783-7	2021	It was observed that mRNA expression patterns of CD44v6, Nanog, AKT1, CDKN2A and beta-catenin of Salinomycin treated CD44+ cells.	salinomycin	97-108	cyclin dependent kinase inhibitor 2A	Homo sapiens	70-76
35254834-5	2022	The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs.	salinomycin	72-83	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	137-142
35254834-5	2022	The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs.	salinomycin	72-83	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	221-226
35254834-5	2022	The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs.	salinomycin	250-261	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	62-67
35254834-5	2022	The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs.	salinomycin	250-261	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	137-142
35254834-5	2022	The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs.	salinomycin	250-261	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	221-226
35170392-8	2022	Interestingly, greater expression of tumour necrosis factor alpha (TNF-alpha) and mucin 2 (MUC2) genes (P=0.039 and P = 0.067, respectively) were detected in the group receiving salinomycin.5.	salinomycin	178-189	tumor necrosis factor	Homo sapiens	67-76
35170392-8	2022	Interestingly, greater expression of tumour necrosis factor alpha (TNF-alpha) and mucin 2 (MUC2) genes (P=0.039 and P = 0.067, respectively) were detected in the group receiving salinomycin.5.	salinomycin	178-189	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	82-89
35170392-8	2022	Interestingly, greater expression of tumour necrosis factor alpha (TNF-alpha) and mucin 2 (MUC2) genes (P=0.039 and P = 0.067, respectively) were detected in the group receiving salinomycin.5.	salinomycin	178-189	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	91-95
3624375-3	1987	A simultaneous determination of three polyether antibiotics, salinomycin, monensin and lasalocid, was established by silica gel and RP-18 high-performance thin-layer chromatography (HPTLC) using 18,19-dihydrosalinomycin and 18,19-dihydro-20-ketosalinomycin as internal standards.	salinomycin	61-72	pre-mRNA processing factor 3	Homo sapiens	132-137
33437206-0	2021	Salinomycin suppresses TGF-beta1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer.	salinomycin	0-11	transforming growth factor beta 1	Homo sapiens	23-32
33529322-6	2021	Treatment with G007-LK, pyrvinium or salinomycin almost completely prevented the development of clinical and histological features in the B10.D2 (H-2d) BALB/c (H-2d) and in the LP/J (H-2b) C57BL/6 (H-2b) model of sclGvHD.	salinomycin	37-48	H2B clustered histone 21	Homo sapiens	198-202
33641902-4	2021	In vivo experiments on zebrafish embryos confirmed the capacity of SAL nanoformulations to interfere with the Wnt/beta-catenin signaling pathway, which is dysregulated in BC, thus identifying a target for further translation into pre-clinical models.	salinomycin	67-70	catenin (cadherin-associated protein), beta 1	Danio rerio	114-126
33347821-6	2021	Our data revealed that SAL ester derivatives, particularly compounds 5 and 7 (2,2,2-trifluoroethyl and benzotriazole ester of SAL, respectively), increase the level of p-eIF2alpha (Ser51) and IRE1alpha proteins.	salinomycin	23-26	eukaryotic translation initiation factor 2A	Homo sapiens	170-179
33347821-6	2021	Our data revealed that SAL ester derivatives, particularly compounds 5 and 7 (2,2,2-trifluoroethyl and benzotriazole ester of SAL, respectively), increase the level of p-eIF2alpha (Ser51) and IRE1alpha proteins.	salinomycin	23-26	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	192-201
33520933-6	2020	By conjugation of CD44 cell-surface glycoprotein with poly(lactic-co-glycolic acid) (PLGA) nanoparticles that are loaded with curcumin and salinomycin, we investigated the cellular uptake of BCSCs, drug release, and therapeutic efficacy against BCSCs.	salinomycin	139-150	CD44 molecule (Indian blood group)	Homo sapiens	18-22
32635858-0	2021	Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells.	salinomycin	0-11	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	42-46
32635858-3	2021	By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs.	salinomycin	49-60	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	116-120
32635858-4	2021	Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs.	salinomycin	75-86	major histocompatibility complex, class II, DR beta 4	Homo sapiens	150-153
33529322-6	2021	Treatment with G007-LK, pyrvinium or salinomycin almost completely prevented the development of clinical and histological features in the B10.D2 (H-2d) BALB/c (H-2d) and in the LP/J (H-2b) C57BL/6 (H-2b) model of sclGvHD.	salinomycin	37-48	H2B clustered histone 21	Homo sapiens	183-187
32564748-6	2021	ELISA assay was performed in order to determining the level of TGFbeta2, COL14A1, CDH2, WNT5A in cell culture under salinomycin treatment in comparison to the control.	salinomycin	116-127	transforming growth factor beta 2	Homo sapiens	63-71
32564748-6	2021	ELISA assay was performed in order to determining the level of TGFbeta2, COL14A1, CDH2, WNT5A in cell culture under salinomycin treatment in comparison to the control.	salinomycin	116-127	Wnt family member 5A	Homo sapiens	88-93
32598254-8	2021	It was noted that 4 of the 9 differentiating mRNAs were characteristic for 12 hours of exposure to the salinomycin and they correspond to the following genes: TUFT1, ABCB1, MTMR11, MX2.	salinomycin	103-114	tuftelin 1	Homo sapiens	159-164
32598254-8	2021	It was noted that 4 of the 9 differentiating mRNAs were characteristic for 12 hours of exposure to the salinomycin and they correspond to the following genes: TUFT1, ABCB1, MTMR11, MX2.	salinomycin	103-114	ATP binding cassette subfamily B member 1	Homo sapiens	166-171
32598254-8	2021	It was noted that 4 of the 9 differentiating mRNAs were characteristic for 12 hours of exposure to the salinomycin and they correspond to the following genes: TUFT1, ABCB1, MTMR11, MX2.	salinomycin	103-114	myotubularin related protein 11	Homo sapiens	173-179
32598254-8	2021	It was noted that 4 of the 9 differentiating mRNAs were characteristic for 12 hours of exposure to the salinomycin and they correspond to the following genes: TUFT1, ABCB1, MTMR11, MX2.	salinomycin	103-114	MX dynamin like GTPase 2	Homo sapiens	181-184
32598254-9	2021	After 24 hours, 2 mRNAs were characteristic for this time of incubation cells with salinomycin: TUFT1, MYD88 and after 48 hours, SLC30A5 could also be observed.	salinomycin	83-94	tuftelin 1	Homo sapiens	96-101
32598254-9	2021	After 24 hours, 2 mRNAs were characteristic for this time of incubation cells with salinomycin: TUFT1, MYD88 and after 48 hours, SLC30A5 could also be observed.	salinomycin	83-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	103-108
32598254-9	2021	After 24 hours, 2 mRNAs were characteristic for this time of incubation cells with salinomycin: TUFT1, MYD88 and after 48 hours, SLC30A5 could also be observed.	salinomycin	83-94	solute carrier family 30 member 5	Homo sapiens	129-136
33437206-3	2021	Sal solidly blocked cell migration and invasion enhancement by TGF-beta1-induced EMT, through recovering E-cadherin loss and suppressing mesenchymal markers induction, as well as TGF-beta1-mediated AMPK/SIRT signaling activity upregulation.	salinomycin	0-3	cadherin 1	Homo sapiens	105-115
33437206-3	2021	Sal solidly blocked cell migration and invasion enhancement by TGF-beta1-induced EMT, through recovering E-cadherin loss and suppressing mesenchymal markers induction, as well as TGF-beta1-mediated AMPK/SIRT signaling activity upregulation.	salinomycin	0-3	transforming growth factor beta 1	Homo sapiens	179-188
33437206-3	2021	Sal solidly blocked cell migration and invasion enhancement by TGF-beta1-induced EMT, through recovering E-cadherin loss and suppressing mesenchymal markers induction, as well as TGF-beta1-mediated AMPK/SIRT signaling activity upregulation.	salinomycin	0-3	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	198-202
33437206-4	2021	The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta1-induced MMP-2 and MMP-9.	salinomycin	88-91	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	45-49
33437206-4	2021	The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta1-induced MMP-2 and MMP-9.	salinomycin	88-91	sirtuin 1	Homo sapiens	53-58
33437206-4	2021	The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta1-induced MMP-2 and MMP-9.	salinomycin	88-91	transforming growth factor beta 1	Homo sapiens	103-112
33437206-4	2021	The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta1-induced MMP-2 and MMP-9.	salinomycin	88-91	matrix metallopeptidase 2	Homo sapiens	121-126
33437206-4	2021	The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta1-induced MMP-2 and MMP-9.	salinomycin	88-91	matrix metallopeptidase 9	Homo sapiens	131-136
33437206-5	2021	In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta1-induced MMP-2 and MMP-9 inhibition by Sal.	salinomycin	108-111	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	13-17
33437206-5	2021	In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta1-induced MMP-2 and MMP-9 inhibition by Sal.	salinomycin	108-111	sirtuin 1	Homo sapiens	21-26
33437206-5	2021	In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta1-induced MMP-2 and MMP-9 inhibition by Sal.	salinomycin	108-111	transforming growth factor beta 1	Homo sapiens	60-69
33437206-5	2021	In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta1-induced MMP-2 and MMP-9 inhibition by Sal.	salinomycin	108-111	matrix metallopeptidase 2	Homo sapiens	78-83
33437206-5	2021	In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta1-induced MMP-2 and MMP-9 inhibition by Sal.	salinomycin	108-111	matrix metallopeptidase 9	Homo sapiens	88-93
33437206-0	2021	Salinomycin suppresses TGF-beta1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer.	salinomycin	0-11	matrix metallopeptidase 2	Homo sapiens	64-69
33437206-6	2021	Next we demonstrated that the MMP-2 and MMP-9 knockdown can act synergistically with Sal to inhibit TGF-beta1-induced EMT.	salinomycin	85-88	matrix metallopeptidase 2	Homo sapiens	30-35
33437206-6	2021	Next we demonstrated that the MMP-2 and MMP-9 knockdown can act synergistically with Sal to inhibit TGF-beta1-induced EMT.	salinomycin	85-88	matrix metallopeptidase 9	Homo sapiens	40-45
33437206-6	2021	Next we demonstrated that the MMP-2 and MMP-9 knockdown can act synergistically with Sal to inhibit TGF-beta1-induced EMT.	salinomycin	85-88	transforming growth factor beta 1	Homo sapiens	100-109
33437206-0	2021	Salinomycin suppresses TGF-beta1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer.	salinomycin	0-11	matrix metallopeptidase 9	Homo sapiens	74-79
33437206-7	2021	Moreover, treatment of PMA of MMP activator increased TGF-beta1-induced MMP-2 and MMP-9, even with Sal.	salinomycin	99-102	transforming growth factor beta 1	Homo sapiens	54-63
33437206-0	2021	Salinomycin suppresses TGF-beta1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer.	salinomycin	0-11	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	88-92
33437206-8	2021	Our results demonstrate that Sal suppresses TGF-beta1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby inhibiting lung cancer cell migration and invasion.	salinomycin	29-32	transforming growth factor beta 1	Homo sapiens	44-53
33437206-8	2021	Our results demonstrate that Sal suppresses TGF-beta1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby inhibiting lung cancer cell migration and invasion.	salinomycin	29-32	matrix metallopeptidase 2	Homo sapiens	84-89
33437206-0	2021	Salinomycin suppresses TGF-beta1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer.	salinomycin	0-11	sirtuin 1	Homo sapiens	93-98
33437206-8	2021	Our results demonstrate that Sal suppresses TGF-beta1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby inhibiting lung cancer cell migration and invasion.	salinomycin	29-32	matrix metallopeptidase 9	Homo sapiens	94-99
33437206-8	2021	Our results demonstrate that Sal suppresses TGF-beta1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby inhibiting lung cancer cell migration and invasion.	salinomycin	29-32	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	112-116
33437206-3	2021	Sal solidly blocked cell migration and invasion enhancement by TGF-beta1-induced EMT, through recovering E-cadherin loss and suppressing mesenchymal markers induction, as well as TGF-beta1-mediated AMPK/SIRT signaling activity upregulation.	salinomycin	0-3	transforming growth factor beta 1	Homo sapiens	63-72
32822738-4	2020	After screening our chemical library, we found that salinomycin potently inhibited IFN-gamma-stimulated kynurenine synthesis with IC50 values of 3.36-4.66 muM in both human cervical and breast cancer cells.	salinomycin	52-63	interferon gamma	Homo sapiens	83-92
33047727-8	2020	Western blot proved that salinomycin could up-regulate the expressions of Caspase-3 and Caspase-9 protein in oral squamous cell carcinoma CAL-27 cells (P < 0.05).	salinomycin	25-36	caspase 3	Homo sapiens	74-83
33047727-8	2020	Western blot proved that salinomycin could up-regulate the expressions of Caspase-3 and Caspase-9 protein in oral squamous cell carcinoma CAL-27 cells (P < 0.05).	salinomycin	25-36	caspase 9	Homo sapiens	88-97
33047727-11	2020	At the same time, salinomycin could trigger apoptosis of oral squamous carcinoma cells and the mechanism is associated with the Akt/p-Akt signaling pathway.	salinomycin	18-29	AKT serine/threonine kinase 1	Homo sapiens	128-131
33047727-11	2020	At the same time, salinomycin could trigger apoptosis of oral squamous carcinoma cells and the mechanism is associated with the Akt/p-Akt signaling pathway.	salinomycin	18-29	AKT serine/threonine kinase 1	Homo sapiens	134-137
32990713-0	2020	Salinomycin nanocrystals for colorectal cancer treatment through inhibition of Wnt/beta-catenin signaling.	salinomycin	0-11	catenin beta 1	Homo sapiens	83-95
32990713-1	2020	Salinomycin (SAL) is one of the first discovered inhibitors of human cancer stem cells (CSCs), which acts via blocking the Wnt/beta-catenin pathway.	salinomycin	0-11	catenin beta 1	Homo sapiens	127-139
32990713-1	2020	Salinomycin (SAL) is one of the first discovered inhibitors of human cancer stem cells (CSCs), which acts via blocking the Wnt/beta-catenin pathway.	salinomycin	13-16	catenin beta 1	Homo sapiens	127-139
32990713-3	2020	In this study, we developed salinomycin nanocrystals (SAL NCs) to treat colorectal cancer through the inhibitory enhancement of Wnt/beta-catenin signaling.	salinomycin	28-39	catenin beta 1	Homo sapiens	132-144
32822738-5	2020	Salinomycin lowered the IDO1 and IDO2 expression with no impact on the expression of tryptophan-2,3-dioxygenase.	salinomycin	0-11	indoleamine 2,3-dioxygenase 1	Homo sapiens	24-28
32822738-5	2020	Salinomycin lowered the IDO1 and IDO2 expression with no impact on the expression of tryptophan-2,3-dioxygenase.	salinomycin	0-11	indoleamine 2,3-dioxygenase 2	Homo sapiens	33-37
32822738-6	2020	Interestingly, salinomycin potently repressed the IDO1 enzymatic activity by directly targeting the proteins in cells.	salinomycin	15-26	indoleamine 2,3-dioxygenase 1	Homo sapiens	50-54
32822738-7	2020	Molecular docking revealed an alignment that favors nucleophilic attack of salinomycin in the catalytic domain of IDO1.	salinomycin	75-86	indoleamine 2,3-dioxygenase 1	Homo sapiens	114-118
32822738-8	2020	Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway by IFN-gamma was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/3 phosphorylation.	salinomycin	144-155	interferon gamma	Homo sapiens	102-111
32822738-8	2020	Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway by IFN-gamma was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/3 phosphorylation.	salinomycin	144-155	Janus kinase 1	Homo sapiens	176-180
32822738-8	2020	Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway by IFN-gamma was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/3 phosphorylation.	salinomycin	144-155	Janus kinase 2	Homo sapiens	182-186
32822738-8	2020	Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway by IFN-gamma was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/3 phosphorylation.	salinomycin	144-155	signal transducer and activator of transcription 1	Homo sapiens	192-199
32822738-10	2020	Furthermore, salinomycin significantly restored the proliferation of T cells co-cultured with IFN-gamma-treated breast cancer cells and potentiated antitumor activity of cisplatin in vivo.	salinomycin	13-24	interferon gamma	Homo sapiens	94-103
32822738-11	2020	These findings suggest that salinomycin suppresses kynurenine synthesis by inhibiting the catalytic activity of IDO1 and its expression by inhibiting the JAK/STAT and NF-kappaB pathways.	salinomycin	28-39	indoleamine 2,3-dioxygenase 1	Homo sapiens	112-116
32822738-11	2020	These findings suggest that salinomycin suppresses kynurenine synthesis by inhibiting the catalytic activity of IDO1 and its expression by inhibiting the JAK/STAT and NF-kappaB pathways.	salinomycin	28-39	Janus kinase 1	Homo sapiens	154-157
32822738-11	2020	These findings suggest that salinomycin suppresses kynurenine synthesis by inhibiting the catalytic activity of IDO1 and its expression by inhibiting the JAK/STAT and NF-kappaB pathways.	salinomycin	28-39	signal transducer and activator of transcription 1	Homo sapiens	158-162
32822738-12	2020	Salinomycin warrants further investigation as a novel dual-functional IDO inhibitor for cancer immunotherapy.	salinomycin	0-11	indoleamine 2,3-dioxygenase 1	Homo sapiens	70-73
32982236-5	2020	Results: Delivery of the SAL- and LA-SN38-based nanoprodrugs effectively promoted apoptosis of HCC cells, exerted inhibition of HCC tumor-sphere formation as well as HCC cell motility and invasion, and reduced the proportion of CD133+ HCC-CSC cells.	salinomycin	25-28	prominin 1	Homo sapiens	228-233
33089100-6	2020	Moreover, we show that salinomycin, an anti-CSC agent, disrupts nucleolus by inducing nucleoplasm translocation of p53 and sensitizing CSC to chemotherapy drugs.	salinomycin	23-34	tumor protein p53	Homo sapiens	115-118
32581555-0	2020	Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo.	salinomycin	0-11	AKT serine/threonine kinase 1	Homo sapiens	142-145
32826863-6	2020	Moreover, we demonstrate that salinomycin, which as a highly effective antibiotic in the elimination of cancer stem cells through the Wnt/beta-catenin signaling, could enhance the inhibition of tumor growth by antisense oligonucleotides (ASO) targeting AC104041.1 in HNSCC cells and PDXs (patient-derived xenograft) model.	salinomycin	30-41	Wnt family member 2B	Homo sapiens	134-137
32826863-6	2020	Moreover, we demonstrate that salinomycin, which as a highly effective antibiotic in the elimination of cancer stem cells through the Wnt/beta-catenin signaling, could enhance the inhibition of tumor growth by antisense oligonucleotides (ASO) targeting AC104041.1 in HNSCC cells and PDXs (patient-derived xenograft) model.	salinomycin	30-41	catenin beta 1	Homo sapiens	138-150
32678032-0	2020	Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor beta.	salinomycin	28-39	estrogen receptor 1	Homo sapiens	132-154
32648839-0	2021	Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and An-ti-Angiogenic/Lymphangiogenic Effect.	salinomycin	119-130	fms related receptor tyrosine kinase 1	Homo sapiens	40-49
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	vascular endothelial growth factor A	Homo sapiens	188-194
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	vascular endothelial growth factor B	Homo sapiens	196-202
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	vascular endothelial growth factor C	Homo sapiens	204-210
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	vascular endothelial growth factor D	Homo sapiens	212-218
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	fms related receptor tyrosine kinase 1	Homo sapiens	220-227
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	kinase insert domain receptor	Homo sapiens	229-236
32648839-3	2021	OBJECTIVE: The study aimed to assess the use of salinomycin as an anti-angiogenic and anti-lymphangiogenic drug during endometrial cancer by examining changes in the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3 depending on the treatment period of the Ishikawa endometrial cancer cells with salinomycin in comparison to the control culture.	salinomycin	48-59	fms related receptor tyrosine kinase 4	Homo sapiens	238-245
32648839-7	2021	RESULTS: For all isoforms of VEGF-A-D as well as receptors of VEGFR-1-3, a decrease in expression under the influence of salinomycin was noted.	salinomycin	121-132	vascular endothelial growth factor A	Homo sapiens	29-35
32648839-7	2021	RESULTS: For all isoforms of VEGF-A-D as well as receptors of VEGFR-1-3, a decrease in expression under the influence of salinomycin was noted.	salinomycin	121-132	fms related receptor tyrosine kinase 1	Homo sapiens	62-71
32648839-8	2021	For VEGF-A and VEGFR-1, the difference in the expression between the culture treated with salinomycin in comparison to the control was statistically significant (p=0.0004).	salinomycin	90-101	vascular endothelial growth factor A	Homo sapiens	4-10
32648839-8	2021	For VEGF-A and VEGFR-1, the difference in the expression between the culture treated with salinomycin in comparison to the control was statistically significant (p=0.0004).	salinomycin	90-101	fms related receptor tyrosine kinase 1	Homo sapiens	15-22
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	vascular endothelial growth factor A	Homo sapiens	59-65
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	vascular endothelial growth factor B	Homo sapiens	67-73
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	vascular endothelial growth factor C	Homo sapiens	75-81
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	vascular endothelial growth factor D	Homo sapiens	83-89
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	fms related receptor tyrosine kinase 1	Homo sapiens	91-98
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	kinase insert domain receptor	Homo sapiens	100-107
32648839-12	2021	CONCLUSIONS: Salinomycin changes the expression pattern of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 in endometrial cancer cells.	salinomycin	13-24	fms related receptor tyrosine kinase 4	Homo sapiens	113-120
32648839-13	2021	The obtained results suggest that salinomycin might exert the effect via VEGF signaling pathways.	salinomycin	34-45	vascular endothelial growth factor A	Homo sapiens	73-77
32627023-0	2020	In vitro demonstration of salinomycin as a novel chemotherapeutic agent for the treatment of SOX2-positive glioblastoma cancer stem cells.	salinomycin	26-37	SRY-box transcription factor 2	Homo sapiens	93-97
32627023-7	2020	It was revealed that salinomycin decreased the expression of the GSC marker SOX2 at both the transcriptional and translational level.	salinomycin	21-32	SRY-box transcription factor 2	Homo sapiens	76-80
32627023-8	2020	However, the effect of salinomycin on the GSC markers Nestin and CD133 was inconsistent between GBM subtypes.	salinomycin	23-34	nestin	Homo sapiens	54-60
32627023-9	2020	Additionally, the present findings provide initial evidence of caspase-3-dependent and independent apoptosis as the method by which salinomycin induces cell death in GBM.	salinomycin	132-143	caspase 3	Homo sapiens	63-72
31971116-12	2021	Moreover, salinomycin could also inhibit the activation of Wnt/beta-catenin signaling in LCSCs.	salinomycin	10-21	catenin beta 1	Homo sapiens	63-75
32014461-3	2020	Here, we employed a MYB-reporter cell line and identified the polyether ionophores monensin, salinomycin, and nigericin as novel inhibitors of MYB activity.	salinomycin	93-104	MYB proto-oncogene, transcription factor	Homo sapiens	20-23
32014461-3	2020	Here, we employed a MYB-reporter cell line and identified the polyether ionophores monensin, salinomycin, and nigericin as novel inhibitors of MYB activity.	salinomycin	93-104	MYB proto-oncogene, transcription factor	Homo sapiens	143-146
32572938-14	2020	CONCLUSIONS: Sal enhances the radiotherapy sensitivity of NPC and reduces the protein expressions of BIRC5 and NEIL2 in cells.	salinomycin	13-16	nei like DNA glycosylase 2	Homo sapiens	111-116
31834633-12	2020	Salinomycin decreased the CD24- /CD44high population in both docetaxel-sensitive PC3 and docetaxel-resistant (DR) PC3-DR.	salinomycin	0-11	chromobox 8	Homo sapiens	81-84
31834633-12	2020	Salinomycin decreased the CD24- /CD44high population in both docetaxel-sensitive PC3 and docetaxel-resistant (DR) PC3-DR.	salinomycin	0-11	chromobox 8	Homo sapiens	114-117
31834633-13	2020	Moreover, treatment of PC3, DU145, PC3-DR, and DU145-DR with salinomycin led to a significant reduction in the colony formation potential by targeting the colonies with high tumor-initiating potential.	salinomycin	61-72	chromobox 8	Homo sapiens	23-26
31834633-13	2020	Moreover, treatment of PC3, DU145, PC3-DR, and DU145-DR with salinomycin led to a significant reduction in the colony formation potential by targeting the colonies with high tumor-initiating potential.	salinomycin	61-72	chromobox 8	Homo sapiens	35-38
32154065-4	2020	Moreover, the induction of PINK1-dependent mitophagy with carbonylcyanide-m-chlorophenylhydrazone (CCCP) or salinomycin, or overexpression of PINK1 leads to inhibition of transwell migration, suppression of myeloma cell homing to calvarium, and decreased osteolytic bone lesions.	salinomycin	108-119	PTEN induced kinase 1	Homo sapiens	27-32
32572938-0	2020	Salinomycin enhances radiotherapy sensitivity and reduces expressions of BIRC5 and NEIL2 in nasopharyngeal carcinoma.	salinomycin	0-11	baculoviral IAP repeat containing 5	Homo sapiens	73-78
32572938-0	2020	Salinomycin enhances radiotherapy sensitivity and reduces expressions of BIRC5 and NEIL2 in nasopharyngeal carcinoma.	salinomycin	0-11	nei like DNA glycosylase 2	Homo sapiens	83-88
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	67-78	baculoviral IAP repeat containing 5	Homo sapiens	103-138
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	67-78	baculoviral IAP repeat containing 5	Homo sapiens	140-145
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	67-78	nei like DNA glycosylase 2	Homo sapiens	151-179
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	67-78	nei like DNA glycosylase 2	Homo sapiens	181-186
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	80-83	baculoviral IAP repeat containing 5	Homo sapiens	103-138
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	80-83	baculoviral IAP repeat containing 5	Homo sapiens	140-145
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	80-83	nei like DNA glycosylase 2	Homo sapiens	151-179
32572938-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of salinomycin (Sal) on expressions of baculoviral IAP repeat-containing 5 (BIRC5) and Nei endonuclease VIII-like 2 (NEIL2) and radiotherapy sensitivity of nasopharyngeal carcinoma (NPC).	salinomycin	80-83	nei like DNA glycosylase 2	Homo sapiens	181-186
32572938-14	2020	CONCLUSIONS: Sal enhances the radiotherapy sensitivity of NPC and reduces the protein expressions of BIRC5 and NEIL2 in cells.	salinomycin	13-16	baculoviral IAP repeat containing 5	Homo sapiens	101-106
31971116-14	2021	Further studies demonstrated that salinomycin also significantly reduces the tumorigenicity of LCSCs in vivo by suppressing the Wnt/beta-catenin signaling pathway.	salinomycin	34-45	catenin beta 1	Homo sapiens	132-144
31971116-15	2021	CONCLUSION: Salinomycin could suppress stemness properties and induce differentiation of LCSCs through the Wnt/beta-catenin signaling pathway, which provides evidence that salinomycin may serve as a potential drug for liver cancer therapy targeting LCSCs in the clinic.	salinomycin	12-23	catenin beta 1	Homo sapiens	111-123
31971116-15	2021	CONCLUSION: Salinomycin could suppress stemness properties and induce differentiation of LCSCs through the Wnt/beta-catenin signaling pathway, which provides evidence that salinomycin may serve as a potential drug for liver cancer therapy targeting LCSCs in the clinic.	salinomycin	172-183	catenin beta 1	Homo sapiens	111-123
30882398-0	2019	Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells.	salinomycin	0-11	HOXA distal transcript antisense RNA	Homo sapiens	116-122
32156244-3	2020	Recently it has been reported that Sal can destabilize TAZ, the hypo pathway transducer in CSLCs.	salinomycin	35-38	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	55-58
32156244-4	2020	OBJECTIVE: Here in the current study, we aimed to assess the differential toxicity of Sal in esophageal CSLCs and its relation to TAZ gene expression.	salinomycin	86-89	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	130-133
32156244-10	2020	ConclusionIn: overall, our results indicate Sal can selectively decrease viability of esophageal CSLCs in a TAZ-independent manner.	salinomycin	44-47	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	108-111
32407273-0	2020	The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line.	salinomycin	17-28	caspase 8	Homo sapiens	82-90
32407273-3	2020	AIM: The aim of this study was to assess the variances in the expression pattern of caspase-dependent signaling pathways in the endometrial cancer cell line when treated with salinomycin.	salinomycin	175-186	caspase 8	Homo sapiens	84-91
31702860-2	2020	Our previous studies have indicated that C1/C20 double-modification of SAL is a useful strategy to generate diverse agents with promising biological activity profiles.	salinomycin	71-74	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	41-47
31702860-7	2020	Additionally, both SAL and 2 were potent ex vivo against human ER/PR+, Her2- invasive mammary carcinoma, with 2 showing minimal toxicity towards normal epithelial cells.	salinomycin	19-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
31746350-0	2020	Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.	salinomycin	0-11	ret proto-oncogene	Homo sapiens	42-45
31746350-2	2020	The present study reports the first preclinical characterization of salinomycin and selected analogs as potent RET transcriptional inhibitors.	salinomycin	68-79	ret proto-oncogene	Homo sapiens	111-114
31746350-3	2020	Reverse transcription-PCR and immunoblotting revealed that salinomycin profoundly decreased RET expression in the TT human MTC cell line by inhibiting RET transcription.	salinomycin	59-70	ret proto-oncogene	Homo sapiens	92-95
31746350-3	2020	Reverse transcription-PCR and immunoblotting revealed that salinomycin profoundly decreased RET expression in the TT human MTC cell line by inhibiting RET transcription.	salinomycin	59-70	ret proto-oncogene	Homo sapiens	151-154
31746350-4	2020	Moreover, salinomycin resulted in remarkable anti-proliferative activity against MTC that is driven by RET (gain of function mutation) by selectively inhibiting the intracellular PI3K/Akt/mTOR signaling pathway.	salinomycin	10-21	ret proto-oncogene	Homo sapiens	103-106
31746350-4	2020	Moreover, salinomycin resulted in remarkable anti-proliferative activity against MTC that is driven by RET (gain of function mutation) by selectively inhibiting the intracellular PI3K/Akt/mTOR signaling pathway.	salinomycin	10-21	AKT serine/threonine kinase 1	Homo sapiens	184-187
31746350-4	2020	Moreover, salinomycin resulted in remarkable anti-proliferative activity against MTC that is driven by RET (gain of function mutation) by selectively inhibiting the intracellular PI3K/Akt/mTOR signaling pathway.	salinomycin	10-21	mechanistic target of rapamycin kinase	Homo sapiens	188-192
31746350-5	2020	Also, flow cytometry and fluorescence-activated cell sorting showed that salinomycin induces G1 phase arrest and apoptosis by reducing the expression of retinoblastoma protein, E2F1, cyclin D and CDK4.	salinomycin	73-84	E2F transcription factor 1	Homo sapiens	177-181
31746350-5	2020	Also, flow cytometry and fluorescence-activated cell sorting showed that salinomycin induces G1 phase arrest and apoptosis by reducing the expression of retinoblastoma protein, E2F1, cyclin D and CDK4.	salinomycin	73-84	cyclin dependent kinase 4	Homo sapiens	196-200
31746350-7	2020	Some of the salinomycin derivatives showed the ability to reduce RET expression where others fail to alter RET expression.	salinomycin	12-23	ret proto-oncogene	Homo sapiens	65-68
31746350-8	2020	These results suggest that the RET-suppressing effect of salinomycin may be largely attributed to disruption of the Wnt pathway, presumably through interference with the ternary LRP6-Frizzled-Wnt complex.	salinomycin	57-68	ret proto-oncogene	Homo sapiens	31-34
31746350-8	2020	These results suggest that the RET-suppressing effect of salinomycin may be largely attributed to disruption of the Wnt pathway, presumably through interference with the ternary LRP6-Frizzled-Wnt complex.	salinomycin	57-68	LDL receptor related protein 6	Homo sapiens	178-182
31718679-10	2019	Mechanistically, Twist1 was fundamental for the salinomycin-enabled CSCs elimination and migration/invasion blockage in UM cells.	salinomycin	48-59	twist basic helix-loop-helix transcription factor 1	Mus musculus	17-23
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	salinomycin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	47-56
31432100-6	2019	Moreover, inhibition of the Wnt/beta-catenin pathway by salinomycin significantly suppressed the simvastatin-associated HUVEC dysfunction.	salinomycin	56-67	catenin beta 1	Homo sapiens	32-44
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	salinomycin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	108-117
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	salinomycin	0-11	X-linked inhibitor of apoptosis	Homo sapiens	180-184
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	salinomycin	0-11	BCL2 apoptosis regulator	Homo sapiens	189-194
31527897-4	2019	Here we show that the polyether ionophore compound salinomycin (SNC) effectively inhibits TGFbeta-induced EMT of RPE cells.	salinomycin	51-62	transforming growth factor alpha	Mus musculus	90-97
31527897-4	2019	Here we show that the polyether ionophore compound salinomycin (SNC) effectively inhibits TGFbeta-induced EMT of RPE cells.	salinomycin	64-67	transforming growth factor alpha	Mus musculus	90-97
31236922-0	2019	Salinomycin exerts anti-colorectal cancer activity by targeting the beta-catenin/T-cell factor complex.	salinomycin	0-11	catenin beta 1	Homo sapiens	68-80
31236922-4	2019	EXPERIMENTAL APPROACH: The inhibitory effect of salinomycin on the Wnt/beta-catenin pathway was analysed with the SuperTopFlash reporter system.	salinomycin	48-59	catenin beta 1	Homo sapiens	71-83
31236922-6	2019	Effects of salinomycin on beta-catenin/TCF4E interaction were examined using co-immunoprecipitation and an in vitro GST pull-down assay.	salinomycin	11-22	catenin beta 1	Homo sapiens	26-38
31236922-10	2019	KEY RESULTS: Salinomycin blocked beta-catenin/TCF4E complex formation in colorectal cancer cells and in an in vitro GST pull-down assay, thus decreasing expression of Wnt target genes.	salinomycin	13-24	catenin beta 1	Homo sapiens	33-45
31236922-11	2019	Salinomycin also suppressed the transcriptional activity mediated by beta-catenin/LEF1 or beta-catenin/TCF4E complex and exhibited an inhibitory effect on the sphere formation, proliferation, and anchorage-independent growth of colorectal cancer cells.	salinomycin	0-11	catenin beta 1	Homo sapiens	69-81
31236922-11	2019	Salinomycin also suppressed the transcriptional activity mediated by beta-catenin/LEF1 or beta-catenin/TCF4E complex and exhibited an inhibitory effect on the sphere formation, proliferation, and anchorage-independent growth of colorectal cancer cells.	salinomycin	0-11	lymphoid enhancer binding factor 1	Homo sapiens	82-86
31236922-11	2019	Salinomycin also suppressed the transcriptional activity mediated by beta-catenin/LEF1 or beta-catenin/TCF4E complex and exhibited an inhibitory effect on the sphere formation, proliferation, and anchorage-independent growth of colorectal cancer cells.	salinomycin	0-11	catenin beta 1	Homo sapiens	90-102
31236922-12	2019	In colorectal tumour xenografts and APCmin/+ transgenic mice, administration of salinomycin significantly reduced tumour growth and the expression of CSC-related Wnt target genes including LGR5.	salinomycin	80-91	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	189-193
31236922-13	2019	CONCLUSIONS AND IMPLICATIONS: Our study suggested that salinomycin could suppress the growth of colorectal cancer by disrupting the beta-catenin/TCF complex and thus may be a promising agent for colorectal cancer treatment.	salinomycin	55-66	catenin beta 1	Homo sapiens	132-144
31236922-13	2019	CONCLUSIONS AND IMPLICATIONS: Our study suggested that salinomycin could suppress the growth of colorectal cancer by disrupting the beta-catenin/TCF complex and thus may be a promising agent for colorectal cancer treatment.	salinomycin	55-66	lymphoid enhancer binding factor 1	Homo sapiens	145-148
30882398-9	2019	Furthermore, our data showed that the salinomycin-elicited MDR-reversion effect was associated closely with suppression of EMT through inhibition of the expression of long noncoding RNA HOTTIP.	salinomycin	38-49	HOXA distal transcript antisense RNA	Homo sapiens	186-192
31177119-10	2019	Since MDA-MB 231 has over 90% cells with the profile CD44+/CD24low/-, these might represent a possible point of attack for salinomycin.	salinomycin	123-134	CD44 molecule (Indian blood group)	Homo sapiens	53-57
30986574-4	2019	In this paper, we present the synthetic pathways, crystal structures and anti-trypanosomal activity of C1 esters, amides and hydroxamic acid conjugates of SAL, its C20-oxo and propargylamine analogues as well novel C1/C20 doubly modified derivatives.	salinomycin	155-158	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	215-221
31028743-0	2019	Salinomycin inhibits breast cancer progression via targeting HIF-1alpha/VEGF mediated tumor angiogenesis in vitro and in vivo.	salinomycin	0-11	hypoxia inducible factor 1, alpha subunit	Mus musculus	61-71
31028743-0	2019	Salinomycin inhibits breast cancer progression via targeting HIF-1alpha/VEGF mediated tumor angiogenesis in vitro and in vivo.	salinomycin	0-11	vascular endothelial growth factor A	Mus musculus	72-76
31028743-10	2019	SAL also suppressed the serum VEGFA level in tumor-bearing mice and induced caspase-dependent apoptosis in breast cancer cells.	salinomycin	0-3	vascular endothelial growth factor A	Mus musculus	30-35
31028743-11	2019	Taken together our findings suggested that SAL inhibits VEGF induced angiogenesis and breast cancer growth via interrupting HIF-1alpha/VEGF signalling and could be used as a promising antiangiogenic agent for breast cancer treatment.	salinomycin	43-46	vascular endothelial growth factor A	Mus musculus	56-60
31028743-11	2019	Taken together our findings suggested that SAL inhibits VEGF induced angiogenesis and breast cancer growth via interrupting HIF-1alpha/VEGF signalling and could be used as a promising antiangiogenic agent for breast cancer treatment.	salinomycin	43-46	hypoxia inducible factor 1, alpha subunit	Mus musculus	124-134
31028743-11	2019	Taken together our findings suggested that SAL inhibits VEGF induced angiogenesis and breast cancer growth via interrupting HIF-1alpha/VEGF signalling and could be used as a promising antiangiogenic agent for breast cancer treatment.	salinomycin	43-46	vascular endothelial growth factor A	Mus musculus	135-139
30890503-0	2019	[Overexpression of autophagy-related gene 3 promotes autophagy and inhibits salinomycin-induced apoptosis in breast cancer MCF-7 cells].	salinomycin	76-87	autophagy related 3	Homo sapiens	19-43
30930999-0	2019	Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies.	salinomycin	58-69	CD44 antigen	Mus musculus	120-124
30930999-5	2019	The present study demonstrated that salinomycin exerts potent activity against CD44+ prostate CICs.	salinomycin	36-47	CD44 antigen	Mus musculus	79-83
30930999-6	2019	To further enhance this anticancer effect, salinomycin-encapsulated lipid-poly(lactic-co-glycolic acid) nanoparticles linked with CD44 antibodies (SM-LPN-CD44) were generated.	salinomycin	43-54	CD44 antigen	Mus musculus	130-134
30930999-6	2019	To further enhance this anticancer effect, salinomycin-encapsulated lipid-poly(lactic-co-glycolic acid) nanoparticles linked with CD44 antibodies (SM-LPN-CD44) were generated.	salinomycin	43-54	CD44 antigen	Mus musculus	154-158
30930999-8	2019	The results revealed that SM-LPN-CD44 could efficiently and specifically promote the delivery of salinomycin to CD44+ prostate CICs, and there by achieve greater inhibition of the cells compared with that achieved by salinomycin and non-targeted nanoparticles.	salinomycin	97-108	CD44 antigen	Mus musculus	33-37
30930999-8	2019	The results revealed that SM-LPN-CD44 could efficiently and specifically promote the delivery of salinomycin to CD44+ prostate CICs, and there by achieve greater inhibition of the cells compared with that achieved by salinomycin and non-targeted nanoparticles.	salinomycin	97-108	CD44 antigen	Mus musculus	112-116
30796972-0	2019	Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells.	salinomycin	104-115	thymidine phosphorylase	Homo sapiens	14-37
30796972-0	2019	Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells.	salinomycin	104-115	heat shock protein 90 alpha family class A member 1	Homo sapiens	52-57
30796972-4	2019	In this study, we report whether Hsp90 inhibitor 17-AAG could enhance salinomycin-induced cytotoxicity in NSCLC cells through modulating TP expression in two non-small-cell lung cancer (NSCLC) cell lines, A549 and H1975.	salinomycin	70-81	heat shock protein 90 alpha family class A member 1	Homo sapiens	33-38
30796972-4	2019	In this study, we report whether Hsp90 inhibitor 17-AAG could enhance salinomycin-induced cytotoxicity in NSCLC cells through modulating TP expression in two non-small-cell lung cancer (NSCLC) cell lines, A549 and H1975.	salinomycin	70-81	N-methylpurine DNA glycosylase	Homo sapiens	52-55
30796972-4	2019	In this study, we report whether Hsp90 inhibitor 17-AAG could enhance salinomycin-induced cytotoxicity in NSCLC cells through modulating TP expression in two non-small-cell lung cancer (NSCLC) cell lines, A549 and H1975.	salinomycin	70-81	thymidine phosphorylase	Homo sapiens	137-139
30796972-5	2019	We found that salinomycin increased TP expression in a MKK3/6-p38 MAPK activation manner.	salinomycin	14-25	thymidine phosphorylase	Homo sapiens	36-38
30796972-5	2019	We found that salinomycin increased TP expression in a MKK3/6-p38 MAPK activation manner.	salinomycin	14-25	activator of HSP90 ATPase activity 1	Homo sapiens	62-65
31023247-0	2019	Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.	salinomycin	0-11	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	58-64
31023247-10	2019	We also found that salinomycin could trigger ER stress, which might be related to ATP2A3-mediated Ca2+ release in PC-3 cells.	salinomycin	19-30	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	82-88
31023247-12	2019	CONCLUSION: This study demonstrates that ATP2A3 might be one of the potential targets for salinomycin, which can inhibit Ca2+ release and trigger ER stress to exert anti-cancer effects.	salinomycin	90-101	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	41-47
30796972-6	2019	Knockdown of TP using siRNA or inactivation of p38 MAPK by pharmacological inhibitor SB203580 enhanced the cytotoxic and growth inhibition effects of salinomycin.	salinomycin	150-161	thymidine phosphorylase	Homo sapiens	13-15
30796972-6	2019	Knockdown of TP using siRNA or inactivation of p38 MAPK by pharmacological inhibitor SB203580 enhanced the cytotoxic and growth inhibition effects of salinomycin.	salinomycin	150-161	activator of HSP90 ATPase activity 1	Homo sapiens	47-50
30796972-7	2019	In contrast, enforced expression of MKK6E (a constitutively active form of MKK6) reduced the cytotoxicity and cell growth inhibition of salinomycin.	salinomycin	136-147	mitogen-activated protein kinase kinase 6	Homo sapiens	36-40
30796972-8	2019	Moreover, Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of salinomycin in NSCLC cells, which were associated with down-regulation of TP expression and inactivation of p38 MAPK.	salinomycin	85-96	heat shock protein 90 alpha family class A member 1	Homo sapiens	10-15
30796972-8	2019	Moreover, Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of salinomycin in NSCLC cells, which were associated with down-regulation of TP expression and inactivation of p38 MAPK.	salinomycin	85-96	N-methylpurine DNA glycosylase	Homo sapiens	29-32
30796972-8	2019	Moreover, Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of salinomycin in NSCLC cells, which were associated with down-regulation of TP expression and inactivation of p38 MAPK.	salinomycin	85-96	thymidine phosphorylase	Homo sapiens	159-161
30796972-9	2019	Together, the Hsp90 inhibition induced TP down-regulation involved in enhancing the salinomycin-induced cytotoxicity in A549 and H1975 cells.	salinomycin	84-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
30796972-9	2019	Together, the Hsp90 inhibition induced TP down-regulation involved in enhancing the salinomycin-induced cytotoxicity in A549 and H1975 cells.	salinomycin	84-95	thymidine phosphorylase	Homo sapiens	39-41
30689374-0	2019	Nucleolin Is a Functional Binding Protein for Salinomycin in Neuroblastoma Stem Cells.	salinomycin	46-57	nucleolin	Homo sapiens	0-9
30689374-2	2019	By utilizing integrated strategies, we identify that nucleolin (NCL) is likely a salinomycin-binding target and a critical regulator involved in human neuroblastoma (NB) CSC activity.	salinomycin	81-92	nucleolin	Homo sapiens	53-62
30689374-2	2019	By utilizing integrated strategies, we identify that nucleolin (NCL) is likely a salinomycin-binding target and a critical regulator involved in human neuroblastoma (NB) CSC activity.	salinomycin	81-92	nucleolin	Homo sapiens	64-67
30890503-1	2019	OBJECTIVE: To study the effects of the overexpression of autophagy-related gene 3 (ATG3) on autophagy and salinomycin-induced apoptosis in breast cancer cells and explore the underlying mechanisms.	salinomycin	106-117	autophagy related 3	Homo sapiens	57-81
30689374-3	2019	Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter.	salinomycin	0-11	CD34 molecule	Homo sapiens	35-39
30689374-3	2019	Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter.	salinomycin	0-11	CD34 molecule	Homo sapiens	63-67
30890503-1	2019	OBJECTIVE: To study the effects of the overexpression of autophagy-related gene 3 (ATG3) on autophagy and salinomycin-induced apoptosis in breast cancer cells and explore the underlying mechanisms.	salinomycin	106-117	autophagy related 3	Homo sapiens	83-87
30689374-3	2019	Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter.	salinomycin	0-11	nucleolin	Homo sapiens	91-94
30890503-5	2019	Western blotting and flow cytometry were used to analyze the effect of autophagy on apoptosis of the ATG3-overexpressing cells treated with salinomycin and 3-MA (an autophagy inhibitor).	salinomycin	140-151	autophagy related 3	Homo sapiens	101-105
30689374-3	2019	Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter.	salinomycin	0-11	nucleolin	Homo sapiens	149-152
30689374-3	2019	Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter.	salinomycin	0-11	CD34 molecule	Homo sapiens	63-67
30689374-5	2019	Altogether, these results indicate that NCL is likely a novel functional salinomycin-binding target that exhibits the potential to be a prognostic marker for NB therapy.	salinomycin	73-84	nucleolin	Homo sapiens	40-43
30890503-7	2019	The inhibition of autophagy obviously weakened the inhibitory effect of ATG3 overexpression on salinomycin-induced apoptosis.	salinomycin	95-106	autophagy related 3	Homo sapiens	72-76
30890503-8	2019	CONCLUSIONS: ATG3 overexpression promotes autophagy possibly by inhibiting the AKT/mTOR signaling pathway to decrease salinomycin-induced apoptosis in MCF-7 cells, suggesting that autophagy induction might be one of the mechanisms of drug resistance in breast cancer cells.	salinomycin	118-129	autophagy related 3	Homo sapiens	13-17
30675240-0	2019	Enhanced anticancer effect of oncostatin M combined with salinomycin in CD133+ HepG2 liver cancer cells.	salinomycin	57-68	prominin 1	Homo sapiens	72-77
30763370-11	2019	These effects are associated with expressional down-regulation of superoxide dismutase-1 (SOD1) in response to salinomycin treatment.	salinomycin	111-122	superoxide dismutase 1	Homo sapiens	66-88
30763370-11	2019	These effects are associated with expressional down-regulation of superoxide dismutase-1 (SOD1) in response to salinomycin treatment.	salinomycin	111-122	superoxide dismutase 1	Homo sapiens	90-94
31080994-7	2019	CAL-27 cells were treated by salinomycin (4 mumol/L) before invasive and migratory abilities were examined.	salinomycin	29-40	filamin binding LIM protein 1	Homo sapiens	0-3
30678671-8	2019	Dose-dependent effects of salinomycin were observed at 15 muM in B4 cells (p = 0.025) and at 10 muM in C10 cells (p = 0.020).	salinomycin	26-37	gene rich cluster, C10 gene	Mus musculus	103-106
30678671-10	2019	However, doxorubicin plus 5 muM salinomycin decreased viability of C10 cells compared to either agent alone at doxorubicin concentrations that can be achieved in vivo (1.84 and 4.6 muM, p &lt; 0.004).	salinomycin	32-43	gene rich cluster, C10 gene	Mus musculus	67-70
30678671-15	2019	We observed that salinomycin may potentiate (C10 cells) or work synergistically (SCCF1 cells) with doxorubicin in certain feline cancer cells.	salinomycin	17-28	gene rich cluster, C10 gene	Mus musculus	45-48
31080994-11	2019	CONCLUSIONS: The proliferative, invasive and migratory ability of CAL-27 cells can be inhibited by salinomycin, which may be related to the inhibition of epithelial-mesenchymal transitions.	salinomycin	99-110	filamin binding LIM protein 1	Homo sapiens	66-69
30273566-0	2018	Salinomycin suppresses cancer cell stemness and attenuates TGF-beta-induced epithelial-mesenchymal transition of renal cell carcinoma cells.	salinomycin	0-11	transforming growth factor beta 1	Homo sapiens	59-67
30273566-7	2018	salinomycin treatment also suppressed the sphere formation ability of RCC cells and decreased the expressions of CD105, ALDH1 and CD44, biomarkers for reflecting the stemness of RCC cells.	salinomycin	0-11	aldehyde dehydrogenase 1 family member A1	Homo sapiens	120-125
30273566-7	2018	salinomycin treatment also suppressed the sphere formation ability of RCC cells and decreased the expressions of CD105, ALDH1 and CD44, biomarkers for reflecting the stemness of RCC cells.	salinomycin	0-11	CD44 molecule (Indian blood group)	Homo sapiens	130-134
30273566-8	2018	salinomycin treatment effectively down-regulated SMO and Gli1, two key proteins in Hedghog signaling pathway, in a dose-dependent manner.	salinomycin	0-11	GLI family zinc finger 1	Homo sapiens	57-61
30273566-9	2018	Moreover, salinomycin could suppress the invasion and migration of RCC cells in the presence of TGF-beta1, as observed in wound-healing and Transwell assays.	salinomycin	10-21	transforming growth factor beta 1	Homo sapiens	96-105
30273566-10	2018	salinomycin treatment attenuated TGF-beta1-induced epithelial-mesenchymal transition (EMT), as evidenced by its ability to increase E-cadherin expression and decrease N-cadherin, Snail and MMP-2 expressions in RCC cells.	salinomycin	0-11	transforming growth factor beta 1	Homo sapiens	33-42
30273566-10	2018	salinomycin treatment attenuated TGF-beta1-induced epithelial-mesenchymal transition (EMT), as evidenced by its ability to increase E-cadherin expression and decrease N-cadherin, Snail and MMP-2 expressions in RCC cells.	salinomycin	0-11	cadherin 1	Homo sapiens	132-142
30273566-10	2018	salinomycin treatment attenuated TGF-beta1-induced epithelial-mesenchymal transition (EMT), as evidenced by its ability to increase E-cadherin expression and decrease N-cadherin, Snail and MMP-2 expressions in RCC cells.	salinomycin	0-11	cadherin 2	Homo sapiens	167-177
30273566-10	2018	salinomycin treatment attenuated TGF-beta1-induced epithelial-mesenchymal transition (EMT), as evidenced by its ability to increase E-cadherin expression and decrease N-cadherin, Snail and MMP-2 expressions in RCC cells.	salinomycin	0-11	snail family transcriptional repressor 1	Homo sapiens	179-184
30273566-10	2018	salinomycin treatment attenuated TGF-beta1-induced epithelial-mesenchymal transition (EMT), as evidenced by its ability to increase E-cadherin expression and decrease N-cadherin, Snail and MMP-2 expressions in RCC cells.	salinomycin	0-11	matrix metallopeptidase 2	Homo sapiens	189-194
30273566-12	2018	Our study provides the evidence that salinomycin possess multiple anti-tumor activities against RCC, as it, in particular, suppressed the cancer stem cell properties and attenuated TGF-beta-induced EMT.	salinomycin	37-48	transforming growth factor beta 1	Homo sapiens	181-189
30484007-7	2018	We investigated how the tumor suppressor maspin may limit carcinoma cell plasticity and affect their context-dependent response to drugs of different mechanisms including docetaxel, histone deacetylase (HDAC) inhibitor MS-275, and ionophore antibiotic salinomycin.	salinomycin	252-263	serpin family B member 5	Homo sapiens	41-47
30290169-0	2018	Salinomycin ameliorates oxidative hepatic damage through AMP-activated protein kinase, facilitating autophagy.	salinomycin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	57-85
30290169-5	2018	As a molecular mechanism, salinomycin induced autophagy through AMP-activated protein kinase (AMPK) activation, as assessed by the accumulation of acidic vesicle organelles, p62 and LC3-II.	salinomycin	26-37	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	64-92
30290169-5	2018	As a molecular mechanism, salinomycin induced autophagy through AMP-activated protein kinase (AMPK) activation, as assessed by the accumulation of acidic vesicle organelles, p62 and LC3-II.	salinomycin	26-37	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
30290169-5	2018	As a molecular mechanism, salinomycin induced autophagy through AMP-activated protein kinase (AMPK) activation, as assessed by the accumulation of acidic vesicle organelles, p62 and LC3-II.	salinomycin	26-37	nucleoporin 62	Homo sapiens	174-177
30290169-6	2018	Moreover, these protective effects were blocked by AMPK inhibition, which indicates the importance of AMPK in the process of salinomycin"s effects.	salinomycin	125-136	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	51-55
30290169-6	2018	Moreover, these protective effects were blocked by AMPK inhibition, which indicates the importance of AMPK in the process of salinomycin"s effects.	salinomycin	125-136	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	102-106
30290169-7	2018	In mice, oral administration of salinomycin protected against carbon tetrachloride (CCl4)-induced oxidative stress and liver injury, and also activated AMPK as well as autophagy-related proteins in the liver.	salinomycin	32-43	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	152-156
30290169-9	2018	Although this beneficial effect was demonstrated under severe oxidative stress, this study showed that salinomycin protected the liver against the oxidative stress and liver damage through AMPK and autophagy, and suggest that salinomycin has a possibility to treat a broad range of diseases.	salinomycin	103-114	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	189-193
30290169-9	2018	Although this beneficial effect was demonstrated under severe oxidative stress, this study showed that salinomycin protected the liver against the oxidative stress and liver damage through AMPK and autophagy, and suggest that salinomycin has a possibility to treat a broad range of diseases.	salinomycin	226-237	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	189-193